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This dissertation uses the concept of cost-effectiveness to compare interventions, 
procedures or treatment options in different clinical areas. This dissertation includes three 
manuscripts comparing specific strategies in the healthcare sector.  
The first assesses the economic value of using antimicrobial-coated sutures (as compared 
to regular sutures) for abdominal incisions to prevent surgical site infections (SSI). We use 
decision tree analysis to evaluate the cost-effectiveness of antimicrobial sutures under a variety 
of circumstances. The results show that antimicrobial coated sutures can be a cost-effective 
measure for preventing  SSIs if they have at least have an efficacy of preventing 10% of 
infections and are used for surgeries with 10% or higher SSI risk.  
The second project compares the clinical outcomes, functional outcomes and costs 
between patients undergoing off-pump and on-pump coronary artery bypass grafting (CABG) 
using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. The 
results show that the off-pump procedure is associated with significantly higher rates of major 
cardiovascular events (death/myocardial infarction/stroke) even though the short-term 
complication rate for the two types of CABG are comparable. From the hospital perspective the 
net health benefits (NHB) were significantly lower for the off-pump patients. From the third 
party payer perspective, the two strategies were comparable in terms of costs, effectiveness and 
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NHB. Overall, we conclude that an off-pump procedure is not the favorable strategy as compared 
to on-pump for patients with diabetes. 
The third manuscript compares the cost-effectiveness of three pharmacotherapy switch 
options for treating depression (bupropion, sertraline and venlafaxine), after failure of initial 
treatment with citalopram, that were assessed as part of Sequenced Treatment Alternatives to 
Relieve Depression trial. The calculated NHBs are comparable for the three switch options. This 
concludes that there is no evidence that any switch option is better/worse than the other in terms 
of cost-effectiveness. 
From a public health perspective, it is essential to determine the cost-effective strategy 
given the limited resources available. Identification and adoption of cost-effective options can 
translate to considerable costs saved per effectiveness unit across the entire nation. Also, 
decisions based on comparing clinical outcomes are further strengthened in cases when strategies 
have similar cost-effectiveness. 
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1.0  INTRODUCTION 
The World health organization (WHO) defines health as a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity1.   
In 2011, United States of America (US) spent approximately $2.7 trillion i.e. 18% of 
nation’s gross domestic product (GDP) on healthcare2. These healthcare costs are predicted to 
increase with each passing year. The US in fact has a higher healthcare expenditure as compared 
to many other countries2. Figure 1-1 shows health expenditure in terms of GDP for many 
countries. Figure 1-2 further illustrates that US healthcare expenditure is higher than countries 
with similar GDP.  
Figure 1-1:  Total health expenditure as percentage GDP for years 2009 – 20113 
1 
 Figure 1-2: Relationship between GDP and healthcare spending per capita4 
 
 
However,  in spite of spending substantial amounts of money, US does not show better 
standards of care or  patient satisfaction5. Rather, US had the third highest infant mortality rate 
(6.1 deaths per 1000 live births) and a life expectancy lower than the median (77.9 versus 79.7 
years) among countries participating in the Organization of Economic Co-operation and 
Development in 20115, 6. Also, the US has been shown to have the highest mortality amenable to 
healthcare conditions (109.7 deaths per 100,000 people) amongst industrialized countries in the 
past7, 8.  
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Thus, newer strategies with better outcomes, higher patient-satisfaction, and lower costs 
are needed. A multitude of healthcare interventions, treatments and programs are already 
available, and many more are under development. The number of choices available increase the 
options that one can choose from but can also be accompanied both by anxiety and growing 
expectations about access to a range of interventions that may improve health and wellbeing9.  
Economic analyses in the healthcare sector can guide the decision making process and help 
healthcare stakeholders make informed decisions. 
1.1 ECONOMIC ANALYSIS IN HEALTH CARE 
1.1.1 Rationale for economic analyses in healthcare sector  
Health and healthcare hold a prime position, not only at an individual and community 
level but also at the political level. National agencies have been investing substantial amounts of 
money towards improving individual and public health. Patient Protection and Affordable Care 
Act (PPACA) enacted in 2010 is a manifestation of the vested interest in nation’s health.  The 
PPACA aims to control healthcare costs, improve healthcare coverage, delivery system and 
establish its sustainability over the long term. Specifically, the act’s comparative-effectiveness 
research initiative and establishment of Patient-Centered Outcomes Research Institute (PCORI) 
can assist patients, clinicians, purchasers, and policy-makers in making informed health 
decisions by advancing the quality and relevance of evidence regarding disease diagnosis, 
management and treatment.  Although the National Institute for Health and Care Excellence 
(NICE) in UK recommend cost-effectiveness research, the PPACA  limits the comparative 
3 
effectiveness research by precluding cost-effectiveness research10.  The precise intent and 
purpose of this restriction has not been described in the law. One possible concern for this could 
be that cost considerations can lead to rationing of care and may support a cheaper alternative. 
However considering costs along with the health outcomes can lead to a more comprehensive, 
useful and practical decision guide11, 12. Especially in the environment of limited resources, 
comparative effectiveness research need to translate incremental costs to the “value” gained by 
an alternate intervention in order to be adopted into practice.  The evaluation of outcomes, 
benefits along with side effects, and the associated heterogeneity by themselves may not be 
sufficient to guide decisions of choosing the appropriate therapy.  Also, different stake holders 
may be interested in different outcomes. An economic analysis can help express results in a 
common denomination and hence make inferences about a strategy across perspectives. 
Moreover, in the absence of economic information, decision makers might default to the lower 
priced option irrespective of improved outcomes associated with the higher priced option. An 
economic analysis can in fact prevent a high price differential between various alternatives to 
override the associated incremental benefits, and help choose an intervention that is beneficial 
overall. An efficient economic analysis may also help determine if a new improved intervention 
is worth the incremental price given its incremental effectiveness and hence keep the rising 
health prices in check. Specifically, the ban on using cost-per-quality adjusted life years (QALY) 
thresholds in the PPACA may also be reflective of the long-standing concerns that this approach 
often discriminates on the basis of age and disability13.  However QALY measures have been 
accepted by many panels in Britain and at the World Health Organization despite its limitations.  
Experts debate that populations with more impairment typically fare better in cost-effectiveness 
analyses in terms of QALYs gained.  Also ban on cost-utility analysis would leave decision 
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makers with less information with which to compare the relative effects of interventions across 
diseases. 
Decision makers including administrators, physicians, payers and patients strive to 
identify the best strategy among the various available choices. Decision-making entails 
answering numerous questions like what works, with what effectiveness, at what cost, for whom, 
in what circumstances, and with what impact? Economic analyses can help demonstrate value in 
the selected choices, and guide decisions in a setting of uncertainty and limited resources14. 
Economic analyses not only facilitate an inform dialogue on achieving affordable and high-
quality healthcare but also guide payment and reimbursement policies15. Thus, economic 
information is a necessary complement to comparative clinical effectiveness information for all 
health care stakeholders. This information will help patients and their physicians make decisions 
that better reflect the needs and preferences of the patient and support the profession's 
commitment to a just distribution of finite resources12.   
 
1.1.2 Economic evaluations 
Economic evaluations can methodologically be done as cost–minimization, cost–benefit, 
cost–effectiveness, or cost–utility analysis16. These analyses involve estimation and comparison 
of net or incremental costs and outcomes of two or more strategies. Cost–minimization analysis 
is performed when outcomes of the alternatives considered are known or can be assumed to be 
equal. Cost-minimization only considers costs and the least costly alternative is chosen as the 
most efficient strategy. However, cost-minimization is rarely used because two interventions 
usually cannot be assumed to have equal effectiveness. The other methods of evaluations like 
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cost-benefit, cost-effectiveness or cost-utility analyses can be conducted to account for the 
differences in outcomes. Cost-benefit analyses express both costs and benefits of an intervention 
in monetary units. This method directly provides an estimate of money saved or spent and can 
incorporate the widest range of effects across many interventions and programs. However, cost-
benefit analyses remain controversial as critics argue that it is unethical to put a monetary value 
on health and death, and also that the willingness-to-pay may vary widely from individual to 
individual17.  Cost-effectiveness is often used when the outcomes of the procedures or programs 
being considered vary, but their outcome can still be expressed in common health-related units 
like number of cases prevented, number of lives saved or disability avoided18, 19.  Such an 
analysis cannot combine the associated morbidity and mortality into a single index and thus 
limits comparison between treatments which differ in these two dimensions. Also, it is limited in 
its ability to assist choices between treatments/strategies if their outcomes vary. In such cases, an 
extension of cost-effectiveness analysis, cost-utility analysis, is often used. Cost-utility is 
commonly based on quality adjusted life years (QALYs), calculated as the multiplicative product 
of utility of a health state and years lived in that state20 or disability adjusted life years (DALYs).  
 
1.1.3 Perspectives for economic analysis 
Perspective of an analysis refers to the standpoint from which costs and outcomes (or 
consequences or benefits) are realized. Conclusions from economic analyses may vary 
depending on the considered perspective. Healthcare economic evaluations can be conducted 
from a patient, third-party payer, hospital, or a societal perspective21, 22.  Each perspective caters 
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to a different set of decision makers involved in evaluating a new or existing intervention or 
strategy.  The following paragraph briefly details the costs associated with each perspective. 
Typically, the patient perspective includes out-of-pocket expenses for treatment and 
hospitalizations along with lost wages. The overall result of this type of analysis could be 
misleading if there are little or no out-of-pocket expenses. Third party payer's perspective 
includes costs paid by the insurance companies for both inpatient and outpatient treatment. Costs 
such as patient’s out-of-pocket expenses or travel costs for treatment are not included in the third 
party payer’s perspective. Generally, costs paid by insurance companies are believed to be good 
proxies in determining the value of health care products and services.  Hospital perspective 
include the costs that hospitals have to bear due to excess attributable length of stay including 
intensive care unit stay, diagnostic testing, antimicrobial treatment, healthcare worker time, and 
isolation supplies (i.e., gloves, gowns, and masks for contact isolation or private rooms for 
respiratory isolation).  Societal perspective is the most inclusive and accounts for all direct and 
indirect costs associated with a condition. The societal perspective includes all direct inpatient 
and outpatient medical costs as well as indirect costs such as lost wages, productivity losses due 
to death and mortality cost.  
 
1.1.4 Estimating costs 
The economic definition of cost is the value of the best opportunity forgone as a result of 
investing resources in an activity23. Costs can be expressed as average, marginal, incremental, 
fixed or total costs, depending on the research question of interest.  
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Economic evaluation of any novel intervention, strategy or program encompass a variety 
of costs involved in providing and accessing the healthcare services24. Costs can be either 
classified as direct or indirect depending on the way they are incurred. Direct costs comprise of 
resources spent to implement and provide an intervention. Direct costs can be medical or non-
medical costs. Direct medical costs are those that arise directly from the treatment and include 
diagnosis, drug therapy, medical care, in-patient treatment costs, and direct nonmedical costs and 
additional resources that may be required to support the medical services such as travel cost or 
care services. On the other hand, indirect costs include productivity losses resulting from illness 
and premature death.  
Productivity losses can be quantified using the human capital approach or the friction 
cost approach. Human capital approach calculates productivity losses based on the period-related 
income of the patient group concerned. If costs specific to the patient group considered are not 
available, then average labor costs (obtained from official database like Bureau of Labor 
Statistics) can be used.  
Loss of productivity = (Number of days having Incapacity to work x Wage per day) 
The friction cost approach assumes costs of productivity losses to be limited to a certain 
period called the friction period, which is until a patient is replaced by another employee and the 
former production level is restored. For estimating costs, the friction cost approach encompasses 
productivity losses in the friction period and transaction costs (searching for and training the new 
employee). With short-term incapacity for work (within the friction period), part of the workload 
might be performed by colleagues of a patient or made up for by the patient upon their return to 
work. Short-term productivity losses as per the friction cost approach are less than that estimated 
by the human capital approach (about 80 % of labor costs). However long-term losses based on 
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friction cost approach may or may not yield conservative estimates, depending on the long-term 
incapacity and mortality rate associated with the condition. Thus, there is lack of  consensus on 
which approach is best to use25.   
 
1.1.5 Estimating effects 
The choice of estimating the effect of an intervention depends on its indication as well as 
on the research question. The outcome parameters must be selected in advance and justified in 
order to avoid bias. The effects may be measured as number of cases prevented, deaths 
prevented, cases cured, morbidity reduced or any other physiological or biochemical end points. 
Effects can also be defined in terms of duration of a health condition.  Some examples of time-
related effects or outcomes include days spent in hospital, days of incapacity for work, healthy 
life years, QALY. Healthy life years indicate the number of years a person of a certain age is 
expected to live without disability26. QALYs have become a common metric of estimating 
effects since they allow for comparisons across different sectors of healthcare27. QALYs are 
expressed as the multiplicative product of the length of time and the health utility for a particular 
health state.  Utility is the desirability and preference that individuals or societies give to a 
particular state, and is used to reflect quality of life28. Popular methods to assess such preferences 
include the visual analog scale, time trade-off or standard gamble method. Utility values range 
from 0 to 129.  
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1.1.6 Adjustments for time differences 
Inflation 
Inflation refers to the general increase in prices of goods and services over time. Analyses 
need to adjust for this increase when comparing costs through time30. Various indexes have been 
devised to measure different aspects of inflation31. Some commonly used are consumer price 
index (CPI), producer price index (PPI), employment cost index (ECI), and GDP deflator. The 
CPI measures inflation as experienced by consumers in their day-to-day living expenses. It 
reflects spending patterns for all urban consumers and wage earners, and clerical workers. The 
PPI measures inflation at earlier stages of the production process. The PPI measures the average 
change over time in selling prices, from the perspective of domestic producers of goods and 
services. ECI is a quarterly index measuring change in labor costs, that is, average costs per hour 
worked, over time. GDP Deflator measures inflation experienced by both consumers themselves 
as well as governments and other institutions providing goods and services to consumers. The 
choice of inflation index depends on the policy question and its perspective. 
Discounting 
Discounting accounts for the fact individuals have a time preference which determines 
their expenditure and consumption at a given time. It allows for the differential time preferences 
of costs (and benefits) between programmes by weighting all costs (and benefits) in terms of 
their present value32. Individuals prefer consumption at present over consumption in the future 
and expenditure in future over expenditure at present. This preference can be attributed to the 
general uncertainties associated with future33. In the case of costs, inflation might be one of the 
reasons for a given number of dollars having more worth earlier in time. Earlier access to costs 
may enable purchase of assets which would lead to further profits.  Individuals may fear that 
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interventions might not benefit them in long course of time. Also, incomes are expected to 
increase over time which lowers the marginal welfare gain from an additional unit of 
consumption. Thus, individuals are more willing to pay (interest) to consume today rather than 
wait until tomorrow.  
Literature shows discounting of costs is generally well-accepted, however there is less of 
an agreement on discounting health effects and its associated discount rates. Health, unlike 
money is not tradable, which generates varied opinions regarding its discounting.  Equal 
discounting of costs and effects has been supported by many established theories like Weinstein 
and Stason’s consistency thesis34 and Keeler and Cretin’s postponing paradox35. Weinstein and 
Stason state that a steady relation between currency and health benefits exists and discounting 
costs and effects at a different rate may lead to inconsistent results. Also, Keeler and Cretin 
illustrate that if a different rate is used to discount costs and non-monetary effects, then the 
results will favor postponing the health intervention to the future as it will be more profitable 
economically although this might not be ethical. However, critics argue that money value of 
health benefits such as QALYs is not stable but may change over time and infinite postponing 
does not seem to be a relevant option in the real world. Recently, there has been an increasing 
number of advocates for differential discounting, whereby health effects are discounted at a 
different (typically lower) rate than costs36. Differential discount rates can be based on distinct 
aspects of quantities such as the growth rates of national income and healthy life expectancy37. 
Given the current debates about discounting, guidelines recommend transparency in reporting the 
discounting methods used38. 
The discrete time formula for discounting is (expressed in terms of cost here): 
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where r is the discount rate and t is the time period when the cost occurs. Most cost-effectiveness 
studies use an annual discount rate of 3 – 5%24. 
 
1.1.7 Cost-effectiveness analyses 
Economic analyses can be expressed as average, marginal or incremental cost-
effectiveness ratios. Average cost effectiveness ratio (ACER) is calculated by dividing the net 
cost of the intervention by the net change in health outcomes (e.g. total number of health 
outcomes prevented) due to the intervention. ACERs deal with a single intervention. ACERs can 
be used to compare two or more alternatives and guide resource allocation if the alternate 
interventions are independent and mutually compatible. However, a major limitation of ACERs 
is that they are unable to compare the competing health care strategies for the same medical 
problem. Marginal or incremental cost-effectiveness ratios (ICERs) are used to compare 
mutually exclusive strategies39. ICER compares the differences between the costs and health 
outcomes of two alternative interventions that are mutually exclusive. ICER is calculated as the 
ratio of difference in cost (ΔC) and difference in effects (ΔE) between the two interventions and 
describes the additional cost per additional health outcome. The incremental costs and effects can 
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Figure 1-3: Cost effectiveness plane to calculate the incremental cost-effectiveness ratio 
 
The horizontal axis divides the plane according to incremental cost (positive above and 
negative below), and the vertical axis divides the plane according to incremental effect (positive 
to the right and negative to the left) resulting in four quadrants. An intervention resulting in 
lower costs and higher quality (dominant strategy) or in  higher costs and lower quality 
(dominated strategy), is accepted and rejected respectively, without any controversies40.  
However, interventions that lie in the northeast and southwest quadrants involve cost-effect 
trade-offs and their acceptability depends on incremental costs-effectiveness ratio (ICER)41. The 
decision of a strategy being cost-effective depends on the ceiling incremental cost-effectiveness 
ratio.   
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The ICER interpretation gets ambiguous without the knowledge of incremental cost-
effectiveness plane quadrants. A negative ICER can be a result of higher cost and lower quality 
or lower cost and higher quality, which have exactly opposite interpretations. The ICER 
distributions often include both negative and positive values, due to associated uncertainties that 
further add to the ambiguity. Moreover, in the case of multiple comparators, the ICERs along 
with uncertainties are associated with additional complications. Theoretically, for multiple 
comparators, the ICERs are calculated after removing all the dominated (more costly and less 
effective) and the extended dominated (more costly and less effective than a combination of two 
comparators). The remaining options are ordered in an increasing cost order and ICER is 
calculated relative to the option immediately preceding it. However, the uncertainty associated 
with the costs and effectiveness introduces uncertainty in the ranking of programs. A single 
intervention can have non-zero probabilities of being dominated, dominant, dominating its 
comparators, and of being ranked between each possible pair of comparators. Additionally, there 
could be more than one intervention which may have the ICER value less than the specified 
threshold. Thus, the uncertainty regarding the ranking, estimated cost-effectiveness and the cost-
effectiveness of other comparator convolutes interpretation.  
In response to the problems associated with the inference of ICERs, Stinnett et al 
proposed Net Health Benefits (NHB) method for evaluating health interventions given the 





In this formula, and represent the mean effectiveness and the mean costs respectively, of 
treatment Ti;  λ represent the threshold cost-effectiveness ratio. The intervention with the highest 
NHB is considered to be an optimal strategy. 
The $50,000 per QALY threshold, which is based on renal dialysis, has been widely used 
in United States. This value represents the approximate cost of one year of dialysis treatment. 
Under Medicare rules, renal dialysis is a federal entitlement to all United States citizens, and is 
thus considered cost-effective by US standards43.  This threshold, however, is surrounded by 
many controversies. The $50,000 limit has not been reevaluated since 1980s, and using the same 
value might be inappropriate. Although there are no accepted standards, studies commonly use 
$50,000 to $100,000 per QALY as the ceiling cost-effectiveness ratio, beyond which an 
intervention is no longer considered cost-effective44. There has been no scientific justification for 
any one threshold and it is more of a sociopolitical decision rather than a medical one. Moreover, 
the threshold is a dynamic quantity and can change over time. Changes in the optimal price of a 
QALY may depend on inflation as well as complex interactions between social desires to control 
health care costs and the rate of development of new health care technologies43. 
1.1.8 Uncertainty in cost-effectiveness 
The uncertainty associated with cost-effectiveness studies raises concerns on the 
reliability and validity of its results. This uncertainty can be due to uncertainties associated with 
parameters, model or generalizability24. Uncertainty not only affects the cost and effect estimates 
but also the decision consequences45 .   
Parameter uncertainty can be due to sampling variation around estimates of unit costs, 
adherence rates, and the efficacy of an intervention or due to lack of agreement about value 
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judgments (e.g. discount rate) required for the cost-effectiveness analysis. Model uncertainty 
refers to the uncertainty around the appropriate functional form of a model used to estimate a 
particular parameter and the explanatory variables. This usually arises due to structural 
complexities when considering all joint interventions and states24, 46.  Probabilistic and 
deterministic sensitivity analysis can be conducted to reflect the combined implications of 
uncertainty in the parameters (inputs), and to quantify the uncertainty associated with the cost-
effectiveness. In probabilistic sensitivity analysis, model parameters are assigned distributions. 
The model parameters are sampled multiple times from the distribution, and the output is 
recorded for each run (using Monte Carlo method, which involves sampling at random). This 
results in a range of outputs which represents the uncertainty in the inputs. Parameters to which 
the cost-effectiveness decision is sensitive can be identified using deterministic sensitivity 
analysis. Deterministic sensitivity analysis sets each parameter at a plausible value, in turn and 
one at a time. The sensitivity of the decision is determined based on how the cost-effectiveness 
changes with the parameter value. Statistically, ICER confidence intervals are based on the joint 
density of ΔC and ΔE. The confidence intervals can be calculated using parametric (Fieller’s 
method) or non-parametric (bootstrap) methods. Cost effectiveness analysis curves (CEAC) can 
also be used to present uncertainty. The CEAC is derived from the joint distribution of 
incremental costs and incremental effects. CEACs are constructed by plotting the probability that 
an alternative is cost-effective for a range of ceiling ratio values47. 
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2.0  SPECIFIC AIMS 
In this dissertation, I will compare specific interventions, procedures and medications for 
three separate clinical problems. The three specific aims proposed for the dissertation are as 
stated below.  
Specific aim for manuscript 1 
To assess the economic value of using antimicrobial-coated sutures (as compared to 
regular sutures) for abdominal incisions to prevent surgical site infections. This aim used 
decision tree analysis to evaluate the cost-effectiveness of antimicrobial sutures under a variety 
of circumstances. The input parameters for the model were obtained from previously published 
studies and expert opinion.  
Specific aim for manuscript 2 
To compare the clinical and functional outcomes between patients undergoing off-pump 
and on-pump coronary artery bypass grafting (CABG). This aim used data from Bypass 
Angioplasty Revascularization Investigation 2 Diabetes (BARI2D) trial to compare the 
associated clinical and functional outcomes between patients undergoing off-pump and on-pump 
CABG (non-randomized groups). We also performed a cost-effectiveness analysis to compare 
the two types of CABGs. 
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Specific aim for manuscript 3 
To compare the cost-effectiveness of three pharmacotherapy switch options for treating 
depression (bupropion, sertraline and venlaflaxine), after failure of initial treatment with 
citalopram. This aim used data from STAR*D clinical trial to compare the pharmacotherapy 
switch options to which patients could be randomized after initial treatment failure with 
citalopram. 
The following sections introduce the clinical areas for the three specific projects included 
in this dissertation. These sections give an epidemiological overview of the clinical area, discuss 
the published literature concerning with the intervention/procedure/drug of interest and identify 
the research gaps. Also, background of the methodologies used for the specific aims is described 




3.0  BACKGROUND AND LITERATURE REVIEW 
3.1 SURGICAL SITE INFECTION AND TRICLOSAN COATED SUTURE 
3.1.1 Overview of Surgical Site Infections 
Healthcare associated infections (HAIs) affect 5 to 10 percent of hospitalized patients 
annually, and have become a major healthcare problem48. In fact,  HAIs are the fifth leading 
cause of death among hospitalized patients, accounting for almost 99,000 deaths each year49. 
HAIs can impose additional costs ranging from $28 billion to $33 billion each year50.  Also, the 
Deficit Reduction Act released in 2005 does not provide reimbursements for select secondary 
diagnosis including some HAIs that are not present on admissions51, 52. Apart from these direct 
cost penalties, many states have enacted legislations that mandate public reporting of HAIs53. 
Such mandatory public reporting of HAIs would allow consumers to make informed choices 
about their health and healthcare facilities, which would impact the hospital clientele. As of 
December, 2009, 37 states either had passed or had pending legislations regarding public 
reporting of HAIs54. The non-reimbursements and mandatory reporting along with additional 
costs create even a greater impetus for hospitals to have a handle on HAIs and its prevention 
strategies.  
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Surgical Site Infections (SSIs) are the second most common HAIs after urinary tract 
infections49. SSI patients are twice as likely to die, 60% more likely to spend time in an ICU, and 
more than five times more likely to be readmitted55. On average, SSI can extend patient’s length 
of stay by 9.7 days while increasing cost by $20,842 per admission. Nationally SSI cases would 
lead to an additional 406,730 hospital-days and hospital costs exceeding $900 million56, 
imposing a huge burden to the hospitals and society.  
SSIs usually occur within 30 days of operation can be classified into three categories 
depending on the anatomic site of infection: superficial incisional, deep incisional and 
organ/space. Superficial infections involve only the subcutaneous tissues and are characterized 
by pain or tenderness, localized swelling, redness or heat; or purulent drainage; or 
microorganisms isolated from an aseptically obtained fluid/tissues from the incision. Deep 
incisional SSIs involve soft tissues like the fascial and muscle layers of the incision, and have 
purulent drainage. Organ/space SSIs are the most severe ones and can involve any part of the 
anatomy (e.g., organs or spaces) opened or manipulated during the operative procedure. Specific 
sites are assigned to organ/space SSI to further identify the location of the infection57.  
SSI rates vary considerably with the type of the operative wound. Surgical wounds can be 
clean, clean-contaminated, contaminated or dirty-infected depending on the degree of intra-
operative microbial contamination. Clean wounds are those with no inflammation and do not 
involve respiratory, alimentary, genital, or urinary tract.  Clean-Contaminated involve invasion 
into the respiratory, alimentary, genital, or urinary tracts under controlled conditions, without any 
unusual contamination. Specifically, operations involving the biliary tract, appendix, vagina, and 
oropharynx are included in this category, provided no evidence of infection or major break in 
technique occurs during the procedure. Contaminated wounds are the open, fresh, accidental 
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wounds and that may arise from procedures having major breaks in sterile technique for 
surgeries like cardiac or gross spillage from the gastrointestinal tract. Incisions which have acute, 
nonpurulent inflammation are also included in this category. Dirty-infected are old traumatic 
wounds with retained devitalized tissue and those that involve existing clinical infection or 
perforated viscera58.  
3.1.2 Prevention of Surgical Site Infection 
The SSIs have received much-deserved attention with many infection prevention 
initiatives implemented in the past. In 2002, Centers for Medicare and Medicaid Services (CMS) 
collaborated with CDC to implement the national Surgical Infection Prevention (SIP) project to 
reduce morbidity and mortality associated with post-operative infections. SIP promotes 
appropriate selection and timing of prophylactic antimicrobials. Specifically SIP measures 
include administrating the prophylactic agent within 60 minutes prior to incision, selecting a 
suitable, safe and narrow spectrum agent, and discontinuing the prophylactic antibiotics within 
24 h after end of surgery59. In 2003, CMC and CDC representatives met with the VA, the 
American College of Surgeons, the American Society of Anesthesiologists, the Agency for 
Healthcare Research and Quality, the American Hospital Association and the institute for 
Healthcare Improvement to further refine SIP. This resulted in the emergence of Surgical Care 
Improvement Project (SCIP). SCIP was implemented in 2006 with a aim to achieve 25% 
reduction in post-operative complications by 201060. SCIP measures include proper hair removal 
from surgery region, blood glucose control in cardiac surgery patients, and maintenance of 
normothermia in addition to the original SIP measures, to effectively reduce surgical site 
infection. Also, this initiative requires facilities to achieve 95% compliance with each of the 
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process measures in order to avoid penalty of 2% reduction in CMS reimbursements61. Studies 
discussing the impact and success of the SCIP project reflect mixed findings. Rosenberger et al 
reviewed numerous studies evaluating SCIP measures62-64 and concluded that implementing 
standardized practices reduce SSI risk60.  One other retrospective study comparing pre and post-
SCIP guidelines implementation SSI rates, supported the SCIP measures. The authors observed 
that when their institution had low SCIP compliance (38%), their institutional superficial SSI 
rates were significantly higher than the national rates (13.3% vs 9.7%) with 38% SCIP 
compliance. However, when the SCIP measures compliance increased to 92% the SSI rates at 
their institution decreased to 8.3% and were comparable to the national rates65.  Many other 
studies do not report significant benefits of SCIP measures. Pastor et al. reported no significant 
reduction of SSI rates among patients undergoing colorectal surgery even when compliance with 
the SCIP measures was increased from 40% to 68%66. Another study concluded that though 
adherence as a composite score of all or no SCIP measures was associated with a lower 
probability of developing post-operative infections, adherence to individual SCIP measures did 
not affect the infection rate67. Many others have also questioned the SCIP measures as 
determinants of reimbursement rates and means to reduce SSIs68, 69.  Also, it is reported that the 
current evidence-based strategies are able to prevent only 55% of SSIs70. This cumulatively 
implies that existing practices might not be sufficient for preventing SSI, and thus new adjunct 
strategies are required to effectively prevent SSIs. 
3.1.3 Triclosan-coated Sutures to Prevent Surgical Site Infection 
The role of suture material in development of wound infection has been under 
speculation since many years71. Studies have shown that bacteria adhere to surgical sutures and 
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that the extent of bacterial adherence is highly dependent on the suture material. The adhered 
microbes form colonies and eventually a biofilm which can increase SSI risk. The bacterial 
biofilm is usually difficult to disrupt as it confers immunity from the antimicrobial treatment and 
the immune system72.  Antimicrobial coating on sutures can prevent the microbial adherence and 
hence reduce SSI development. Triclosan (2, 4, 4-trichloro-2-hydroxydiphenyl ether) is a stable, 
synthetic, polychlorinated, aromatic hydrocarbon with broad, antimicrobial properties and  an 
established safety profile73. Triclosan has also found its niche in surgical sutures. Presently, there 
are three commercially triclosan-coated sutures available: Monocryl Plus (poliglecaprone 25 
suture), Coated Vicryl Plus Antibacterial (polyglactin 910 suture), and PDS Plus antibacterial 
(polydioxanone suture). In vitro studies have shown that these triclosan coated sutures are 
effective against common surgical site bacteria like Staphylococcus aureus, Staphylococcus 
epidermidis, Methicillin-resistant S aureus (MRSA), Methicillin-resistant S epidermidis 
(MRSE), Escherichia coli, and Klebsiella pneumonia74-76.  
There have been several clinical studies published in the past few years which evaluate 
the antimicrobial sutures. The published studies report varied efficacy and effectiveness of 
triclosan coated sutures to prevent SSI. This variation can possibly be due to differences in 
studies regarding the type of surgery, study design, sample size, incision closure method, SSI 
definition, country or other external factors. In a nonrandomized study, Justinger et al showed 
that using triclosan coated sutures lowered SSI rates by more than 50% for patients undergoing 
abdominal incisions77.   Many other randomized clinical trials conducted across the world also 
support the use of these triclosan coated sutures. Rasic et al conducted a randomized un-blinded 
study which showed that patients undergoing elective colorectal cancer surgery had a 
significantly lower SSI rates (4.3% vs 13.2%) when operated using coated vicryl sutures78. 
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Another double blind trial showed that using triclosan-coated PDS suture lowered the odds of 
developing a wound infection in abdominal surgery to 0.501 (95% confidence interval 0.3–0.9, P 
< .05)79 .  Galal et al conducted a randomized prospective multicenter study for patients 
undergoing any surgery and reported significant differences in SSI rates between triclosan coated 
and uncoated sutures (7% versus 15%)80.  Recently, Nakumera et al conducted a randomized 
clinical trial showed that triclosan coated sutures are effective for preventing SSIs after 
colorectal surgery and also cost saving (saving upto $40,219 during the study period of 30 days). 
However, this estimate is based on results from just one controlled study conducted in Japan81. 
Apart from these studies demonstrating beneficial effects of triclosan coated sutures, one 
multicenter study did not find any beneficial effects of triclosan coated sutures82. The authors 
concluded that abdominal wall closure with looped polydiaxenine had lower SSI rates, 
independent of whether the suture was coated or uncoated. Triclosan coated sutures are shown to 
be effective even for cerebrospinal shunt and breast surgeries70, 83, 84. Initial results for SSI 
prevention among patients undergoing cardiac vascular surgeries do not indicate additional 
benefits of triclosan coated sutures, which could be because such surgeries have a sterile 
environment85-87.  Two recent meta-analysis also support the use the triclosan coated sutures, in 
spite of the included studies reporting a wide range of effectiveness for the coated-sutures88, 89.  
Thus, there is clearly a growing evidence of clinical benefits of using triclosan coated 
sutures. However, triclosan coated sutures are almost 40% more expensive than regular sutures 
which may limit their adoption into practice.  We aim to evaluate the cost-effectiveness of using 
triclosan coated sutures for abdominal incisions among adults, which is associated with a high 
SSI rate90.   
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3.1.4 Methods Used 
Decision analytic modeling is a systematic approach to decision making under uncertain 
conditions91. It allows comparison of expected consequences of different strategies after 
considering the relevant events and complication with their probabilities and accordingly 
weighting the outcomes and costs. A decision analytic model uses a logical mathematical 
framework that integrates health outcomes and costs which follow alternative courses of action. 
These models are often built as trees that allow visual representation of all the possible options 
and the consequences following each option. Decision trees are typically built from left to right, 
starting with a decision node (denoted by a square) to represent the decision question. Each 
alternative action is followed by branches representing the possible events with their respective 
probabilities at the chance nodes (denoted by circle). Probabilities and associated outcomes may 
depend on the different strategies and the patient characteristics (e.g. age). At the end of the tree 
each path leads to an outcome, such as symptoms, clinical score, survival, and death. The end 
points of each pathway are denoted by terminal nodes (triangular symbols) to which values or 
pay-offs, such as costs, life years, or QALYs can be assigned. For each alternative action the 
expected value of the clinical outcome can be calculated as a weighted average of all possible 
outcomes, applying the path probabilities as weights92. 
We developed a decision tree using TreeAge software to simulate the decision of 
choosing triclosan-coated sutures versus the standard uncoated sutures for adult patients 
undergoing abdominal surgeries (TreeAge software Inc, Williamstown, Massachusetts developed 
this software that allows visual modeling of decision trees and can support markov models, cost-
effectiveness analysis, net benefits, healthcare reporting and patient-specific simulations).  
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Each patient in the model underwent an abdominal surgery and had a probability of 
developing superficial SSI, deep SSI. The probability of developing superficial or deep SSI was 
based on the risk of SSI and the probability of it being deep or superficial.  Each type of SSI 
could either be mild/moderate or severe, which determined the treatment. The duration of 
hospitalization attributable and finally the probability of death depended on the type of SSI. Each 
of the pathways had the associated cost specific to each perspective. Extensive literature review 
and expert opinion determined the input parameters of the model. Separate analyses were carried 
out from hospital, third party payer, and societal perspectives to determine the economic benefits 
of using antimicrobial-coated sutures.   
The results of any decision analytical model are influenced by random variability, 
uncertainty in the parameters, patient heterogeneity and structural uncertainty. These 
uncertainties must be handled appropriately or reflected in the results93-95.   
The individual variability in decision trees is reflected by using random numbers when 
determining whether an event with a given probability of occurring happens or not in any given 
cycle or model run. This individual patient variability is also called stochastic or first order 
uncertainty. A first-order Monte Carlo analysis simulates subjects one by one to determine the 
individual’s path. Probabilities at chance nodes and random number generator result in a 
subject’s path along the chance nodes. This path is called a random walk or a trial. This accounts 
for the variability due to an identical patient experiencing different outcomes. The first-order 
uncertainty is usually eliminated by running the model repeatedly until a stable estimate is 
obtained.  
Secondly, there is always some uncertainty and imprecision surrounding the value of 
model variables such as transition probabilities, costs, and health utilities. The uncertainty about 
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the parameter values can be represented by probability distributions in the model. This is 
commonly referred as the second-order uncertainty or probabilistic sensitivity analysis (PSA). 
PSA involves randomly drawing a value for each parameter from its probability distribution, 
generating a set of values commonly referred to as a sample. 
In our model, we accounted for random variability along with parameter uncertainty; we 
parameterized the distributions in the model representing the first-order variability by sampling 
each distribution per individual. Monte Carlo simulation used dynamic information from the 
computer’s clock to initialize a sequence of pseudo-random numbers. Also, sensitivity analyses 
systematically varied the risk of developing an SSI (range: 5% - 20%), the cost of tricolsan 
coated sutures (range: $5 - $25 per inch), and the efficacy of tricolsan suture to prevent infection 
(range: 5% - 50%). Experts speculate that antimicrobial coated sutures will be more effective in 
preventing superficial SSI as compared to deep SSIs, so we also varied the efficacy of preventing 
superficial (range: 10% – 50%) and deep SSIs (range: 5 – 20%) differentially. 
Additional method details and results are presented in the manuscript 1.
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 3.2 CABG SURGERY AMONG DIABETIC PATIENTS 
3.2.1 Coronary Artery Disease among Diabetics 
The prevalence of diabetes is increasing at an epidemic rate worldwide. The number of 
people with diabetes is projected to rise from 171 million in 2000 to 366 million in 203096. 
Diabetes patients have many complications including amputation, lower extremity infection, 
gangrene, blindness, acute myocardial infarction, ischemic heart disease, stroke, and metabolic 
disorders97. Diabetes has been shown to be a major risk factor for cardiovascular disease in 
numerous studies. The risk of having cardiovascular disease is almost two to four times higher 
among individuals with diabetes as compared to those without diabetes98-100. This association 
between diabetes and cardiovascular disease persists even after adjusting for many 
cardiovascular risk factors like age, cholesterol level, systolic blood pressure and tobacco use. 
Coronary artery disease among diabetic individuals is more severe, diffused and is associated 
with a higher atherosclerotic burden and inadequate compensatory remodeling of the arterial 
wall101-103.  Diabetes and cardiovascular disease, both, impose an enormous burden on the 
society104, 105. Many interventions like cardiovascular risk factor control, glycemic risk factor 
control, screening for diabetes complications, have been introduced to reduce the burden of 
diabetes and cardiovascular disease99. Never the less, the prevalence of cardiovascular disease 
among patients with diabetes continues to be high. As a corollary, diabetes has become 
disproportionately represented in patients having cardiovascular disease. 
28 
3.2.2 Coronary artery bypass grafting: On-pump and Off-pump 
Coronary artery bypass grafting (CABG) is commonly performed for patients with severe 
coronary artery disease. CABG, first performed by Kolesov in  1967106, even today,  is one of the 
leading heart operations. According to the National Hospital Discharge Survey (NHDS), almost 
232,000 patients in US underwent a total of 408,000 coronary artery bypass procedures in 
2007107.  Specifically, the percentage of patients undergoing CABG having diabetes has 
increased from 16.7% in 1988 - 1990 to 33.9% in 2003 - 2005108. CABG involves strategic 
placement of bypass grafts that provide an alternative route for the blood to circumvent the 
blockage. Arteries and veins from patient’s body, which can be removed from their primary 
location without harming or disrupting any of the other body functionalities, are often used as 
bypass grafts.  These blood vessels are grafted onto a blood supply source (mostly the aorta) and 
then in turn onto the coronary artery in a location beyond the blockage109.  CABG can either be 
performed as an on-pump or off-pump strategy. On-pump CABG is often considered to be the 
gold standard and uses cardiopulmonary bypass (CPB) with cardioplegia arrest. Off-pump 








On-pump CABG commonly results in myocardial ischemic injury, neurocognitive 
deficits, strokes, and activates other inflammatory pathways that may contribute to pulmonary, 
renal, and hematologic complications110-112. Advocates believe that performing the off-pump 
CABG may decrease the post-procedure morbidity, mortality, and costs by eliminating CPB and 
hence reducing the detrimental effects associated with it. Although several randomized 
controlled trials, prospective and observational studies have compared on-pump and off-pump 
CABGs, the optimal surgical strategy remains in question113-120.  A large randomized controlled 
trial including patients with mixed operative risk profile compared the off-pump and on-pump 
CABG with respect to outcomes at 30-days and at 1 year121.  The results of the trial showed that 
the composite outcome (death and complications) rate was not significantly different at 30 days, 
however the rate at 1 year was significantly higher for off-pump patients. A few other studies 
support favorable short-term outcomes with off-pump CABGs; however such beneficial effects 
do not persist when considering long-term outcomes122-124.  Also, studies suggesting that off-
pump CABG is comparable to  on-pump in terms of complete revascularization and graft 
patency125-127  have been questioned by reports of inferior graft patency and higher rates of repeat 
target-vessel revascularization associated with off-pump CABG128-130.   Adverse neurologic 
outcome rates have also been reported to be similar between the two procedures120, 131, 132. The 
randomized controlled trials for comparison of the two types of CABGs, have been criticized for 
their strict patient inclusion/exclusion criteria and that the randomization process may require the 
surgeons and health centers to perform the assigned procedure even if they are not comfortable 
with it. Many observational and prospective studies, in contrary to randomized trials, show that 
off-pump strategy have a beneficial impact on patient mortality and morbidity114-118.  A recent 
retrospective study including patients who underwent CABG between 2005 - 2010 in the Society 
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of Thoracic Surgeons (STS) national database, showed that off-pump procedure had significantly 
fewer adverse events of death, stroke, renal failure, and prolonged length of stay as compared to 
on-pump procedure, after adjusting for patient risk factors, center and surgeon identity133. 
Observational studies of course have the potential for confounding factors or treatment selection 
bias.  
There is ongoing debate regarding the use of off-pump CABG over on-pump CABG. 
Most of the above described studies include patients with low or moderate risks of complications 
after CABG. Initial evidence suggests that off-pump strategy might be of maximum benefit to 
high risk patients134. Two recent trials, namely  Danish On-Pump Versus Off-Pump 
Randomization Study (DOORS) 135 and German Off-Pump Coronary Artery Bypass Grafting in 
Elderly (GOPABE)136  included only elderly patients. Elderly patients are a subgroup of people 
who have higher risk of adverse outcomes after surgery. Both the trials showed no significant 
difference in the outcomes of death, myocardial infarction or stroke between off-pump and on-
pump surgeries. Although DOORS trial observed trends towards fewer strokes and more 
myocardial infarctions in the off-pump group, the differences were not significant. In GOPABE 
trial, repeat revascularization within 30 days was more common among patients undergoing off-
pump CABG in comparison to those undergoing on-pump CABG; however this difference was 
not significant at 12 months after surgery. Another recent study, though single institution had 
over 5000 patients, evaluated the long-term outcomes of patients undergoing on-pump and off-
pump CABG137. This study showed that patients undergoing off-pump procedure had a 
significantly higher risk of mortality as compared to those undergoing on-pump procedure. 
Diabetic patients have a different cardiovascular disease profile and a higher risk of 
adverse events after surgery. In the studies described above, patients with diabetes form only a 
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fraction of the sample population. To date, there are no randomized controlled trials comparing 
effects of off-pump and on-pump strategies in diabetic individuals with coronary artery disease. 
The limited comparative data available are based on retrospective, observational, non-
randomized studies and continue to be controversial.  A retrospective review of STS data for 
diabetic patients undergoing CABG during the years 1995 to 1999 showed no significant 
differences in mortality (2.89% versus 3.69%, p = 0.452) between the off-pump and on-pump 
surgeries. However, the patients undergoing off-pump CABG had fewer complications, 
including decreased blood product use (34.39% versus 58.4%, p = 0.001), reduced incidence of 
prolonged ventilation (6.94% versus 12.10%, p = 0.005), atrial fibrillation (15.90% versus 
23.26%, p = 0.002), and renal failure requiring dialysis (0.87% versus 2.75%, p = 0.036)138.  
Another retrospective analysis, which identified diabetes patients undergoing CABG during 
April 1997 – Sept 2002 from a cardiothoracic center, had similar conclusions as the previous 
STS review. The results showed that although the in-hospital mortality (2.1% versus 3.7%, p = 
0.25) was not significantly different between the off-pump and on-pump groups, patients 
undergoing off-pump procedure had fewer post-operative complications like stroke (OR 0.15; 
95% CI 0.02 - 0.96; p = 0.039) , renal failure (OR 0.38; 95% CI 0.16 - 0.94; p = 0.036) and 
required lesser blood transfusion (OR 0.21 ; 95% CI 0.14 – 0.32; p<0.0001) 139.  
A recent retrospective study comparing off-pump and on-pump strategy among 
individuals with diabetes, however showed survival benefits on using the off-pump procedure140. 
In this study, patients undergoing off-pump CABG had a significantly lower mortality rate (OR 
= 0.11; CI 95% 0.01–0.68; p=0.018) as well lower odds of non-cardiac complications (including 
respiratory failure, renal failure, and thoracotomy compositely) (OR =0.46; CI 95% 0.35–0.91; 
p<0.001) as compared to those undergoing on-pump CABG. Cardiac complications such as 
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stroke, reoperation for bleeding, postoperative intra-aortic balloon pump implantation were also 
less frequent in the off-pump group, though the differences were not statistically significant. It 
should be noted that in most of the studies described above, the time to event was not clearly 
specified. Only one recent observational study defined time periods (30 days, 6 months and 1 
year) to compare mortality rates between off-pump and on-pump procedures141. The study 
showed that off-pump CABG was associated with a significantly lower 30-day mortality rate 
(OR 0.09; 95% CI: 0.01 - 0.70; p = 0.021). The analyses revealed survival benefits on using off-
pump strategy even at 6 months (HR 0.27 [95% CI: 0.12 to 0.61] p = 0.002) and 1 year (HR= 
0.40 [95% CI: 0.22 to 0.75] p = 0.004) after surgery.  The study also found off-pump CABGs to 
have fewer neurologic complications and less frequent hemofiltration until discharge. However, 
this study was limited to a single center and did not include long-term outcomes.   
Overall, the current evidence is not sufficient to draw conclusions regarding the 
superiority of off-pump procedure among diabetic individuals. Moreover, none of the studies 
have compared the economic impact of using off-pump and on-pump procedures among diabetic 
patients. This study aims to fill the dearth of comparative data between the two procedures. The 
analyses will compare clinical and functional outcomes for diabetic patients undergoing off-
pump and on-pump surgeries.  
3.2.3 Methods Used 
Sample Population 
This aim uses data from Bypass Angioplasty Revascularization Investigation 2 Diabetes 
(BARI2D). BARI2D was a 2X2 factorial design clinical trial which included 2,368 patients with 
type 2 diabetes and angiographically documented coronary artery disease. Randomization was 
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stratified by the intended revascularization method (i.e. whether a patient was more suitable for 
CABG or percutaneous coronary intervention (PCI), determined by the individual site 
physicians). After stratification, the eligible patients were randomly assigned to either prompt 
revascularization or medical therapy within each stratum. Simultaneously, the patients were 
randomly assigned to either insulin sensitization or insulin provision therapy to achieve a target 
HbA1c < 7.0%. Trial participants were enrolled starting January 1, 2001 to March 31, 2005 from 
49 sites across 6 countries including United States, Canada, Brazil, Mexico, the Czech Republic 
and Austria.  This analysis focused on BARI2D patients who underwent a CABG procedure 
irrespective of their intended method revascularization and assigned treatments. In the case that a 
patient had more than one CABG, the index CABG within the trial was considered for all 
evaluations and comparisons. The surgery could either be performed as an on-pump or off-pump 
procedure. The decision to perform an off-pump versus an on-pump procedure in the trial was 
based on clinical site practice patterns, individual surgeon preference, clinical characteristics of 
the patient, and the perceived target quality. This aim will compare clinical and functional 
outcomes between patients undergoing off-pump and on-pump CABG.  
 
Statistical Analyses 
This study compares two nonrandomized groups from the BARI 2D trial, namely the off-
pump and on-pump group. Summary statistics for the baseline characteristics are presented as 
means and standard deviation in case of continuous variables, and as numbers and percentages in 
case of categorical variables. The continuous variables were compared using Wilcoxon rank-sum 
test and categorical variables using chi-square or Fischer’s exact, where appropriate.   
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The clinical outcomes (over the period of four years) were evaluated using Kaplan-Meier 
curves with log-rank statistics and multivariate Cox proportional hazard regression models. Two 
approaches were undertaken to evaluate the clinical outcomes of death and death/MI/stroke: 1) 
standard multivariate regression and 2) propensity score analysis. 
 
Multivariable Cox Regression Model 
The Cox proportional hazard regression models are commonly used for time-to-event 
analyses. Such analyses have an advantage of including censored data. Cox proportional hazard 
models provide an estimate of the ratio of hazards of two groups. The candidate variables for 
models for each of the two outcomes included those baseline variables that were significantly 
different between the off-pump and on-pump group (alpha = 0.05). The final models were 
determined by backward selection algorithm. We tested the proportional-hazard assumption for 
the cox regression model. 
 
Propensity Score Analysis 
Propensity score methodology was used to account for the imbalances between the off-
pump and on-pump group that may be present due to non-randomization of the procedure. 
Propensity scores for each patient were calculated using multivariable logistic regression model. 
The propensity scores represented the conditional probability that a patient would undergo an 
off-pump given his/her preoperative characteristics. Three commonly used propensity scores 
methodology for cardiovascular research are: stratification, covariate adjustment, and matching.  
We used propensity score matching method to obtain a balanced sample for comparing the off-
pump and on-pump group. The following text describes the propensity score techniques briefly.  
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Creation of Propensity Score Model: 
Propensity scores are most commonly estimated using binomial logistic regression model 
where the treatment selected is the outcome measure. Other methods such as the probit models, 
classification tress, neural networks and recursive partitioning can also be used for calculating 
the propensity scores. The basic rule for covariate selection for any of the methods is that a 
liberal criterion should be used to identify the factors that lead to treatment selection choice and 
are related to the outcome. 
 
Stratification based on Propensity Scores: 
Stratification involves dividing individuals into groups or strata based on their propensity 
score values. The optimal number of strata depends on the sample size and the amount of overlap 
between the treatment and control groups’ propensity scores. However, Rosenbaum and Rubin 
have demonstrated that stratifying on the quintiles of the estimated propensity score eliminates 
approximately 90 per cent of the bias due to the observed covariates142. The basic principle of 
stratification is that the treated and untreated subjects will have roughly similar values of the 
propensity score within each stratum. The average treatment effect can be estimated by a 
weighting average of the within-strata estimates of the effect of the exposure, with proportion of 
subjects who are within that stratum. Alternately, the average treatment effect among the treated 
can be estimated by weighting the strata by the fraction of the exposed in each strata143, 144.  
 
Matching based on Propensity Scores: 
Matching on propensity score allows one to obtain groups of treatment and control 
subjects by matching individual observations which have similar distribution of measured 
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baseline variables. Typically, 1:1 nearest neighbor matching within a specified caliper width is 
used. By this method, treated subjects are randomly sorted and matched to the untreated subject 
with the closest propensity score within a specified range (the caliper width). If the algorithm is 
unable to find a match within a specified caliper width of the treated subject’s propensity score, 
then that treated subject is left unmatched and is not used in subsequent analyses. Matching 
without replacement is usually employed. The propensity score–matched sample cannot be 
assumed to consist of independent observations, as the treated and untreated subjects within the 
same matched pair would be more similar than two randomly selected treated and untreated 
subjects. Thus any analyses within the propensity matched sample should account for the within-
pair homogeneity143, 145.  The results obtained from the propensity score matched sample 
estimate the average treatment effect among the treated. 
 
Covariate Adjustment: 
Propensity scores can also be used as a covariate in a regression model. The choice of 
regression model depends on the nature of the outcome. The treatment effect may be estimated 
by adjusted difference in means/odds ratio/hazard ratio depending on the outcome type. This 
method assumes that the relationship between the propensity score and the outcome has been 
correctly modeled. The average treatment effect and the average treatment effect among the 
treated can be estimated by evaluating the exposure effect at sample mean and the sample mean 





Propensity Score Matching Compared to Other Propensity Score Methodologies 
Propensity score matching is increasingly gaining popularity for analyzing observational 
data. Propensity score matching allows direct comparison of the treated and untreated subject 
within a sample which has reduced or no baseline differences. Propensity score matching results 
in the elimination of a greater degree of systematic differences between treated and untreated 
subjects as compared to the stratification methodology. Also, when matching on propensity 
scores, one can check if the propensity score model has been adequately specified by confirming 
that the treated and untreated subjects have similar distribution of measured baseline variables. 
However, this is unclear when propensity scores as used as a covariate.   Covariate adjustment 
using the propensity score is a model-based approach and thus requires the assumption that the 
outcomes model is correctly specified.  
Propensity Assumptions 
Propensity score analyses have some underlying assumptions. The first assumption is that 
the treatment assignment should temporally precede the effect. Secondly, every subject should 
have a non-zero probability to receive either treatment. Also propensity score analyses assume 
that the outcomes from two individuals, irrespective of their treatment assignment, are 
independent from each other. Finally, these analyses require that the assigned treatment is 
independent of the potential outcome, given the observed baseline covariates, i.e. there are no 
unmeasured confounders that can affect the treatment assignment or outcome. 
Additional methods and results comparing the outcomes between patients undergoing 
off-pump and on-pump are presented in manuscript 2. 
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3.2.4 Methods Used in Cost-effectiveness Addendum 
We conducted an economic analysis to compare the cost-effectiveness of off-pump and 
on-pump among patients who had CABG as their index procedure and had 2 years of potential 
follow-up data.  A separate set of propensity scores was calculated to balance the baseline 
characteristics in this subset of patients. Analyses were conducted from hospital and third party 
payer perspective. We assessed cost-effectiveness in terms of the net health benefits. Non 
parametric bootstrap technique was used to reflect the uncertainty associated with the analyses. 
The bootstrap method involved estimating the sampling distribution of a statistic through a large 
number of simulations, based on sampling with replacement from the original data. The 
advantage of bootstrap technique is that it does not rely on the parametric assumptions of the 
distribution. Confidence intervals can be estimated using the empirical estimate of the sampling 
distribution146. The bootstrapping involved resampling the patients undergoing off-pump and on-
pump separately. The cost and effects for were sampled jointly, and the mean cost and effect 
estimates from each of the two groups were used to calculate the required NHBs. Also, after 
1000 bootstrap replications, the probability that off-pump is the optimum strategy was calculated 
as the percentage of iterations for which Ti is estimated to have the highest average NHB. 
Additional methods and results comparing the cost-effectiveness of off-pump versus on-
pump procedure are presented in manuscript 2 addendum . 
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3.3 MAJOR DEPRESSION DISORDER AND SECOND-LINE ANTIDEPRESSANTS  
3.3.1 Overview of Major Depressive Disorder 
The global burden of depressive disorders is continuing to increase due to population 
growth and higher life expectancy. Major depressive disorder (MDD) is a widespread medical 
illness, affecting 15 million American adults, i.e. approximately 5-8 percent of the adult 
population in a given year147.  According to the Composite International Diagnostic Interview 
(CIDI) scores,  MDD has a life time prevalence of 16.2% (95% confidence interval: 15.1-17.3),  
equivalent to a population projections of 32.6 to 35.1 million US adults148. Women are almost 
twice as likely to suffer from depression than males, with the lifetime prevalence ranging from 
10 – 25% among females and the prevalence of 5 – 12% among males149. Also, MDD typically 
is a recurrent condition, with 50 – 85% of MDD patients suffering from a subsequent episode150.  
The common symptoms of depression include persistently sad or irritable mood, 
pronounced changes in sleep, appetite and energy, difficulty thinking, concentrating and 
remembering, physical slowing or agitation, lack of interest in leisure activities, feelings of guilt, 
worthlessness, hopelessness and emptiness, recurrent thoughts of death or suicide, persistent 
physical symptoms that do not respond to treatment, such as headaches, digestive disorders and 
chronic pain. MDD is in fact one of the leading cause of disability. Depressive disorders can 
result in 65.5 million disability adjusted life years (DALYs) and are responsible for about 4.3% 
of total DALYs151. A recent systematic review showed that MDD was the second leading cause 
of years lived with disability (YLD) , accounting for 8.2% of YLDs in 2010152. The largest 
proportion of YLDs from depressive disorders occurred among adults of working age. MDD also 
resulted in substantial disability adjusted life years (DALYs) accounting for 2.5% (1.9% - 3.2%) 
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global DALYs. Moreover, in their analyses MDD explained an additional 16 million DALYs 
and 4 million DALYs when it was considered as a risk factor for suicide and ischemic heart 
disease, respectively, thus increasing the overall burden of depressive disorders to 3.8% of global 
DALYs. Overall, MDD is associated with significant social, educational, and vocational 
impairment, high utilization health care services; and increased morbidity and mortality153. MDD 
can cause over $44 billion/year including direct and indirect costs. Depressed patients incur 
almost twice the annual health care costs of that by patients lacking depression154. 
Appropriate treatment of depression is essential. An untreated depression episode can last 
approximately 6 months and in 20% of cases it can even extend to 2 years or more.  Also, when 
the major depressive episode remits without treatment, 20% to 30% of patients retain residual 
symptoms, which can be distressing and associated with disability.  
There are many options available to treat MDD, including pharmacotherapy and 
psychotherapy. Pharamacotherapy aims to achieve the chemical balance between the 
neurotransmitters, disruption of which is often believed to be the biological cause of depression. 
Antidepressants usually work by increasing the availability of neurotransmitters or by changing 
the sensitivity of the receptors for these chemical messengers. Almost 50% to 70% of patients 
respond (usually defined as a ≥50% decrease in depressive symptoms) to the first choice of 
antidepressants155. However, only 50 – 70% of those who respond achieve full remission156, 157 . 
Thus, a proportion of patients continue to have residual depression symptoms despite apparently 
adequate antidepressant therapy. Treatment-resistant depression (TRD) is defined as the failure 
to achieve full remission with an antidepressant used at an adequate dose and duration. TRD is 
associated with 40% higher costs 158. When patients have such treatment resistant depression, 
they should be switched to or augmented with another treatment.  
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3.3.2 Cost-effectiveness of Second-Line Antidepressants 
Though there have been studies evaluating efficacy and tolerability of antidepressant 
medications, data on cost-effectiveness comparing the treatments remain limited. The growing 
burden of depression and the range of choices available warrant an economic analysis to identify 
the cost-effective treatment option to treat depression159.  Most of the existing economic 
evaluations for depression treatment focus on the first-line treatment options, though some do 
consider switch, titration and augmentation in their calculations160.  These studies offer valuable 
insight, however decision on which second line treatment to choose remains ambiguous. 
The literature on economic analyses of second-line treatment options for MDD remains 
sparse. There are two cost analyses studies which used administrative databases to compare 
second-line therapies for MDD.  Both studies showed that the costs associated with various 
second-line therapies were not significantly different161, 162, although one of them revealed 
differences in depression-coded expenditures between SSRI and tricyclic antidepressant therapy 
even after adjusting for baseline characteristics162. However, these were observational studies 
and the authors indicated that there might be differences in medication prescribing patterns for 
various drugs which can affect the outcomes and/or costs.  
Also, two recently published studies use computational models to evaluate second-line 
MDD treatment options. One of the studies developed a decision analysis model to compare 
generic SSRIs consisting of citalopram, fluoxetine, and paroxetine; escitalopram (Lexapro); 
paroxetine CR (Paxil CR); sertraline (Zoloft); and venlafaxine XR (Effexor XR) 163. The study 
reported generic SSRI to have the lowest cost per patient while venlafaxine was the most 
favorable option in terms of costs per patient achieving remission. However, this study obtained 
costs data from an observational study which included patients from a single prepaid health plan 
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and also did not consider differences in side effect profiles between various agents. Another 
modeling study used STAR*D clinical data to compare the cost-effects of sertraline and 
venlafaxine after initial failure with SSRI in Thailand settings164. The generalizability of both the 
studies is questionable. Also, none of the studies have appropriately represented the uncertainty 
of the cost-effective analyses. To the best of our knowledge there have been no studies 
simultaneously comparing the cost-effectiveness of the three switch options (Bupropion-SR, 
Sertraline or Venlafaxine-XR) after initial SSRI treatment failure. This aim will use STAR*D 
data to determine optimum switch option after initial failure with SSRI based on cost-
effectiveness. The STAR*D trial design and previously published effectiveness results for the 
level 2 pharmacotherapy switch options are briefly described below. 
3.3.3 STAR*D Trial 
The STAR*D trial was designed to evaluate the relative efficacy and tolerability of 
various antidepressant treatment for outpatient with nonpsychotic major depressive disorder, 
who failed the initial selective serotonin –reuptake inhibitor (SSRI) or subsequent treatments.  
The STAR*D trial was designed to evaluate the relative efficacy and tolerability of 
various antidepressant treatment for outpatients with nonpsychotic major depressive disorder, 
who failed the initial selective serotonin –reuptake inhibitor (SSRI) or subsequent treatments. It 
is a multisite, equipoise randomized, multistep clinical trial. The patients in the trial were 
initiated on a SSRI (citalopram) and those who failed this initial therapy entered level 2 of the 
trial. At Level 1 of the trial, Citalopram dosing was recommended to start at 20 mg/day,  could 
be raised to 40 mg/day by week 4 and to 60 mg/day (final dose) by day 42 (week 6) depending 
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on the dose duration, symptom changes, and side effect burden. Appropriate flexibility was 
allowed in the regimen.  
At level 2 of the trial, patients could be randomized to one of the seven different 
treatments including four switch options (venlafaxine, sertraline, bupropion, and cognitive 
therapy) and three augment options (bupropion, buspirone or cognitive therapy added to CIT). In 
this analysis, we focus on the patients on the patients who were switched to pharmacotherapy 
(venlafaxine, sertraline, bupropion ) after initial failure with Citalopram. 
 
Patient Enrollment; Inclusion and Exclusion Criteria 
Patients in the trial were enrolled from primary psychiatric public and private practice 
settings during July 2001 – August 2004156, 165.  The study used a broad inclusion and exclusion 
criteria, including patients aged 18 – 75 year who had a score greater or equal to 14 on Hamilton 
Rating Scale of Depression (HRSD – 17) and had single or recurrent nonpsychotic MDD by the 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Patients were excluded if they 
had a history of bipolar disorder, schizophrenia, schizoaffective disorder, current anorexia, 
bulimia or primary compulsive disorder or a psychosis otherwise not specified. Patients who had 
a history of clear cut intolerability to, or lack of effect with, an adequate trial of at least one of 
the protocol medications, lack of response to 16 or more sessions of cognitive therapy 7 or more 
sessions of electroconvulsive therapy or if they  had already been taking citalopram for more 
than 7 days at the time of enrollment were also not included. Other than this, only pregnant 
women and patients with general medical conditions that contraindicated the use of medications 
used in the first 2 levels of study and substance dependence requiring immediate detoxification, 
or those who required immediate hospitalization were excluded.   
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Determination of Movement to Next Level or Follow-up 
The decision to move to follow-up phase or the next level depended on clinical judgment 
which was based on remission, intolerance and non-response. The remission and response was 
informed by the Quick Inventory of Depressive Symptomatology – Clinician Rating (QIDS-C16) 
and obtained at each treatment visit.  
Remission (the absence of depressive symptoms) was defined as ≤5 on the QIDS-C16, 
while response without remission is a ≥ 50% reduction in baseline QIDS-C16 score but a QIDS-
C16 score > 5 at exit from a treatment level (as long as exit is not due to intolerance). Intolerance 
was when a participant discontinued treatment within the first 4 weeks for any reason or due to 
intolerable side effects after that time, independent of the symptomatic status. The patient was 
said to be not responding if the reduction in symptom severity as measured by QIDS-C16 was 
<50%, at exit (except for when the exit is due to intolerance). Those without response at 
completion of a treatment level could move to the next treatment level, while those with 
remission entered the follow-up phase. Those with response but without remission could enter 
follow-up, but were encouraged to proceed to the next treatment level after an adequate dose and 
duration have been achieved. Participants with intolerance or minimal reduction in baseline 
symptom severity (e.g., <15% by week 6 or <25% by week 9) were encouraged to move to the 
next treatment level.  
 
Clinic Visits and Research Outcome 
 
Protocol clinic visits were required at weeks 0, 2, 4, 6, 9, and 12 at all treatment levels. 
The visit schedule was flexible and could be held within +/-6 days of the assigned week. Extra 
visits could be held if clinically needed. If a participant exhibited a response or remission only at 
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week 12, two additional visits may be used to determine if that status is sustained. At each clinic 
visit, information related to symptoms, side-effects and medications was collected in the trial. 
The primary outcome of STAR*D was remission defined as a HRSD-17score of 7 or 
less, as assessed by treatment-blinded raters. A secondary remission outcome was a QID-SR-16 
score of 5 or less. The secondary outcome of STAR*D trial was response, defined as at least a 
50% reduction in the baseline QIDS-SR-16 scores at the end of the treatment.  The research 
outcomes were assessed by Interactive Voice Response (IVR) and telephone systems. These 
were recorded at pretreatment, at exit from each treatment level, and at months 3, 6, 9, and 12 in 
follow-up. Interim research outcomes (QIDS-SR16, five-item Work and Social Adjustment Scale 
[WSAS], six-item Work and Productive Activity Impairment Questionnaire [WPAI], and 
Frequency and Intensity of Side Effects Ratings (FISER)/ Global Rating of Side Effect Burden 
(GRSEB) were also collected by IVR, at week 6 in each treatment level and at months 1, 2, 4, 5, 
7, 8, 10, and 11 in follow-up. 
 
Level 2 of STAR*D Trial 
 
The patients entering Level 2 of the trial could be randomized to one of the seven 
different treatments including four switch options (venlafaxine, sertraline, bupropion, and 
cognitive therapy) and three augment options (bupropion, buspirone or cognitive therapy added 
to CIT). However, at randomization patients could choose to opt out of being randomized to 
select options (medication switch, medication augmentation, cognitive therapy switch, cognitive 
therapy augmentation). This equipoise design served several purposes, one it reflects the real life 
practices where in patient with mood disorders are encouraged to be involved in treatment 
decision making in order to empower patients, optimize treatment adherence and improve 
outcome; second, it increases generalizability by facilitating recruitment of a broadly 
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representative participant population including the population for which lack of influence over 
treatment decisions could have been unacceptable; and finally this design also improves patient 
retention. Similar to Level 1, patients with a satisfactory therapeutic response in level 2 entered 
the 12-month naturalistic follow-up phase and those who did not entered the subsequent level of 
randomization. 
CIT was discontinued without a tapering or washout period at Level 2. The recommended 
daily doses of the three medications to which patients could be switched in Level 2 are detailed 
as below. These dosing regimens were however flexible and could be altered as per clinical 
judgment. The recommended daily dosing sustained-release (SR) bupropion was 150 mg for 
seven days, 200 mg from day 8 to 27, 300 mg from day 28 to 41, and 400 mg from day 42 
onward. Bupropion-SR is a non-SSRI agent which can affect a number of neurotransmitters.  
Bupropion is a norepinephrine and dopamine reuptake inhibitor but its action mechanism is only 
partly understood.  Sertraline was recommended to be initiated at a daily dose of 50 mg and 
increased to 100 mg at day 14, to 150 mg at day 28, and to 200 mg at day 63. The switch from 
CIT to sertraline was a within-class switch which has  a higher recommended dosing regimen. 
For extended-release (ER) venlafaxine, the dose of 37.5 mg for 7 days was increased to 75 mg 
from day 8 to 14, to 150 mg from day 15 to 27 to 225 mg from day 28 to 41, to 300 mg from day 
42 to 62, and to 375 mg from day 63 onward. Extended-release venlafaxine, a dual-action agent, 
of the serotonin-norepinephrine reuptake inhibitor (SNRI) class that inhibits the reuptake of both 
serotonin and norepinephrine. 
 
Clinical Comparison between Bupripion-SR, Sertraline and Venlafaxine-XR 
 
Overall 21.3% of patients who were switched to an alternative therapy after failure of 
initial SSRI treatment achieved remission in STAR*D trial. The trial compared effectiveness of 
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the three pharmacotherapy switch options among patients who moved to Level 2 of the trial in 
terms of remission and response. Patients receiving bupropion, sertraline and venlafaxine-XR 
had remission rates of 21.3% (51 of 239), 17.6% (42 of 238) and 24.8% (62 of 250) respectively, 
that were not significantly different (χ2 = 3.649 with 2 df, P = 0.16). Also the treatments did not 
differ significantly with respect to QIDS-SR response rates, remission rates or percent 
reductions. The treatments were also similar with respect time to remission and time to response. 
The overall burden of side effects or the proportion of patients with any serious psychiatric 
adverse event did not differ significantly between the treatment groups, though there was a 
difference in the distribution of the frequency of side effects166.  
 
3.3.4 Methods Used 
Using data from STAR*D trial, we will identify the cost-effective second-step 
pharmacological switch choice (Bupropion-SR, Sertraline, or Venlafaxine-XR) after failure of 
SSRIs for depression. Figure 3–1 (adopted from NEJM) shows the possible acceptable treatment 
combinations for patients who did not achieve an adequate response with SSRI166. There were a 
total of 727 patients switched to one of the medication switch options (Bupropion-SR, Sertraline, 
or Venlafaxine-XR).  
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 Reproduced with permission from Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg 
AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for 
depression. The New England journal of medicine. 2006; 354:1231-42, Copyright Massachusetts 
Medical Society. 
 
Figure 3-1: Overview of STAR*D (Level 2) Study Design 
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Costs and effects 
Calculated costs were based on three components: 1) antidepressant study medications, 2) 
other antidepressants and concomitant medications and 3) healthcare utilization. The prices for 
the medications were obtained from the Red Book Pharmacy’s Fundamental Reference 
(Physicians’ Desk Reference)167. The total drug costs depended on the dosage and the treatment 
duration. The healthcare facility utilization costs were calculated by multiplying patient-specific 
resource use with the corresponding unit cost. The total costs were calculated as the sum of costs 
related to medications and healthcare facility utilization. The effectiveness of the three switch 
options were in terms of remission and response (based on QIDS-SR questionnaire), as 
previously assessed166.  
Cost-effectiveness Analysis 
The determination of cost-effective switch option based on the direct costs incurred over 
the duration of Level 2 of the STAR*D trial. The NHB were calculated for Bupropion–SR, 
Sertaline, Venlafaxine–XR from the sample data available. The treatment option with the highest 
NHB was designated as the optimum choice. A stochastic analysis performed using bootstrap 
replications, provided the confidence interval. After 1000 bootstrap replications, the probability 
that a given treatment (Ti) is better than others (in terms of cost-effectiveness) were calculated as 
the percentage of iterations for which Ti was estimated to have the highest NHB.  
 
Additional method details and results are presented in the manuscript 3 
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Background:  While the persistence of high surgical site infection (SSI) rates have 
prompted the advent of more expensive sutures that are coated with antimicrobial agents to 
prevent SSIs, the economic value of such sutures have yet to be determined. 
Methods: Using TreeAge Pro, we developed a decision analytic model to determine the 
cost-effectiveness of using antimicrobial sutures in abdominal incisions from the hospital, third 
party payer, and societal perspectives.  Sensitivity analyses systematically varied the risk of 
developing an SSI (range: 5% - 20%), the cost of triclosan-coated sutures (range: $5 - $25 per 
inch), and triclosan-coated suture efficacy in preventing infection (range: 5% - 50%) to highlight 
the range of costs associated with using such sutures. 
Results: Triclosan-coated sutures saved $4,109 – $13,975 (hospital perspective), $4,133 
– $14,297 (third party payer), and $40,127 – $53,244 (societal) per SSI prevented, when a 
surgery had a 15% SSI risk, depending on their efficacy. If the SSI risk was ≤5% and the 
efficacy in preventing SSIs was ≤10% triclosan-coated sutures resulted in extra expenditure for 
hospitals and third party payers (resulting in extra costs of $1,626 and $1,071 per SSI prevented 
for hospitals and third party payers respectively, SSI risk 5% and efficacy 10%).   
Conclusion: Our results suggest that switching to triclosan-coated sutures from the 
uncoated sutures can both prevent SSIs and save substantial costs for hospitals, third party 
payers, and society, as long as efficacy in preventing SSIs is ≥10% and SSI risk is ≥10%.  
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4.2 INTRODUCTION 
Antimicrobial surgical sutures are a relatively new intervention to prevent surgical site 
infections (SSIs), the second most common hospital acquired infections in the United States.168  
This intervention emerged as SSIs remain a continuing major problem despite the various 
existing infection measures.66, 169  Intra-abdominal surgeries are especially associated with a high 
SSI rate (approximately 15%170 depending on procedure).171-173  Since approximately 4 million 
out of the 51.4 million surgeries performed annually in the United States are open abdominal 
surgeries,174 preventing SSIs for such surgeries may be highly beneficial.  
Since suture material may be a potential medium for infection,175, 176 there is increasing 
interest in employing antibacterial sutures to lower SSI risk.  Recent studies have found the 
efficacy of triclosan-coated sutures (Vicryl Plus, PDS Plus, and Monocryl plus) in preventing 
SSIs 77, 78, 82, 85, 177-184 to be variable. These mixed findings and higher cost of triclosan-coated 
sutures may limit their whole-scale adoption.  It could be that such sutures are best used under 
certain circumstances.  For example, triclosan-coated sutures may be particularly useful for 
abdominal surgeries since most involve clean-contaminated wounds, i.e., the operative procedure 
enters into a colonized viscus or cavity of the body, but under elective and controlled 
circumstances.  To identify the situations for which such sutures may be appropriate, we 
developed a decision analytic simulation model to determine the cost and health effects of 
triclosan-coated absorbable sutures as compared to their uncoated counterparts for prevention of 
incisional infections in abdominal surgeries.  
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4.3 METHODS 
Utilizing TreeAge Pro 2013 (Williamstown, MA), we developed a decision analytic 
model (illustrated in Figure 4-1) to simulate the decision of choosing triclosan-coated sutures 
versus the standard uncoated sutures for adult patients undergoing abdominal surgeries. Table 4-
1 lists the model inputs, their values, and distributions (references listed in Table 4-2). Extensive 
literature review along with expert opinion determined the model inputs.  
The distribution type of model inputs was based on the data’s structural form and 
availability. The probabilities were modeled as beta distribution (the probability of severe SSI in 
the model was based on expert opinion and modeled as uniform distribution). The beta 
distribution is parameterized by two positive shape parameters, defined over an interval of [0,1]. 
Costs related to hospitalization, treatment and sutures were modeled as Gamma distribution 
(two-parameter family of continuous probability distributions, with a shape parameter k and a 
scale parameter θ). Triangular distribution represented the mortality costs and hourly wages. The 
duration of hospital stay and antibiotic treatment were modeled as gamma and uniform 
distribution (all intervals of the same length on the distribution’s support are equally probable) 
respectively. 
Each patient entering the model underwent an abdominal surgery and had a risk of 
developing an incisional SSI.  The SSI could be either superficial or deep and could be either 
mild or severe.  Superficial infections are defined as those that occur within 30 days of a 
procedure involving only the skin and subcutaneous tissues, whereas deep incisional infections 
are more severe, including those that occur within 30 or 90 days after an operative procedure 
involving deeper soft tissues (fascial muscles).  Patients who developed an SSI had an extended 
attributable length-of-stay (LOS) and increased mortality rate, depending on the type of SSI. The 
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amount of suture used for each surgery was assumed to be four times the incision length, as 
recommended by previous studies.185-187  
SSI treatment was dependent on the severity and type of SSI.  Patients with a mild 
superficial SSI were treated with oral antibiotics, whereas severe superficial SSIs were 
administered intravenous (IV) antibiotics along with simple incision and drainage (I&D). All 
patients with a deep incisional SSI were administered IV antibiotics.  Along with antibiotic 
treatment, deep incisional SSIs that were mild in severity received simple percutaneous I&D, 
whereas severe ones underwent complex I&D. Antibiotic regimens were determined using 
Micromedex and UptoDate (refined by expert opinion). Oral antibiotics included broad spectrum 
antibiotics like metronidazole (500 mg every 6-8 hours) and ciprofloxacin (500 mg every 12 
hours).  Intravenous antibiotics included vancomycin (15-20 mg/kg every 6-12 hours), linezolid 
(600 mg every 12 hours), ampicillin/sulbactam (1.5-3 mg every 6 hours), ceftriaxone (1-2 gm 
every 12-24 hours), or piperacillin/tazobactam (3.375 gm every 6-8 hours), depending on the 
causative pathogen and infection severity. Antibiotic treatment duration ranged from 7-14 days.  
In cases where the patient was undergoing IV antibiotic treatment and treatment duration 
exceeded the hospital stay, he/she switched to oral antibiotics a day prior to discharge.  
Separate analyses were carried out from hospital, third-party payer, and societal 
perspectives to determine the economic benefits of using antimicrobial-coated sutures.  The 
hospital perspective accounted for the suture costs and opportunity cost of lost bed-days caused 
by the increased LOS associated with superficial and deep SSI188-190, which could have been 
filled by another patient.  The third-party payer perspective included the direct hospitalization 
and treatment costs, along with suture costs. The societal perspective included both direct (i.e., 
hospitalization costs, treatment costs) and indirect costs (i.e., productivity loss due to 
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absenteeism and mortality, and general mortality costs that include operational costs related to 
death, such as transportation and burial). Productivity losses were based on median hourly and 
annual wages for all occupations (assuming an 8 hour work day and a 5 day work week), for the 
duration of hospitalization. Death resulted in the net present value of lost wages for the 
remainder of the person's life expectancy based on his/her age191.  All costs were discounted to 
2013 values using a 3% discount rate.  
The following formula determined the cost per SSI prevented: 
Cost per SSI prevented= [Cost (coated) – Costs (uncoated)]/ [Number of SSIs (coated) – 
Number of SSIs (uncoated)] 
Each simulation run sent 1000 individuals undergoing an abdominal surgery 1000 times 
through the model (1,000,000 total trials). Sensitivity analyses systematically varied the risk of 
developing an SSI (range: 5-20%) to account for heterogeneity among different surgical 
techniques and the presence/absence of various pre-surgical antibiotic prophylaxis regimens. 
Additional analyses ranged triclosan-coated suture cost (range: $5 - $25 per inch) and efficacy 
(range: 5-50%). The wide range of efficacy values accounted for the debate over the true efficacy 
of the sutures. Experts speculate that antimicrobial coated sutures will be more effective in 
preventing superficial SSI as compared to deep incisional SSIs, so we also varied the efficacy of 
preventing superficial (range: 10-50%) and deep incisional SSIs (range: 5-20%) differentially. 
Monte Carlo probabilistic sensitivity analysis simultaneously varied all parameters throughout 
their ranges in Table 4-1. Monte Carlo simulation used dynamic information from the 




Table 4-3 shows the cost per SSI prevented when triclosan-coated sutures are used for an 
eight inch long incision, varying the risk of SSI.  Triclosan-coated sutures 5% efficacious 
incurred extra costs when used for surgeries having ≤10% SSI risk; resulting in an average 
expenditure of $46 (5% SSI risk) and $8 (10% SSI risk) per surgery. However, triclosan-coated 
sutures progressively saved greater costs per surgery  (compared to uncoated sutures) when used 
for surgeries with ≥15% SSI risk, even with an efficacy as low as 5% (saved $30 per surgery, 
preventing 7 SSIs per 1000 surgeries at 5% efficacy which increased to $1,046 per surgery, 
preventing 75 SSIs per 1000 surgeries at 50% efficacy).  When used for surgeries with a higher 
infection risk triclosan-coated sutures prevented a greater number of SSIs and consequently 
prevented their related costs.  
A lower suture cost ($5 vs the current price, $9.93 per inch) generated even more cost-
savings, leading to an additional savings ≥$150 per surgery; less expensive triclosan-coated 
sutures resulted in cost-savings per surgery even if only 5% efficacious, saving $186 per surgery 
with a 15% SSI risk. The costs-savings per abdominal surgery increased linearly with increasing 
efficacy.  Cost-savings would decrease proportionately with higher priced sutures (Figure 4-2A). 
A more expensive triclosan-coated suture, costing ≥$20 per inch, resulted in cost-savings per 
surgery only if they had an efficacy ≥20% (saving $48 per surgery when costing $20 per inch). 
The costs associated with triclosan-coated suture use for various scenarios changed, if 
they were assumed to prevent superficial SSIs only. Sutures that prevented only superficial SSIs 
for surgeries having a 15% SSI risk were not cost-effective at a 5% efficacy, incurring an extra 
cost of $2,885 per SSI prevented. An increase in efficacy to prevent superficial SSIs resulted in 
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rapid increases in costs saved per SSI prevented, as superficial SSIs are more common. Table 4-4 
shows the costs saved per SSI averted when using sutures having a differential efficacy to 
prevent superficial and deep incisional SSIs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
Third-Party Payer Perspective 
Third-party payers saved slightly more costs per SSI prevented than hospitals (Table 4-
3), but followed a similar trend. For a 15% SSI risk, triclosan-coated sutures resulted in 7-14 
SSIs per 1000 surgeries, while traditional uncoated sutures resulted in approximately 15 SSIs per 
1000 surgeries; thus saving  $4,133 (5% efficacious) to $14,297 (50% efficacious) per SSI 
prevented.  The trend of cost saved per surgery for varied costs and efficacies of triclosan-coated 
sutures were also similar to the hospital perspective (Figure 4-2).  
Societal Perspective 
Using triclosan-coated sutures for surgeries having a 15% risk of SSI saved $40,127 to 
$53,244 per SSI prevented, depending on efficacy (Table 4-3).  For such surgeries, triclosan-
coated sutures (5% efficacy) saved $296 per surgery while preventing 0.29 deaths per 1000 
surgeries; this increased to $4,001 per surgery and prevented 3.2 deaths per 1000 surgeries at an 
efficacy of 50%.  This shows that an intervention which can reduce number of deaths, even 
marginally, can lead to substantial cost-savings.  
Triclosan-coated sutures with a 5% efficacy, priced at $5 per inch resulted in savings of 
$492 per surgery. A $15 per inch triclosan-coated suture (efficacy >5%) also resulted in cost-
savings per surgery. Such a triclosan-coated suture having 25% efficacy saved $1,745 per 
surgery while preventing 37 SSIs per 1000 surgeries. Using triclosan-coated sutures with 5% 
efficacy resulted in extra $34 and $171 per surgery if their costs further increased to $20 and $25 
per inch, respectively. A 5% increase in triclosan-coated suture efficacy increased the cost saved 
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per surgery by >$300, so at efficacies ≥10% these more expensive sutures resulted in costs saved 
per surgery.  
Triclosan-coated sutures continued to save costs per SSI prevented from the societal 
perspective, even if they only prevented superficial SSIs and not deep incisional SSIs. For 
surgeries having a 15% SSI risk, triclosan-coated sutures saved $35,116 (5% efficacious) to 
48,684 (50% efficacious) per SSI prevented (Figure 4-2C). The figure shows a non-linear 
relationship for when efficacy of the coated suture was 20%. To further examine this, we ran a 
simulation experiment increasing the number of samples and trials each to 10,000. The graph 
obtained showed the linear trend indicating that the non-monotonic point estimate was due to 
variability and stochasticity (Figure 4-3).   
4.5 DISCUSSION  
Our analyses show that even though triclosan-coated sutures are almost 40% more 
expensive than the traditional uncoated sutures ($9.93 vs $7.32 per inch),  the cost-savings 
generated by preventing abdominal SSIs offsets the extra suture costs, even when SSI risk is 
15% and efficacy in preventing SSIs is as low as 5%.  Depending on their efficacy, triclosan-
coated sutures may in fact save more costs per SSI prevented than many of the other 
interventions.  A study showed that collagen-gentamycin sponges for cardiothoracic surgeries 
save $84 per patient, preventing 45 surgical wound infections;192 leading to $1,773 (2013 values) 
saved per SSI prevented.  According to our model, triclosan-coated sutures when used for 
abdominal surgeries with 15% SSI risk saved approximately 2-8 times more costs per SSI 
prevented than that by collagen-gentamycin (hospital perspective).  Also, as new technologies 
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become available (e.g., wound retractors193 and antimicrobial abdominal meshes194), quantifying 
their potential cost-effectiveness becomes important given the limited resources available for 
infection prevention and control.  Hospitals may want to implement strategies that minimize 
costs while achieving a maximal reduction in SSIs.  Head to head comparison of these multiple 
interventions in terms of costs and benefits will guide the policy makers to determine the best 
strategy. Current guidelines may need to reevaluate their recommendations in light of the 
upcoming interventions to determine the most cost-effective strategies to prevent SSIs. 
Moreover, our results are not necessarily specific to triclosan as other antimicrobials such as 
silver, gentamycin or neomycin could be used for coating sutures.195, 196   
There are two  systematic reviews  regarding the efficacy of triclosan-coated sutures; one 
concluded that triclosan-coated sutures do not have a beneficial effect in preventing SSIs,72 
whereas the other demonstratedsignificant SSI reduction  on using triclosan-coated sutures.89  
These reviews include studies for colorectal, cardiac, breast, and shunt surgeries, which may 
have diverse SSI risks and risk-factors.  One review performed a subgroup analysis on 
abdominal procedures, showing that triclosan-coated sutures significantly reduce SSI risk by 
31% (relative risk 0.69, 95% CI: 0.50 – 0.97).89  Among the studies evaluating abdominal 
procedures,77, 78, 82, 177, 178, 184  two showed no effect,82, 178 while others showed a substantial 
reduction in SSIs (35% to 65%).  The reasons for such a wide range in results are unclear and 
could be due to design limitations (small sample size and limited controls), varied incision 
closure method, SSI definitions, incomplete data, or reporting biases.   
Since the results from this analysis are sensitive to efficacy of triclosan-coated sutures, 
additional studies are needed to establish the efficacy of such sutures and evaluate their benefits 
for surgeries with varied SSI rates. While evaluating the sutures, it is important to use standard 
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SSI definitions, in order to allow comparisons across studies and gain more insight. Also, it will 
be beneficial if future studies incorporate details on SSI type; this would give a better handle on 
cost and health benefits, if any, obtained by using triclosan-coated sutures. If sufficiently 
efficacious in preventing SSIs, triclosan-coated sutures can be cost-effective even when higher-
priced. The benefits obtained by using triclosan-coated sutures also depend on the SSI risk. 
Accurate quantification of SSI risk prior to surgery, using risk scores, may help stratify patients 
and consequently determine effective preventive strategies for various subgroups. National 
Nosocomial Infections Surveillance (NNIS) risk score is commonly used, but is often criticized 
for its discriminatory abilities and over-simplistic nature. Recently there have been attempts to 
develop alternate indices to better predict SSI rates197, 198. However these need to be further 
tested and validated.  
One concern is that antimicrobial sutures may prevent only incisional SSIs and not organ 
space infections which are associated with a higher morbidity, mortality, and costs.199  However, 
a majority of SSIs are confined to incisions,200 hence interventions focusing on prevention of 
incisional SSIs could save substantial costs per SSI prevented as reflected in our results ($40,127 
to $53,244 per SSI prevented, societal perspective). Another concern is that the wide use of 
triclosan may lead to the development of antimicrobial resistance and thus decreased suture 
efficacy in preventing SSIs.201 This is a very serious concern and suggests that efficacy numbers 
reported in the literature may not necessarily apply in the future. Also, in-vitro studies suggest 
that triclosan use may further lead to the development of antibiotic resistance.43,44  This highlights 
the need for more judicious and targeted use of triclosan, something that models such as ours can 
help guide.  
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It is important that policy makers consider the indirect costs along with the direct costs in 
order to be able to make an informed and well-rounded decision. Hospital and insurance 
databases typically do not capture productivity losses. When considering the societal perspective, 
the cost-savings per surgery were 4-13 times higher than that from the hospital or third-party 
payer perspectives. This shows that preventing productivity losses can save considerable costs 
per surgery, even when the SSIs are not associated with a high mortality rate (3.9% for 
superficial and 5.7% for deep incisional SSIs). Therefore, focusing on only the direct costs 
overlooks the impact of complicated cases that rapidly accrue costs.  
 
Limitations 
All models, by definition, are simplification of real life202, 203 and cannot account for 
every possible SSI outcome. All data inputs for the model were obtained from sources of varied 
quality and rigor, including public databases, published literature, and expert opinion. We 
assumed that all pathogens had an equal probability of causing SSI in clinical settings. Our 
model was conservative about the potential benefits of triclosan-coated sutures, considering their 
efficacy to be as low as 5%. It did not consider that some severe incisional SSIs may progress to 
organ space infections incurring additional resources and costs. Also, for the societal perspective 
our productivity loss calculations assumed a 40-hour work week and did not account for 
decreased productivity while recovering. 
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4.6 CONCLUSIONS 
Our results show that triclosan-coated sutures save ≥$4000 per SSI prevented for  
hospitals and third-party payers and ≥$23,500 per SSI prevented for society, if their efficacy is 
≥10% and SSI risk is ≥10%.  The high cost and risk of abdominal SSIs compensate for the cost 
premium of antimicrobial sutures as long as it has some efficacy in preventing SSIs.  Future 
studies should better characterize this efficacy, but our study suggests that such sutures have the 
potential to save considerable costs.   
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4.7 TABLES AND FIGURES 
Table 4-1: Model inputs and parameters† 
Parameter Distribution 
Type 
Mean/Median Standard Deviation/Range 
Probabilities    
Surgical Site Infection 
(SSI) 
- 0.15 - 
Superficial SSI β 0.697 0.305 
Deep SSI β 0.302 0.305 
Severe SSI Within Each 
Type 
U - 0.20 – 0.30 
Death due to Superficial 
SSI 
β 0.039 0.024 
Death due to Deep SSI - 0.057 - 
Durations (Days)    
Length of Hospitalization 
due to Superficial SSI 
γ 6.22 4.25 
Length of Hospitalization 
due to Deep SSI 
γ 9.675 0.96 
Antibiotic treatment  U - 7 – 14  
Costs    
Triclosan Coated Suture γ 9.93 6.39 
Regular Absorbable Suture γ 7.32 3.175 
Hospitalization due to SSI    
       1-17 years γ 12,318 1,013 
       18-44 years γ 12,429 418 
      45-64 years γ 15,299 443 
      65-84 years γ 17,025 488 
      85+ years γ 15,164 663 
Simple Incision and 
Drainage 
γ 98.32 7.63 
Complex Incision and 
Drainage 
γ 185.52 15.03 
IV Insertion - 9.53 - 
Intravenous Antibiotic* γ 51.03 70.00 
Oral Antibiotics** γ 13.65 12.81 
Mortality Δ 7,563 5,672 – 9,862 
Productivity Losses due to 
death*** 
- - 139,801 – 1,483,215 
Hourly wage Δ 9.29 20.32 – 93.42 
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† Sources are listed in Appendix Table 1 
*IV antibiotics include vancomycin, linezolid, piperecillin/tazobactam, ceftriaxone, 
ampicillin and sulbactam 
**Oral antibiotics include ciprofloxacin and metronidazole 





Table 4-2:  References for Model Input Parameters 
Parameter Reference 
Probabilities 
Surgical Site Infection 
(SSI) 
Alexander JW, Rahn R, Goodman HR. Prevention of surgical 
site infections by an infusion of topical antibiotics in morbidly obese 
patients. Surg Infect (Larchmt). 2009;10(1):53-57 
Superficial SSI Watanabe A, Kohnoe S, Shimabukuro R, et al. Risk factors 
associated with surgical site infection in upper and lower 
gastrointestinal surgery. Surgery Today. 2008;38(5):404-412 
Baracs J, Huszar O, Sajjadi SG, Horvath OP. Surgical site 
infections after abdominal closure in colorectal surgery using triclosan-
coated absorbable suture (PDS Plus) vs. uncoated sutures (PDS II): a 
randomized multicenter study. Surg Infect (Larchmt). 2011;12(6):483-
489. 
Millbourn D, Cengiz Y, Israelsson LA. Effect of stitch length 
on wound complications after closure of midline incisions: a 
randomized controlled trial. Arch Surg. 2009;144(11):1056-1059. 
Coello R, Charlett A, Wilson J, Ward V, Pearson A, Borriello 
P. Adverse impact of surgical site infections in English hospitals. J 
Hosp Infect. 2005;60(2):93-103. 
Deep SSI Watanabe A, Kohnoe S, Shimabukuro R, et al. Risk factors 
associated with surgical site infection in upper and lower 
gastrointestinal surgery. Surgery Today. 2008;38(5):404-412 
Baracs J, Huszar O, Sajjadi SG, Horvath OP. Surgical site 
infections after abdominal closure in colorectal surgery using triclosan-
coated absorbable suture (PDS Plus) vs. uncoated sutures (PDS II): a 
randomized multicenter study. Surg Infect (Larchmt). 2011;12(6):483-
489. 
Millbourn D, Cengiz Y, Israelsson LA. Effect of stitch length 
on wound complications after closure of midline incisions: a 
randomized controlled trial. Arch Surg. 2009;144(11):1056-1059. 
Coello R, Charlett A, Wilson J, Ward V, Pearson A, Borriello 
P. Adverse impact of surgical site infections in English hospitals. J 
Hosp Infect. 2005;60(2):93-103. 
Severe SSI Within 
Each Type 
Expert Opinion 
Death due to 
Superficial SSI 
Coello R, Charlett A, Wilson J, Ward V, Pearson A, Borriello 
P. Adverse impact of surgical site infections in English hospitals. J 
Hosp Infect. 2005;60(2):93-103. 
66 
Astagneau P, Rioux C, Golliot F, Brucker G. Morbidity and 
mortality associated with surgical site infections: results from the 
1997-1999 INCISO surveillance. J Hosp Infect. 2001;48(4):267-274. 
Death due to Deep SSI Astagneau P, Rioux C, Golliot F, Brucker G. Morbidity and 
mortality associated with surgical site infections: results from the 
1997-1999 INCISO surveillance. J Hosp Infect. 2001;48(4):267-274. 
Durations (Days) 
Length of 
Hospitalization due to 
Superficial SSI 
Coello R, Charlett A, Wilson J, Ward V, Pearson A, Borriello 
P. Adverse impact of surgical site infections in English hospitals. J 
Hosp Infect. 2005;60(2):93-103. 
Fukuda H, Morikane K, Kuroki M, et al. Impact of surgical site 
infections after open and laparoscopic colon and rectal surgeries on 
postoperative resource consumption. Infection. 2012;40(6):649-659. 
Length of 
Hospitalization due to 
Deep SSI 
Fukuda H, Morikane K, Kuroki M, et al. Impact of surgical site 
infections after open and laparoscopic colon and rectal surgeries on 
postoperative resource consumption. Infection. 2012;40(6):649-659. 
Merle V, Germain JM, Chamouni P, et al. Assessment of 
prolonged hospital stay attributable to surgical site infections using 
appropriateness evaluation protocol. Am J Infect Control. 
2000;28(2):109-115. 
Antibiotic treatment UpToDate, Micromedex, Expert Opinion 
Costs 
Sutures Medical Supply Pricings http://www.mmsmedical.com/, 
http://twgmedicalsupplies.com/ 
Hospitalization due to 
SSI 
National and regional estimates on hospital use for all patients 
from the Healthcare Cost and Utilization Project (HCUP) Nationwide 
Inpatient Sample (NIS) 2010. http://hcupnet.ahrq.gov/. Accessed 
March 2013. 
Incision and Drainage American Medical Associaton. CPT Code/Relative Value 
Search. 2012; https://ocm.ama-
assn.org/OCM/CPTRelativeValueSearch.do. Accessed February, 2013. 
IV Insertion American Medical Associaton. CPT Code/Relative Value 
Search. 2012; https://ocm.ama-
assn.org/OCM/CPTRelativeValueSearch.do. Accessed February, 2013. 
Antibiotics Physicians Desk Reference. Red Book Pharmacy's 
Fundamental Reference. Montvale, NJ: Thompson Reuters 
(Healthcare); 2010. 
Mortality Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-
molecular-weight heparins compared with unfractionated heparin for 
treatment of acute deep venous thrombosis. A cost-effectiveness 
analysis. Ann Intern Med. 1999;130(10):789-799. 
Productivity Losses 
due to death 




Hourly wage Bureau of Labor Statistics. Occupational employment statistics: 
May 2011 National Occupational Employment and Wage Estimates, 
United States. 2013; http://www.bls.gov/oes/current/oes_nat.htm#00-
0000. Accessed Febraury, 2013. 
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Table 4-2 Continued
Table 4-3: Costs per SSI Averted for Varied Efficacies of Antimicrobial Coated Sutures to 
Prevent SSI and Risk of Developing SSI for an 8  inch204  incision from the Hospital, Third 
Party Payer, and Societal Perspectives 
Cost Associated with Coated Sutures per SSI prevented* 
Risk of Surgical Site Infection (%) 
Efficacy of the 
Coated Sutures 
5 10 15 20 
Hospital Perspective 
5 18,870 1,625 -4,019 -6,689 
10 1,626 -6,685 -9,497 -11,059 
15 -3,750 -9,555 -11,515 -12,378 
25 -8,560 -11,650 -12,936 -13,494 
50 -11,784 -13,529 -13,975 -14,309 
Third Party Perspective 
5 17,687 1,280 -4,133 -7,198 
10 1,071 -6,879 -9,750 -11,242 
15 -4,474 -9,821 -11,652 -12,683 
25 -8,773 -12,035 -13,170 -13,730 
50 -12,036 -13,740 -14,297 -14,577 
Societal Perspective 
5 -23,519 -38,198 -40,127 -46,847 
10 -46,779 -46,207 -50,187 -52,187 
15 -47,291 -49,151 -51,724 -52,382 
25 -47,303 -50,902 -52,424 -53,698 
50 -51,759 -53,160 -53,244 -54,704 
*Negative costs indicate cost-savings
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Table 4-4: Costs per SSI Averted from Hospital’s Perspective for Differential Efficacies of 
Antimicrobial Coated Sutures to Prevent Superficial and Deep Incisional SSI and 
Associated Risk of Infection for an 8 Inches Incision 
Risk of Developing SSI (%) 
Efficacy to Prevent 
Deep SSI (%) 
5 10 15 20 
Efficacy to Prevent Superficial SSI = 10% 
0 2,558 -957 -5,131 -6,848 
5 5,710 -4,491 -7,592 -9,446 
Efficacy to Prevent Superficial SSI = 15% 
0 2,731 -4,751 -7,641 -9,002 
5 338 -6,901 -9,216 -10,393 
Efficacy to Prevent Superficial SSI = 25% 
0 -3,277 -8,333 -9,813 -10,501 
5 -4,440 -9,245 -10,616 -11,227 
Efficacy to Prevent Superficial SSI = 50% 
0 -8,410 -10,523 -11,442 -11,825 
5 -8,539 -11,141 -11,776 -12,020 
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Figure 4-1: Model Outline 
71 
Figure 4-2: Costs Associated with Coated Sutures of varying costs and efficacies for a 
surgery having 15% risk of developing SSI 
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Figure 4-3: Costs Associated with Coated Sutures of varying costs and efficacies for a 
surgery having 15% risk of developing SSI (Societal Perspective; 10,000X10,000 runs) 
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Background: Conclusive evidence is lacking regarding the benefits and risks of 
performing off-pump versus on-pump coronary artery bypass graft (CABG) for patients with 
diabetes. This study aims to compare clinical outcomes after off-pump and on-pump procedures 
for patients with diabetes.  
Methods: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 
2D) trial enrolled patients with type 2 diabetes and documented coronary artery disease, 615 of 
whom underwent CABG during the trial. The procedural complications, 30-day outcomes, long-
term clinical and functional outcomes were compared between the off pump and on-pump 
groups overall, and within a subset of patients matched on propensity score.  
Results: On-pump CABG was performed in 444 (72%) patients and off-pump CABG in 
171 (28%). The unadjusted 30-day rate of death/MI/stroke was significantly higher after off-
pump CABG (7.0% versus 2.9%, p = 0.02) despite fewer complications (10.3% versus 20.7%, p 
= 0.003). The long-term risk of death (adjusted hazard ratio (aHR): 1.41, p = 0.2197) and major 
cardiovascular events (death, MI or stroke) (aHR: 1.47, p = 0.1061) did not differ statistically 
between the off-pump and on-pump patients. Within the propensity-matched sample (153 pairs), 
patients who underwent off-pump CABG had a higher risk of the composite outcome of death, 
MI or stroke (aHR: 1.83, p = 0.046); the rates of procedural complications and death did not 
differ significantly, and there were no significant differences in the functional outcomes.  
Conclusions: Patients with diabetes had greater risk of major cardiovascular events long 
term after off-pump CABG than after on-pump CABG.  
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5.2 INTRODUCTION 
The risk of cardiovascular disease is two to four times higher among individuals with 
diabetes than among those without diabetes98-100. The BARI trial demonstrated that coronary 
artery bypass graft procedure (CABG) improves survival as compared with percutaneous 
coronary intervention in patients with diabetes and multi-vessel coronary artery disease205.  A 
decade later, the BARI 2D trial established that major cardiovascular outcomes were lower with 
CABG as compared to medical therapy alone for patients with diabetes and stable coronary 
artery disease206.     
Traditionally, CABG has been performed on-pump, i.e. using the cardiopulmonary artery 
bypass (CPB) and cardioplegic arrest. Use of CPB has been associated with post-procedure 
myocardial, pulmonary, renal and cerebral complications110-112, 207.  However, it has been 
suggested that off-pump CABG, which does not require CPB, may avoid many of these 
complications and thus result in better clinical outcomes. 
The comparative effectiveness of the off-pump procedure has been controversial and few 
studies compared off-pump and on-pump CABG among patients with diabetes138-141. These 
studies are single-centered, retrospective, and lack long-term outcomes. Consequently, the 
current evidence is inadequate to make conclusions regarding the relative risks and benefits of 
using off-pump versus on-pump CABG for diabetic individuals.  
We aim to determine the risks and benefits of off-pump CABG compared to on-pump 




The design, patient characteristics, and primary results of the BARI 2D clinical trial have 
been previously described in detail206.  Briefly, BARI 2D was a 2x2 factorial design clinical trial 
that included 2,368 patients with type 2 diabetes and angiographically documented coronary 
artery disease. Participants were enrolled between January 1, 2001 to March 31, 2005 from 49 
sites across the United States, Canada, Brazil, Mexico, the Czech Republic and Austria.  All 
patients underwent informed consent prior to entry into the study, and every site had IRB 
approval.  In addition, the Coordinating Center maintained the IRB approval for the study as a 
whole.  Randomization was stratified by the intended revascularization method (i.e. whether a 
patient was more suitable for CABG or percutaneous coronary intervention (PCI), determined by 
the individual site physicians). The eligible patients were randomly assigned to either prompt 
revascularization or medical therapy within each stratum. Simultaneously, the patients were 
randomly assigned to treatment of hyperglycemia with either insulin sensitization or insulin 
provision therapy to achieve a target HbA1c < 7.0%. The trial actively managed diabetes and 
cardiovascular risk factors for all patients through the patient’s 6 year visit or until the last annual 
visit prior to December 1, 2008. Clinic visits for all patients were scheduled on a monthly basis 
for the first 6 months and quarterly thereafter. 
This analysis included BARI 2D patients who underwent a CABG procedure, irrespective 
of their intended method of revascularization or the assigned treatment arm. If a patient had more 
than one CABG, the first CABG procedure was used for all evaluations and comparisons.  
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Surgical Techniques 
Characteristics of patients having CABG within the trial have previously been described 
in detail208. All operations in BARI 2D were performed by experienced and established surgeons 
certified by the trial. The decision to perform an off-pump versus an on-pump procedure was 
based on clinical site practice patterns, individual surgeon preference, clinical characteristics of 
the patient, and the perceived target vessel quality. The trial protocol called for bypassing all 
stenosis that were believed to contribute to a patient’s clinical symptoms and ischemia; however, 
incomplete revascularization could be planned in cases where the morphological features did not 
allow bypass of all lesions. It was also strongly recommended to use at least one internal 
mammary conduit if possible.  
Outcomes 
The primary end point of BARI 2D trial was mortality, and the principal secondary end 
point was the composite of death, myocardial infarction (MI), and stroke. The average follow-up 
time in the BARI 2D trial was 5.3 years. For this analysis, we also considered a repeat 
revascularization outcome defined as any PCI, CABG or laser myocardial revascularization 
required after CABG as a secondary outcome. The peri/post-procedural complications (within-
hospital) were categorized as neurological, cardiac, renal, vascular, pulmonary, bleeding, and 
inotrope use for > 48 hours. Neurological complications included transient cerebrovascular 
event, cerebrovascular accident, dementia and coma. Cardiac complications encompassed non-
fatal cardiac arrest, suspected MI, congestive heart failure, pulmonary edema (cardiac), 
cardiogenic shock, and cardiac tamponade. Vascular complications included arterial embolism of 
extremity or loss of pulse requiring treatment. Renal failure requiring dialysis was categorized as 
a renal complication. Respiratory failure, pulmonary embolus, chest tube> 3 days post-procedure 
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were classified as pulmonary complications. Bleeding complications comprised of hemorrhage 
that required transfusion and any reoperation for bleeding.  
In addition to the clinical outcomes, we assessed functional outcomes during the 4 years 
after surgery in the off-pump and on-pump groups. The functional outcomes included angina and 
Duke Activity Status Index (DASI) scores. DASI is a 12-item index (0 [worst] to 58.2 [best]) 
that assesses the patient’s ability to perform specific physical activities. The trial collected 
information on angina and quality of life on a quarterly and yearly basis respectively. 
Statistical Analyses 
Baseline demographic and clinical characteristics were compared between patients 
undergoing on-pump and off-pump CABG procedures. Summary statistics for the baseline 
characteristics are presented as means and standard deviation in case of continuous variables, and 
as numbers and percentages in case of categorical variables. Continuous variables were 
compared using Wilcoxon rank-sum test and categorical variables using chi-square or Fischer’s 
exact, where appropriate.   
Two separate sets of analyses were conducted to compare the outcomes between off-
pump and on-pump CABG. The first analysis included all patients who underwent CABG within 
the trial and had information regarding the use of pump during the procedure. The procedural 
(within-hospital) complications, short-term clinical outcomes (within 30 days of CABG), any 
repeat revascularizations were compared using chi-square or Fischer’s test. Only unadjusted 
analyses were conducted for complications, repeat revascularization and short term clinical 
outcomes, due to small number of events. The clinical outcomes of death and major 
cardiovascular events (death/MI/stroke) over the follow-up period were evaluated as time-to-
event outcomes using Kaplan-Meier curves, log-rank statistics and multivariate Cox proportional 
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hazard models.  The proportional hazards assumptions between the on-pump and off-pump 
groups were tested.  Generalized linear models, with time specified as a within-subject effect, 
were used to compare the functional outcomes including angina and DASI scores between 
patients undergoing off-pump and on-pump CABG. 
The candidate variables included in multivariable models as possible confounders 
comprised of the baseline characteristics that were significantly different between the two CABG 
groups. The final sets of covariates for outcomes death and major cardiovascular events were 
based on stepwise backward selection model building algorithm that used an alpha = 0.10 for 
variable elimination, and the off-pump/on-pump variable was forced into the model after the 
covariates were selected. The final covariates for the functional outcomes included the baseline 
characteristics that were significantly different between the two groups. We tested for statistical 
interaction between the type of CABG and country of surgery for the clinical and functional 
outcomes. In addition, we tested for statistical interaction between CABG type and time for 
longitudinal functional outcomes. 
In the second analysis, a propensity score methodology was used to control for the non-
randomized treatment selection of the two groups. The propensity scores represent the 
probability that a patient would undergo an off-pump CABG as compared to an on-pump CABG 
given his/her preoperative characteristics. Propensity scores for each patient were calculated 
using multivariable logistic regression model. The model considered a broad set of candidate 
variables, baseline characteristics that were different between the off-pump and on-pump group 
at a significance level of 0.20 (excluding country). Backward-selection methods utilizing a 
liberal alpha = 0.20 for eliminating variables were used to further refine the model.  Based on the 
calculated propensity scores, patients undergoing off-pump CABG were matched with those 
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undergoing on-pump (1:1 match, without replacement) using a caliper of 0.01. Regional 
differences were not included in the propensity score and were handled with model adjustment. 
Within the matched dataset, baseline characteristics were compared using Wilcoxon signed-rank 
test for continuous variables, McNemar’s test of symmetry for categorical variables. The post-
procedural complications and short-term clinical outcomes, and repeat revascularization rates 
were compared using McNemar tests. Cox proportional-hazards regression models adjusted for 
region with robust standard errors were created to determine the association between type of 
surgery and time to death and time to the composite of death, MI or stroke. Functional outcomes, 
angina and DASI scores, were compared using generalized linear model accounting for the 
correlations within the matched pairs and repeated observations per patient. 
For all analysis, missing covariate values were imputed using the mean or the most 
common value so that all patients with non-missing outcome data are incorporated in the clinical 
and functional outcomes models. The geographic regions were categorized as US/Canada and 
others (Mexico, Brazil, Czech Republic and Austria). The time-to-event analyses used the date 
and time of the index CABG procedure as ‘time zero.’ The event time was calculated based on 
the number of days to the first event.  If no event occurred, data were censored at the last 
available follow-up patient date for death/MI/stroke or the vital status record date (when 




Of the 2,368 patients enrolled in BARI 2D, 621 (26 %) underwent a CABG procedure 
during the trial (illustrated in Figure 5-1).  Of the patients assigned revascularization procedure 
(i.e. they were assigned to the prompt revascularization, 347 received a CABG as their first 
revascularization procedure within 6 months of study entry), 76 received a CABG as their first 
surgical revascularization procedure but it occurred after a PCI procedure (n = 65) or more than 6 
months after study entry (n = 11).  Of the 1192 patients randomized to medical therapy, 198 
patients received a subsequent CABG.   Overall, 468 (75%) of the patients who received a 
CABG, were allocated prior to randomization to the CABG stratum (117 patients were those 
who were randomized to medical therapy and 351 patients were those who were randomized to 
revascularization) and the remainder to the PCI stratum. Six CABG patients had missing off-
pump/on-pump use information and were excluded from the analysis. This resulted in a final 
sample size of 615 patients, of whom 171 (27.8%) underwent off-pump and 444 (72.2%) 
underwent on-pump CABG.  The average (standard deviation) follow-up time for this sample of 
patients was 4.2 (1.7) years where the time of the CABG procedure was considered as time 0.   
Patients undergoing off-pump CABG were more likely to be randomized to prompt 
revascularization, have CABG as their assigned index procedure, and have been allocated to the 
CABG intended method of revascularization stratum (Table 5-1).  Patients undergoing off-pump 
were also younger, more likely to be female, had undergone a non-coronary vascular surgery 
prior to CABG, had higher glomerular filtration rate, lower serum creatinine levels, higher left 
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ventricular ejection fraction (LVEF), higher Hba1c, and higher energy scores. The distribution of 
CABG type varied significantly by country. The majority of CABGs performed in Brazil and 
Czech Republic/Austria were off-pump, whereas most in USA/Canada were on-pump.  The two 
groups also differed in terms of their aspirin and diuretic medications within 48 hours prior to 
procedure.   
Outcomes for All Patients undergoing CABG 
Rates of within-hospital complications (Table 5-2) were significantly lower among 
patients undergoing off-pump (10.3%) as compared to those undergoing on-pump procedures 
(20.7%, p = 0.003). In contrast, the 30-day composite outcome of death/MI/stroke rate was 
significantly higher among the off-pump patients (7.0% versus 2.9%, p = 0.02). Over the long-
term follow-up after CABG, 18 (10.5%) off-pump versus 33 (7.3%) on-pump patients required 
repeat revascularization (p = 0.21).  
Unadjusted event-free rates at four years (Figure 5-2) did not differ significantly for 
mortality (88.0% off-pump vs 91.2% on-pump, p=0.11) or death/MI/stroke (80.0% off-pump vs 
85.4% on-pump, p=0.06). Adjusted long-term risk of death among off-pump patients was 1.41 
times higher than that among the on-pump patients, but this difference was not statistically 
significant (p = 0.22) . Similar effects were observed the outcome of death, MI or stroke (Table 
3). There were no significant interactions between the procedure type and geographic region, 
indicating that the effect of performing off-pump CABG on death and death/MI/stroke was 
consistent across the regions.   
At follow-up, patients undergoing off-pump CABG had less angina and higher DASI 
scores (Figure 5-3A, Figure 5-4A) but these differences were not significant after adjusting for 
the baseline characteristics (Table 5-4). The treatment effect on angina did not vary with time; 
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however, there was a significant interaction between treatment type and time for DASI score 
(p=0.002). The DASI scores tended to be higher among patients undergoing on-pump CABG 
one and two years after surgery but higher among patients undergoing off-pump CABG four 
years after surgery.   
Propensity Score Analysis 
 The propensity score logistic regression model predicting use of off-pump CABG was 
well calibrated (Hosmer-Lemeshow p-value = 0.14; c-index = 0.734). The propensity scores 
(ranging from 0.024 – 0.910) were based on timing of the CABG (index versus subsequent), 
randomization arm (revascularization versus medical therapy), sex, obesity status (body mass 
index > 30), myocardial jeopardy score, left ventricular ejection fraction, glomerular filtration 
rate, and occurrence of non-coronary vascular surgery, and occurrence of chronic obstructive 
pulmonary disease prior to CABG. There was modest overlap in the distribution of propensity 
score by type of procedure (Figure 5-5). Matching resulted in 153 off-pump patients matched 
with 153 patients in the on-pump group. The two study groups were comparable with respect to 
baseline clinical characteristics (Table 5-1), ensuring a well-balanced matched dataset with the 
exception of regional differences that were handled through model adjustment.   
Outcomes for Propensity Score Matched Subset 
In the matched sample, the within-hospital complications did not differ significantly 
between the off-pump (11.1%) and on-pump (15.7%) patients, p = 0.25. The 30-day clinical 
outcomes did not differ significantly for death (1.3% on-pump versus 2.6% off-pump, p = 0.41) 
or death/MI/stroke (3.9% versus 7.8% patients, p = 0.16).  A significantly higher proportion of 
patients undergoing off-pump CABG (11 %) than those undergoing on-pump CABG (2.6%) 
required repeat revascularization in the long-term (p = 0.005). 
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The long-term risks of death were not statistically different (Table 5-3), but the risk of 
death/MI/stroke was significantly higher (adjusted HR: 1.83, p = 0.046) among the off-pump 
patients. The off-pump and region interaction terms were not significant for any of the clinical 
outcomes.  
As shown in Figure 5-3B, the proportion of patients suffering from angina within the 
matched sample was lower in the off-pump than the on-pump. However, the difference was not 
significant after adjusting for region and time after surgery (Table 5-4).  The DASI scores in the 
matched sample were similar in the two groups (Figure 5-4B, adjusted β: -1.79, 95% CI: -4.92 to 
1.34). There were no significant interactions between treatment type and time or treatment type 
and region for the functional outcomes in this patient set.  
5.5 DISCUSSION 
The use of off-pump CABG continues to be controversial with distinct advantages and 
disadvantages compared with on-pump CABG. In this study we found that the rates of death and 
major cardiovascular events (death, MI or stroke) were 40% – 80% higher after off-pump 
CABG, but these trends were only marginally significant because of the relatively small sample 
size. These patterns suggest that these trends could increase longer term.  Our findings suggest 
that off-pump CABG should be used in patients with diabetes with caution.  
One limitation of this study is that there was no randomization between the two surgical 
techniques.  We therefore used two statistical methods to compare the off-pump and on-pump 
groups, enabling us to make robust inferences. Multivariable Cox regression models were used 
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to estimate hazard risks in the whole population, whereas the matching restricted the comparison 
to patients that are analogous between the two groups. The estimates obtained from multivariable 
regression models may not effectively account for treatment selection bias but are representative 
of the real world scenario where in the physicians were allowed to choose between off-pump and 
on-pump CABG as a means of offering their best approach to surgical revascularization. On the 
other hand, the estimates obtained based from matched subset of patients ensure that clinical 
covariates are uniformly distributed between the two groups, thus estimating the effect of off-
pump CABG among those who actually receive off-pump procedures. However, unmeasured 
confounders that can lead to residual selection biases may exist. We did not have sufficient 
information regarding the off-pump to on-pump conversions which may affect our estimates. 
Also, details on the off-pump procedure technique (aortic manipulation, side-clamp use) were 
not available. Finally, since many of the revascularizations considered in this analysis were 
subsequent procedures, there was missing information regarding the completeness of 
revascularization for a large proportion of the procedures. The reasons for higher rates of adverse 
clinical outcomes during the course of follow-up may have been easier to decipher if this 
information was available. 
In our analysis, we observed significant differences in the peri/post-procedural 
complications and short-term clinical outcomes between off-pump and on-pump patients when 
analyzing all patients but these were attenuated in the matched subset. The off-pump patient’s 
marginally higher estimated risks of death that failed to reach statistical significance in both the 
analyses. However, the risk of death/MI/stroke which was not significantly higher among off-
pump patients when considering all patients was significantly higher in the matched subset of 
patients. Also, a significantly larger proportion of off-pump patients in the matched subset 
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required repeat revascularization. These differences in results may reflect the treatment selection 
biases.  In the BARI 2D population, patients undergoing off-pump CABG were younger, a lower 
proportion of them were obese, had higher glomerular filtration rate, lower serum creatinine 
levels, higher left ventricular ejection fraction (LVEF), higher Hba1c, higher energy scores and 
were more often from countries outside of the US and Canada.  
A limited number of studies have compared off-pump with on-pump CABG among 
patients with diabetes138-141.  Some have shown that although off-pump CABG had fewer 
complications, there were no survival advantages of off-pump CABG over on-pump CABG 
among diabetic patients138, 139. Other studies indicate that patients undergoing off-pump CABGs 
have lower complication rates as well as lower mortality140, 141; however, these are single center 
studies that did not consider long-term outcomes. The literature indicates that off-pump 
procedures may be associated with inferior graft patency studies and incomplete 
revascularization that may adversely affect in the long-term128-130, 209. To the best of our 
knowledge, there have been no multicenter observational studies or randomized trials comparing 
outcomes occurring more than 1 year after surgery. There has been a recent study, though single 
institution but with over 5,000 patients with a median follow-up of 6 years which shows a long 
term survival advantage with on pump surgery19.  This is consistent with our study which 
includes data from multiple clinical sites, with patients having an average follow-up for more 
than 4 years. 
There were no significant differences in angina and DASI reports after adjusting for 
patient characteristics at the time of surgery. Although angina rates were higher in the on-pump 
patients in the matched dataset, after accounting for region and repeated measures these 
differences were attenuated and non-significant. This indicates that the association between 
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surgery type and angina may have been confounded by the region where the procedure was 
performed. 
Since the type of surgery was not randomly assigned, we performed propensity score 
analyses to account for the treatment selection bias. However, unmeasured confounders that can 
lead to residual selection biases may exist. We did not have sufficient information regarding the 
off-pump to on-pump conversions which may affect our estimates. Finally, many patients 
undergoing CABG had missing information regarding the completeness of revascularization 
procedure. The reasons for higher rates of adverse clinical outcomes during the course of follow-
up may have been easier to decipher if this information was available.  
5.6 CONCLUSIONS 
In summary, our results demonstrate that in the BARI 2D trial, diabetic patients 
undergoing off-pump CABG had significantly higher risks of death/MI/stroke over the long term 
as compared to those undergoing on-pump CABG. This occurred despite having lower or 
comparable within-hospital complication rates. Thus, off-pump CABG is not recommended for 
patients with diabetes. 
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5.7 TABLES AND FIGURES 
Table 5-1: Baseline Characteristics of All Patients and Those in the Propensity Scored 
Matched Dataset by Type of Procedure 
All Patients undergoing 
CABG with type of procedure 
information 
Patients in the 
Propensity Score Matched 
Dataset 
On-Pump 
(N = 444) 
Off Pump 
(N = 171) P-value
ϯ On-Pump(N = 153) 
Off-Pump 
(N = 153) 
P-
valueϯϯ 




278 (63%) 145 (85%) <0.0001* 134 (88%) 127 (83%) 0.50 
Assigned to Insulin 
Providing  231 (52%) 86 (50%) 0.70 73 (48%) 76 (50%) 0.74 
Index CABG (all 
strata) 222 (50%) 125 (73%) <0.0001* 116 (76%) 111 (73%)  0.45 
Time to CABG after 
randomization  in 
days, mean (standard 
deviation) 
341 (506) 167.3 (385) <0.0001* 206 (424) 152 (341) 0.34 
Geographic Region <0.0001* <0.0001* 
   USA 253 (57%) 53 (31%) 82 (54%) 46 (30%) 
   Canada 115 (26%) 8 (4.7%) 35 (23%) 8 (5.2%) 
   Mexico 15 (3.4%) 21 (12%) 10 (6.5%) 18 (12%) 
   Brazil 43 (9.7%) 85 (50%) 16 (11%) 78 (6.0%) 
   Czech 
Republic/Austria 18 (4.1%) 4 (2.3%) 10 (6.5%) 3 (2.0%) 
Other Baseline 
Characteristics 
Age in years, mean 
(standard deviation) 64 (8.7) 62 (8.2) 0.03* 64 (8.8) 62 (8.04) 0.13 
Male sex 340 (77%) 116 (68%) 0.03* 42 (73%) 50 (67%) 0.30 
Race White non-
Hispanic 305 (69%) 112 (66%) 0.45 103 (67%) 102 (67%) 0.90 
Obesity (BMI >30 
kg/m2) at baseline 240 (54%) 64 (38%) 0.0002* 64 (42%) 61 (40%) 0.56 
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Number of vessels 
with  >50% lesions, % 0.88 0.43 
    1 – Vessel disease, 
% 81 (18%) 28 (16%) 23 (15%) 22 (14%) 
    2 – Vessel disease, 
% 174 (39%) 72 (42%) 71 (46%) 63 (41%) 
    3 – Vessel disease, 
% 182 (41%) 69 (40%) 57 (37%) 66 (43%) 
Myocardial Jeopardy 
Score  60.0 (22) 56 (22) 0.10 58 (23) 59 (21) 0.89 
LVEF at time of 
evaluation - prior to 
randomization 
57 (12) 60.0 (9.5) <0.001 59 (12) 60 (9.7) 0.69 
Conditions Any Time 
Prior to CABG 
Previous MI 160(36%) 71 (42%) 0.21 52 (34%) 67 (44%) 0.09 
CVA prior to CABG 45 (10%) 13 (7.6%) 0.34 9 (5.9) 12 (7.8) 0.51 
COPD prior to CABG  17 (3.8) 2 (1.2) 0.09 0 2 (1.3) - 
Non-coronary vascular 
surgery prior to 
CABG  
7 (1.6) 8 (4.8) 0.03* 3 (2.0) 4 (2.6) 0.71 
Any CHF therapy 
prior to CABG 76 (17%) 21 (12%) 0.14 25 (16%) 20 (13%) 0.11 
    NYHA class 0.46 
    Class I 34 (7.7%) 9 (5.3%) 12 7 
    Class II 32 (7.2%) 6 (3.5%) 11 6 
    Class III 6 (1.4%) 2 (1.2%) 0 2 
    Class IV 2 (0.5%) 2 (1.2%) 2 2 
Previous percutaneous 
coronary intervention 112 (25%) 40 (23%) 0.64 35 (23) 34 (22.2) 0.90 
Dyspnea or SOB 315 (89%) 92 (92%) 0.35 94 (85%) 85 (93%) 0.17 
Conditions at the 
Last Visit Prior to 
CABG 
Hypertension at visit 
prior to surgery 
(Sitting BP > 130/80) 
168 (38%) 81 (42%) 0.03* 66 (44%) 74 (49%)  0.43 
Triglycerides at visit 
prior to surgery, mean 
(sd) 
168 (107) 168 (81) 0.19 162 (90) 168 (79) 0.17 
GFR, ml/min/1.73m2, 
mean (sd) 73 (22) 80 (24) 0.01* 78 (22) 79 (24) 0.77 
Serum creatinine, 




(0.26) 1.03 (0.28) 0.48 
91 
Table 5-1 Continued
Smoking 0.5908 0.90 
    Current 61 (14%) 19 (11%) 17 (11.11) 17 (11.11) 
    Previous 232 (55.9%) 89 (52.05%) 79 (51.63) 80 (52.29) 
    Never 150 (34%) 63 (37%) 57 (37.25) 56 (36.60) 
HbA1c % 7.5 (1.5) 7.8 (1.8) 0.048* 7.5 (1.6) 7.8 (1.8) 0.43 
QoL at Last Visit 
Prior to CABG 
Health rating 64 (20) 63 (20) 0.49 64 (21) 63 (20) 0.68 
Self-rated health 0.22 0.31 
    Poor 49 (11%) 17 (10%) 17 (11%) 14 (9%) 
    Fair 149 (34%) 65 (39%) 54 (36%) 57 (38%) 
    Good 187 (43%) 75 (45%) 59 (39%) 70 (47%) 
    Very good 47 (11%) 8 (4.8%) 20 (13%) 7 (4.7%) 
    Excellent 7 (1.6%) 3 (1.8%) 2 (1.3%) 2 (1.3%) 
DASI (0 – 58.2) 18 (13) 16 (10) 0.25 18 (13) 16 (10) 0.31 
Health distress score 
(0 – 100) 39 (26) 38 (24) 0.70 38 (25) 38 (24) 0.96 
At Time of Surgery 
Angina status at time 
of surgery 0.52 0.56 
    Stable 358 (81%) 138 (81%) 132 (86%) 123 (80%) 
    Class I 109 28 38 24 
    Class II 135 75 65 67 
    Class III 88 25 25 23 
  Class IV 20 6 3 6 
    Unstable 71 (16%) 30 (18%) 18 (12%) 27 (18%) 
    Acute MI 15 (3.4%) 3 (1.8) 3 (2.0%) 3 (2.0%) 
Medication pre-
procedure  
(within 48 hours), % 
Aspirin 284 (64%) 71 (42%) <0.0001* 91 (59.48) 62 (40.52) 0.40 
Beta-Blockers 388 (87%) 157 (92%) 0.12 135 (88%) 142 (93%) 0.16 
ACE inhibitors 284 (64%) 102 (60%) 0.32 100 (65%) 91 (59%) 0.27 
Calcium antagonists 155 (35%) 55 (32%) 0.52 49 (32%) 48 (31%) 0.90 
Nitrates 249 (56%) 85 (50%1) 0.16 77 (50%) 78 (51%) 0.91 
Diuretics 181 (41%) 49 (29%) 0.0054* 56 (37%) 43 (28%) 0.11 
Other vasodilators 27 (6.1%) 4 (2.3%) 0.057 7 (4.6%) 4 (2.6%) 0.37 
Digitalis 13 (2.9%) 3 (1.8%) 0.41 5 (3.3%) 3 (2.0%) 0.48 
Clopidogrel 49 (11%) 14 (8%) 0.29 13 (8.5%) 13 (8.5%) 0.99 
Antiarrythmics 12 (2.7%) 5 (2.9%) 0.88 8 (5.2%) 5 (3.3%) 0.41 
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Table 5-1 Continued
Note: Baseline characteristics had no or <3% observations missing until unless indicated. The 
percentages are calculated based on available data and may not add to 100% 
^ 45 patients missing LVEF information (43 patients in the off-pump group and 2 
patients in the on-pump group) 
164 patients missing Dyspnea or SOB information (93 patients in the on-pump group and 
71 patients in the off-pump group) 
Ϯ P-value calculated using Kruskal-Wallis test for continuous variables and using chi-
square/Fischer’s exact for categorical variables 
ϯϯ P-value calculated using Signed rank test for continuous variables and McNemar 
test/test of symmetry for categorical variables 
*indicates p-value < 0.05
MI=myocardial infarction, CVA= cerebrovascular accident, CHF=congestive heart 
failure, SOB=shortness of breath, QoL=quality of life 
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Table 5-2: Complications and Short-term Clinical Outcomes for Patients Undergoing 
CABG Surgery 
On pump 
(N = 444) 
Off pump 
(N = 171) 
P-value* 
Complications (within hospitalization) 
Peri/Post-procedure complications 90 (20.3) 17 (9.9) 0.003 
Neurological 14 (3.2) 2 (1.2) 0.26 
Cardiac 25 (5.6) 2 (1.2) 0.016 
Renal 2 (0.45) 2 (1.17) 0.31 
Vascular 0 0 - 
Pulmonary 19 (4.3) 7 (4.1) 0.92 
Bleeding 19 (4.3) 3 (1.8) 0.13 
Inotropes >48 hours, n (%) 50 (11.4) 9 (5.3) 0.023 
Short-term Clinical Outcomes (within 30 days) 
Death/MI/Stroke 13 (2.9) 12 (7.0) 0.021 
Death 3 (0.68) 4 (2.3) 0.10 
MI 9 (2.03) 6 (3.5) 0.29 
Stroke 1 (0.23) 3 (1.8) 0.07 
*P-values based on Chi-square/Fishers test
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Table 5-3: Effects of Performing Off-pump Procedure on Clinical Outcomes 
Outcomes for All Patients 
(N = 615) 
Unadjusted  
(Off-pump vs On-pump) 
Adjusted 
(Offpump vs On-pump) 
HR 95% CI P-value HRф 95% CI P-value 
Death (events = 69) 1.49 0.91 – 2.4 0.114 1.41 0.81 – 2.45 0.220 
Death/MI/Stroke (events = 103) 1.47 0.98 – 2.21 0.060 1.47 0.92 – 2.33 0.106 
 Outcomes for Propensity Score Matched Patients 
(N=306, 153 Pairs) 
Unadjusted Adjusted 
HR 95% CI P-value HR* 95% CI P-value 
Death (events = 36) 1.82 0.92 – 3.16 0.090 1.55 0.71 – 3.37 0.270 
Death/MI/Stroke (events = 54) 1.88 1.09 – 3.25 0.023 1.83 1.01 – 3.32 0.046 
Ф Model for outcome of Death adjusted for region, age, need of diuretics pre-surgery; Model for outcome of Death/MI/Stroke 
adjusted for region, age, sex, blood pressure greater than 130/80, need of aspirin, diuretics pre-surgery and energy scores 
*Adjusted for region (region: US/Canada versus Others)
95 
Table 5-4: Effects of Performing Off-pump Procedure on Functional Outcomes 
Effectsϯ All Patients Matched Sample 
Angina N = 564 N = 283 
Unadjusted OR 95% CI P-value Type III 
SS P-value 
OR 95% CI P-value Type III 
SS P-value 
Off-pump (Yes vs No) 0.51 0.31 – 0.81 0.005 0.002 0.47 0.26 – 0.83 0.01 0.01 
Time after Surgery 0.30 0.87 
Year 2 (Ref: Year 1) 1.22 0.89 – 1.69 0.21 1.12 0.69 – 1.77 0.66 
Year 3 (Ref: Year 1) 1.13 0.77 – 1.67 0.52 1.21 0.68 – 2.15 0.52 
Year 4 (Ref: Year 1) 0.86 0.55 – 1.36 0.53 0.97 0.52 – 1.94 0.94 
Adjusted ORǂ 95% CI P-value Type III 
SS P-value 
OR* 95% CI P-value Type III 
SS P-value 
Off-pump (Yes vs No) 0.74 0.44 – 1.21 0.24 0.22 0.68 0.36 – 1.28 0.23 0.22 
Time after Surgery 0.29 0.87 
Year 2 (Ref: Year 1) 1.25 0.90 – 1.76 0.19 1.12 0.69 – 1.80 0.65 
Year 3 (Ref: Year 1) 1.17 0.78 – 1.77 0.45 1.21 0.68 – 2.17 0.52 
Year 4 (Ref: Year 1) 0.87 0.54 – 1.40 0.56 0.98 0.52 – 1.82 0.94 
DASI N = 553 N = 277 
Unadjusted Betaǂǂ 95% CI P-value Type III 
SS P-value 
Beta 95% CI P-value Type III 
SS P-value 
Off-pump (Yes vs No) 2.52 0.61 – 4.43 0.01 0.01 0.34 -2.48 – 3.17 0.81 0.81 
Time after Surgery 0.36 0.44 
Year 2 (Ref: Year 1) 0.20 -0.80 – 1.21 0.69 0.28 -1.01 – 1.56 0.67 
Year 3 (Ref: Year 1) -0.57 -1.56 – 0.43 0.26 -0.13 -1.53 – 1.28 0.86 
Year 4 (Ref: Year 1) 0.15 -0.98 – 1.27 0.80 1.05 -0.54 – 2.65 0.20 
Adjusted Betaǂǂǂ 95% CI P-value Type III 
SS P-value 
Beta* 95% CI P-value Type III 
SS P-value 
Off-pump - - - - -1.79 -4.92 – 1.34 0.26 0.27 
Time after Surgery 0.044 0.44 
Year 2 (Ref: Year 1) 0.25 -0.98 – 1.48 0.69 0.28 -1.01 – 1.56 0.68 
Year 3 (Ref: Year 1) -1.22 -2.43 – -0.01 0.048 -0.15 -1.55 – 1.26 0.84 
Year 4 (Ref: Year 1) -1.12 -2.45 – 0.21 0.10 1.03 -0.56 – 2.62 0.21 
Interaction between Procedure Type and Time 0.005 - - - - 
Off-Pump (Yes vs No) -1.93 -4.42 – 0.56 0.13 
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ǂ Model adjusted for baseline characteristics that differed between off-pump and on-pump patients including region, 
randomization assignment, whether the surgery was performed as  an index procedure, sex, age, obesity, left ventricular ejection 
fraction, hypertension (yes/no), glomerular filteration rate, prior pvd, hba1c level, aspirin medication prior to surgery, diuretics 
medication prior to surgery, energy scores in addition to time after surgery 
ǂǂ Model adjusted for baseline DASI scores and characteristics that differed between off-pump and on-pump patients including 
region, randomization assignment, whether the surgery was performed as  an index procedure, sex, age, obesity, left ventricular 
ejection fraction, hypertension (yes/no), glomerular filteration rate, prior pvd, hba1c level, aspirin medication prior to surgery, 
diuretics medication prior to surgery, energy scores, time and interaction between time and off-pump *Model adjusted for region 
where the procedure was performed and time after surgery 
at Year 1 
Off-Pump at Year 2 -2.17 -4.68 – 0.35 0.09 
Off-pump at Year 3 -0.08 -2.35– 2.19 0.95 
Off-pump at Year 4 2.04 -0.76 – 4.84 0.15 
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Table 5-4 Continued
Figure 5-1: Sample Population from BARI 2D trial undergoing a CABG procedure
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Number of Patients  at Risk at the Specified Time Points 
CABG Type 1 year 2 year 3 year 4 year 
On-pump (N = 444) 418 389 350 273 
Off-pump (N = 171) 161 157 145 111 
Figure 5-2: Survival for Patients Undergoing Off-pump and On-pump CABG 
Number of Patients at Risk at the Specified Time Points 
CABG Type 1 year 2 year 3 year 4 year 
On-pump (N = 444) 379 344 287 190 
Off-pump (N = 171) 150 144 115 65 
Figure 5-3: Freedom from Death/MI/Stroke for Patients Undergoing Off-pump and On-
pump CABG 
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Number of Patients at Risk at the Specified Time Points 
CABG Type 1 year 2 year 3 year 4 year 
On-pump (N = 444) 402 371 335 268 
Off-pump (N = 171) 158 154 143 111 
A: Patients Experiencing Angina at 1, 2, 3 and 4 Years after Surgery 
Number of Patients at Risk at the Specified Time Points 
CABG Type 1 year 2 year 3 year 4 year 
On-pump (N = 153) 141 131 123 106 
Off-pump (N = 153) 142 139 129 99 
B: Patients in the Matched Sample Experiencing Angina at 1, 2, 3 and 4 Years after Surgery 
Figure 5-4:  Angina among Patients Undergoing Off-pump and On-pump CABG 
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Number of Patients  at Risk at the Specified Time Points 
CABG Type 1 year 2 year 3 year 4 year 
On-pump (N = 444) 388 346 313 256 
Off-pump (N = 171) 149 147 135 104 
A:  DASI Scores at 1, 2, 3 and 4 Years after Surgery (All Patients) 
Number of Patients at Risk at the Specified Time Points 
CABG Type 1 year 2 year 3 year 4 year 
On-pump (N = 153) 135 126 118 102 
Off-pump (N = 153) 134 132 121 93 
B: DASI Scores at 1, 2, 3 and 4 Years after Surgery (Matched Sample) 
Figure 5-5: Average DASI Scores for Patients Undergoing Off-pump and On-pump CABG
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Figure 5-6: Distribution of Propensity Scores by Procedure Type 
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6.0  MANUSCRIPT 2 (ADDENDUM): ECONOMIC ANALYSES COMPARING OFF-
PUMP AND ON-PUMP CABG  
Specific Aim 
To determine whether off-pump coronary artery bypass grafting (CABG) is a cost-
effective strategy as compared to on-pump CABG. This aim uses data from Bypass Angioplasty 
Revascularization Investigation 2 Diabetes (BARI-2D) trial to identify the cost-effective strategy 
(comparing off-pump and on-pump CABG)  at two years after surgery. 
6.1 METHODS 
This analysis includes a subset of patients who underwent a CABG procedure in the 
BARI 2D trial. The subset comprised of patients who underwent CABG as their index procedure, 
had at least 2 years of potential follow-up data. Of the 347 patients who underwent CABG as 
their index procedure, there were 269 (77.5%) patients who had at least 2 years of potential 
follow-up data.  Of these, 2 patients had no follow-up for their quality of life assessments after 
surgery and hence were not included in the analyses. This resulted in a sample size of 267 
patients, 159 (59.6%) of which underwent the on-pump procedure and 108 (40.4%) underwent 
the off-pump procedure.  
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In BARI 2D, an Economics Core Laboratory at Stanford University School of Medicine 
collected data regarding medical utilization. The patients had to consent specifically to 
participate in the economic research of the BARI-2D study. A core lab staff or a site designate 
contacted the consented patients every 3 months by telephone to document occurrence of 
hospital admissions, physician visits, outpatient tests and procedures, and prescription 
medications. The Economics core team attempted to collect records for hospital admissions to be 
able to verify the inpatient procedure and admissions data. They determined medical care costs 
for each patient by applying a standardized cost weight to each medical resource used. Hospital 
admissions were assigned to a Diagnosis Related Group and costs were calculated using the 
fiscal year weights and the national conversion factor. Physician fees from the Medicare 
schedule were used to determine costs for office tests and physician visits and for inpatient 
procedures. Prescription drugs were assigned costs based on average wholesale prices obtained 
from the Red Book, Pharmacy’s Fundamental Reference210.  
Costs and Effectiveness 
The cost-effectiveness analyses were conducted for two perspectives: hospital and third 
party payers. The hospitals perspective costs included the procedure costs and opportunity costs 
of bed-days for the duration of hospitalization. The third-party payer perspective included the 
costs related to the procedure, hospitalization, nursing home and rehabilitation, outpatient visits, 
outpatient procedures and medication.  
For the hospital perspective, we obtained cost estimates of the two procedure types from 
the literature since the trial data did not differentiate between the off-pump and on-pump costs. 
The costs associated per bed-day were obtained using the Healthcare Cost and Utilization Project 
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(HCUP) data. The hospitalization duration (obtained from trial data) multiplied with the bed day 
costs determined the total bed-day costs. 
For the third party perspective, the CABG procedure costs were obtained from the 
Physician Fee Schedule using the Healthcare Procedure Coding System Codes (33533 – 33536 
along with 33517 – 33523). The costs related to hospitalization, nursing home, outpatient visits, 
medications and other procedures were obtained from the trial’s economic core team.  The costs 
obtained from literature and online databases were modeled as gamma distribution to reflect the 
variability among patients. The shape and scale parameters of the gamma distributions were 
approximated using means and standard deviations obtained from the HCUP and/or Physician 
Fee Schedule data. All costs were discounted to year 2014 using a 3% discount rate. 
The associated effectiveness of each treatment was expressed as quality adjusted life-
years. The quality adjusted life-years were calculated as the product of utility score of each 
patient and the mean survival time for the respective group. Melsop et al used a multiple linear 
regression model to determine the relationship between the time trade-off scale and quality of 
life scales, for patients with coronary disease211.  The utility scores depended on Duke Activity 
State Index, self-reported health status, Canadian Cardiovascular Society class for angina, and 
health rating, as determined previously. Among all patients who lived for at least 2 years after 
surgery, 12 (4.5%) had missing angina and quality of life data. The last observations noted for 
the respective measures were used to impute the missing information for these patients.  
Analyses 
We determined the costs between all patients undergoing off-pump and on-pump CABG 
procedures as their initial procedure and had at least 2 years of potential follow-up data. The 
summary statistics for costs are presented as mean and standard deviation and compared using 
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the non-parametric Wilcoxon rank-sum test. Baseline demographic and clinical characteristics 
were compared between patients undergoing on-pump and off-pump procedure. Summary 
statistics for the baseline characteristics are presented as means and standard deviation in case of 
continuous variables, and as numbers and percentages in case of categorical variables. 
Continuous variables were compared using Wilcoxon rank-sum test and categorical variables 
using chi-square or Fischer’s exact, where appropriate.   
The propensity score methodology was used to control for non-randomized treatment 
selection of the off-pump and on-pump CABG. Two sets of propensity scores were calculated 
for each patient, using separate multivariable logistic regression model. The candidate variables 
for the first model comprised of objective baseline characteristics (demographic and clinical) 
which were different between the off-pump and on-pump group at a significance level of 0.10. 
The second model included all candidate variables used for the first model except for geographic 
region.  Backward-selection methods utilizing an alpha = 0.20 for eliminating variables were 
used to further refine each model.  Based on the calculated propensity scores, patients 
undergoing off-pump CABG were matched with those undergoing on-pump (1:1 match, without 
replacement) using a caliper of 0.01. 
The cost-effectiveness analyses within the matched sample were carried out from the 
hospital and third-party payer’s perspective. Bootstrapping involved resampling the costs and 
effects from the resulting matched sample jointly with replacement. The incremental net health 
benefit was calculated using this data to report the cost-effectiveness results. This process was 
repeated 1000 times. The 1000 bootstrap estimates of the net health benefits then provided the 
empirical sampling distribution,  using which the percentiles were calculated. The net health 
benefits (NHB) framework was introduced in response to the inference issues associated with 
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incremental cost-effectiveness ratios, especially when the distribution of costs and effects extend 
to more than one quadrant42.  NHB transforms cost and effect into a linear function, having a 
more comprehendible interpretation of the estimate and its uncertainty. 
Thus the incremental NHB of off-pump (T1) compared to on-pump (T0) was calculated as 
Where and  represent the mean effectiveness and the mean costs respectively, of 
treatment Ti;  λ represents the threshold cost-effectiveness ratio. 
The uncertainty associated with incremental NHBs was depicted using the cost-
effectiveness acceptability curve. The off-pump was considered the optimum strategy if the 
resulting incremental health benefit was greater than 0. All costs were discounted to 2014 US 
dollars. As a sensitivity analyses, we examined the costs and effects for patients undergoing 
CABG in US/Canada within the matched sample, recognizing that costs can vary significantly by 
country.  
6.2 RESULTS 
There were 347 patients who underwent CABG as their index procedure in the BARI 2D 
trial. Of the 347 patients, 267 had  at least 2 years of follow-up or had experienced a death. 
Among these, 159 (59.6%) patients had an on-pump procedure and 108 (40.4%) underwent the 
off-pump procedure.  
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Table 6-1 lists and compares cost components and effectiveness between patients 
undergoing the on-pump and off-pump CABG. The on-pump CABG procedure costs to the 
hospital are slightly higher than the off-pump CABG; but they are not significantly different. The 
total number of hospitalization days for patients in the off-pump group was significantly higher 
than the patients in the on-pump group (On-pump: 19.8 days (s.d = 22.7) ; off-pump: 24.2 days 
(s.d = 23.8), p = 0.0003). This translated to significantly higher bed costs incurred to the hospital. 
The total hospital perspective costs were significantly higher for off-pump patients. The 
hospitalization, outpatient, medication and other procedure costs were comparable between the 
off-pump and on-pump patients. Thus there were no significant differences in the total third 
party payer perspective costs. The mean survival time was not significantly different between the 
two groups. The truncated mean survival time was 1.89 (s.d. = 0.39) and 1.88 (s.d. = 0.45) years 
for the on-pump and off-pump patients respectively. As shown in figure 6-1, the two year 
survival Kaplan-Meier estimates were not significantly different between the two groups (On-
pump group survival: 94.9% and 91.2%, Off-pump group survival: 94.4% and 93.5% at 1 year 
and 2 year respectively). However, the quality of life was significantly higher for patients in the 
off-pump group as compared to the patients in the on-pump group (Table 6-1).  
The on-pump and off-pump groups are the not randomized in the BARI-2D clinical trial. 
There therefore were certain baseline differences between patients undergoing on-pump and off-
pump CABG (Table 6-2).  The distribution of country of origin varied significantly across the 
two procedure groups. In addition, patients in the off-pump group were younger, had lower 
serum creatinine levels and were less likely to be males, obese, have a prior history of chronic 
obstructive pulmonary disease. Patients undergoing off-pump and on-pump also differed in terms 
of medications administered prior to surgery (aspirin, diuretics, angiotensin-converting-enzyme 
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inhibitor) and self-reported quality of life measures (energy scores and health rate). Since 
baseline differences among patients can influence the costs, further economic analyses were 
based on the propensity score analyses. 
Propensity Score Model 1 (including region as a candidate variable), Table 6-3 
 All of the baseline characteristics listed in Table 6-1 that were significantly different 
between the off-pump and on-pump group, and potentially affected the treatment selection 
decision were included as candidate variables to determine the final model for calculating 
propensity scores. The pre-procedural therapy (within 48 hours) was not included since it was 
considered part of procedural delivered rather than a predictor of treatment selection. Also, since 
we focused on objective measures, the self-reported quality of life assessments were not 
considered as candidate variables. The propensity scores model obtained from the backward 
selection methods included region (US/Canada versus Others) and obese (BMI greater than 30 
versus less than 30). As illustrated in Figure 6-2, the distributions of the propensity scores were 
substantially different between the two procedure groups, with no overlap. Thus, an alternate 
model which did not include geographic region as a candidate variable was considered for 
calculating the propensity scores. 
Propensity Score Model 2 (not including region as a candidate variable), Table 6-4 
The second set of propensity scores were based on sex, age, obesity and prior history of 
chronic pulmonary obstructive disorder, as determined by the backward selection methodology. 
The model was further refined by including if the patient had CABG as the preferred method of 
revascularization to result in a more balanced off-pump and on-pump groups. There was a 
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modest overlap in the distribution of propensity scores between the two groups, as shown in 
figure 6-3. The matching resulted in 84 pairs of patients. The matched patient groups differed 
with respect to region, self-reported energy and rated health scores, and aspirin use within 48 
hours prior to surgery.  The energy and health rating scores are subjective. The medication use 
within 48 hours prior to surgery could be a part of the procedure protocol and hence was not 
adjusted for in the propensity scores.  Since costs may vary with region, we did a sub-analysis 
for patients undergoing surgery in US/Canada. Within the matched set, the truncated mean 
survival time was 1.89 (s.d = 0.43) and 1.85 (s.d. = 0.50) among on-pump and off-pump patients 
respectively (Figure 6-4).  
Economic Analyses in the Matched Set of Patients 
Table 6-5 shows the costs and effectiveness measures along with the associated 2.5th and 
97.5th percentiles for patients undergoing the on-pump and off-pump surgery obtained by 
bootstrapping the matched subsample. Within the matched patients, there were no significant 
differences in life years or quality adjusted life years. From the hospital perspective, the patients 
undergoing off-pump had significantly higher costs as compared to on-pump group. Combining 
the costs and effectiveness estimates, the net health benefits were significantly lower for  patients 
undergoing off-pump  as compared to patients undergoing on-pump CABG.  
From the third party payer perspective, the two strategies are comparable in terms of 
costs, effectiveness and the net health benefits. 
The ICER planes (Figure 6-5 and 6-6) show the variability among the bootstrap samples. 
The choice of the effectiveness measure (i.e. QALY or life years) also affected the decision of 
determining the cost-effectiveness strategy. Among the 1000 bootstrap samples, off-pump 
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CABG was the optimal strategy from the hospital perspective in only 0.6 – 2% of iterations 
when effectiveness was calculated in terms of QALY and in 0.7 - 3% when effectiveness 
assessed in terms of life years, the range depending on the cost-effectiveness threshold (Figure 6-
7).   When considering the third party payers perspective, off-pump was the optimal strategy 41 - 
49% iterations with effectiveness measured in QALYs; 26 - 30% iterations showed off-pump 
strategy was optimal when effectiveness was measured in terms of life years. 
Analyses Restricted to Patients Undergoing CABG in US or Canada 
Of the 168 patients in the aforementioned matched sample, 80 patients underwent CABG 
in US or Canada. The on-pump CABG was more common this geographical region, 60 (75%) 
were performed as on-pump and only 20 (25%) as off-pump procedure. Table 6-6 lists the 
bootstrap mean costs and effectiveness estimate along with the 2.5th and 97.5th percentiles.  The 
estimates obtained showed trends similar to what were observed within the entire matched 
sample, but none of the differences between the two procedures were statistically significant. 
6.3 DISCUSSION 
Results from this analysis further support the results obtained from comparison of clinical 
outcomes between the two types of procedure. The results show that from the hospital 
perspective, off-pump was not the favorable option as compared to on-pump patients. The net 
health benefits achieved by using off-pump procedures were significantly lower than that 
achieved by the on-pump procedure. This was mainly driven by higher costs incurred to the 
hospitals due to significantly greater number of inpatient days for patients in the off-pump group. 
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This trend was not observed for third party payers. The off-pump and on-pump strategies were 
very comparable from the third party perspective. 
This analysis has certain limitations.    First of all, the economic component of BARI-2D 
trial was designed to address primary randomized groups (which were revascularization and 
medical therapy for treatment of coronary artery disease, and insulin sensitization and insulin 
provision therapy for management of diabetic conditions). Due to this limitation we could not 
include all CABG procedures performed in the trial and had limited sample size. Also 
generalizability of costs particularly across geographic regions is an issue. We performed a sub-
analysis on patients undergoing CABG in US and Canada patients. However, this further limited 
the sample size. This analysis however gives useful insight into the cost-effectiveness analysis of 
on-pump and off-pump CABG procedure. Off-pump procedure costs (to the hospital) by 
themselves might tend to be lower since for such procedures the purchase of CPB machine is 
avoided. However over a period of time, off-pump procedure in fact accumulates excess costs to 
on-pump. Also the quality of life data were well collected and document in the BARI-2D trial. 
Out of the 269 patients, there were only 2 patients who had no angina or quality of life 
assessment after surgery. Also, we did not perform the cost-effectiveness analyses from societal 
perspective since indirect costs were not measured in BARI-2D trial.  Never the less, based on 
the observed worse long-term clinical outcomes along with the calculated higher/comparable 
short-term costs for patients in the off-pump group, it is inferable that off-pump is not an 
optimum CABG strategy for patients with diabetes from a societal perspective. However 
systematic research is required to make conclusions about the cost-effectiveness of off-pump 
CABG from the societal perspective. 
112 
6.4 CONCLUSIONS 
Our results show that the off-pump CABG is not a cost-effective strategy as compared to 
the on-pump CABG from the hospital perspective. When considering cost-effectiveness from the 
perspective of third party payers, the two procedures are comparable. Also keeping in view the 
worse clinical outcomes and comparable direct costs we can deduce that off-pump procedure 
will not be cost-effective from the societal perspective. Thus we conclude that on-pump should 
be the preferred CABG type  for patients  with diabetes, until unless contraindicated due to 
clinical conditions like cannulation of the aorta and cardiopulmonary bypass 
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6.5 TABLES AND FIGURES 
Table 6-1:  Costs and Effectiveness (Mean, Standard Deviation) for Patients undergoing 
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Quality Adjusted Life Years 1.698, 0.121 1.673, 0.131 1.733, 0.096 <.0001 
LIFE_YRS, mean, SD 1.890, 0.415 1.893, 0.393 1.885, 0.446 0.5472 
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*(Based on costs per bed-day obtained from HCUP (Mean = $2435, sd = $23) and 
hospitalization duration (On-pump: Mean = 19.8 days, sd = 22.7 ; Off-pump: Mean = 24.2 days, 
sd = 23.8, p = 0.0003) 
Table 6-2: Baseline Characteristics of Patients Undergoing On-pump and Off-pump CABG 
(All patients and Matched Subgroup) 











Insulin Providing Arm, 
% 
53.5 49.1 0.4816 53.6 45.2 0.2801 
CABG Strata, % 96.9 99.1 0.2299 98.8 98.8 1.0000 
Male, % 79.9 64.8 0.0060* 75.0 70.2 0.4889 
White non-hispanic, % 66.7 74.1 0.1963 66.7 76.2 0.1719 
BMI >= 30, % 52.5 34.3 0.0033* 38.1 42.9 0.5153 
SMK_STATUS, % 0.7168 0.6746 
Never 34.6 38.9 38.1 35.7 
Former smoker 54.1 49.1 47.6 53.6 
Current smoker 11.3 12.0 14.3 10.7 
Computed number of 
vessels with lesions 
>=50%, % 
0.6326 0.7730 
1 10.7 15.7 9.5 13.1 
2 44.7 39.8 44.0 36.9 
3 44.0 43.5 45.2 48.8 
Prior PCI, % 12.6 13.0 0.9263 11.9 15.5 0.5007 
Prior MI, % 30.8 35.2 0.4549 26.2 34.5 0.2402 
Earlier than 90 days 40.8 57.9 63.6 55.2 
Within 90 days 59.2 42.1 36.4 44.8 
Prior CVA, % 8.8 6.5 0.4888 11.9 6.0 0.1761 
Prior COPD, % 6.3 0.9 0.0305* 0.0 1.2 0.3159 
Prior PVD, % 1.3 2.8 0.3686 0.0 3.6 0.0805 
US/Canada, % 76.1 21.3 <.0001* 71.4 23.8 <.0001* 
Patient angina status 
surg, % 
0.1913 0.3326 
Stable 91.8 89.8 92.9 89.3 
Canadian card class 
surgery, % 
Class I 36.6 18.9 30.3 19.2 
115 
Class II 43.7 64.2 48.7 65.8 
Class III 18.3 13.7 21.1 12.3 
Class IV 1.4 3.2 0.0 2.7 
Unstable 6.3 10.2 6.0 10.7 
Acute MI 1.9 0.0 1.2 0.0 
Prior Coronary Heart 
Failure, % 
14.5 12.0 0.5685 7.1 11.9 0.2931 
Hypertension 
(BP>13080), % 
44.9 54.2 0.1368 42.0 56.6 0.0606 
Short Breathness at Last 
Visit Prior Surgery, % 
85.3 92.9 0.1585 85.2 93.6 0.1748 
Age at date of Surgery, 
mean, SD 
63.9, 9.0 60.9, 7.9 0.0028* 62.9, 8.9 62.5, 7.0 0.5864 




22.9, 16.3 0.1300 33.7, 32.7 22.9, 15.9 0.1097 
Serum Creatinine 
(mg/dl), mean, SD 
1.1, 0.3 1.0, 0.3 0.0192* 1.1, 0.3 1.1, 0.3 0.4182 
HbA1C, mean, SD 7.5, 1.6 7.8, 1.9 0.3273 7.3, 1.5 7.8, 1.9 0.1181 




77.3, 19.1 0.1493 74.5, 18.8 75.6, 19.3 0.8451 











59.4, 21.5 0.3289 63.9, 22.4 59.6, 21.2 0.1847 




58.9, 8.5 0.1376 56.5, 12.1 58.7, 8.8 0.1628 




62.6, 20.5 0.8324 62.4, 21.7 62.5, 21.5 0.9637 
DASI Scores, mean, SD 16.5, 
13.1 
15.4, 9.3 0.7056 17.3, 14.2 14.5, 8.9 0.7586 




36.9, 24.5 0.5960 36.8, 24.5 34.6, 23.5 0.6350 
Energy Score, mean, SD 51.8, 
23.9 
62.7, 22.4 0.0002* 50.9, 22.2 61.0, 23.1 0.0035 
Self-rated Health, % 0.0074* 0.0995 
Poor 11.5 15.0 12.0 13.3 
Fair 36.9 28.0 34.9 32.5 
Good 37.6 52.3 38.6 49.4 
Very Good 13.4 2.8 13.3 2.4 
Excellent 0.6 1.9 1.2 2.4 
Therapy Pre-Procedure, 
% (within 48 hours) 
Aspirin, % 56.6 35.2 0.0006* 52.4 34.5 0.0196* 
Beta Blocker, % 88.1 92.6 0.2270 86.9 91.7 0.3184 
Ace Inhibitor, % 70.4 60.2 0.0819* 72.6 60.7 0.1017 
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Table 6-2 Continued
Diuretic, % 35.2 25.0 0.0766* 31.0 27.4 0.6106 
Digitalis Derivative, % 1.9 0.9 0.5259 2.4 1.2 0.5602 
Ticlodipine Clop, % 6.3 2.8 0.1907 9.5 2.4 0.0504 
Antiarrhythmic Agent, 
% 
3.1 3.7 0.8038 2.4 4.8 0.4057 
Vasodilator, % 3.8 2.8 0.6581 3.6 3.6 0.9999 
Calcium Blocker, % 29.6 25.0 0.4139 27.4 26.2 0.8617 
 Nitrate,% 42.8 46.3 0.5688 33.3 46.4 0.0831 
Table 6-3: Propensity Score Logistic Regression Model 1 for Undergoing an Off-pump 
CABG (Propensity Score Model 1, With Region in the Model) 





Pr > ChiSq 
Intercept 1.0577 0.2376 19.8101 <.0001 
Bmi>30, yes/no -0.6175 0.3051 4.0978 0.0429 
region_us_can -2.4631 0.3057 64.9160 <.0001 
Table 6-4: Propensity Score Logistic Regression Model 2 for Undergoing an Off-pump 
CABG (Propensity Score Model 2 (without region as candidate variable) 





Pr > ChiSq 
Intercept 1.7854 1.4716 1.4718 0.2251 
Male -0.8028 0.2969 7.3111 0.0069 
Prior COPD -1.6640 1.0692 2.4219 0.1196 
Bmi>30, yes/no -0.7782 0.2710 8.2463 0.0041 
Age -0.0429 0.0156 7.5493 0.0060 
CABG Strata 1.5056 1.1255 1.7895 0.1810 
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Table 6-2 Continued
Table 6-5: Bootstrap Mean and Percentile Intervals of Costs and Effectiveness for Patients 





Total Hospital Perspective Costs (US $) 58376 
(50891 – 67074) 
74707 
(62908 – 90078) 
Incremental Hospital Perspective Costs (US $) 16331 (3607 – 31987)* 
Total Third Party Payers Perspective Costs (US $) 71904 
(67912 – 76443) 
72729 
(67742 – 78021) 
Incremental Third Party Payers Costs (US $) 824 (-5719 – 7433) 
QALY, mean, SD 1.696 
(1.665 – 1.722) 
1.701 
(1.680 – 1.720) 
Incremental QALY 0.005 (-0.03 – 0.044) 
LIFE_YRS, mean, SD 1.888 
(1.784 – 1.97) 
1.852 
(1.734 – 1.943) 
Incremental LY -0.03 (-0.18 – 0.102) 
Cost-effectiveness Estimates 
Hospital Perspective 
Net Heath Benefits, In terms of QALY 0.528 
(0.354 – 0.684) 
0.207 
-0.102 – 0.446) 
Incremental NHB QALY -0.32 (-0.644 – -0.06)* 
Net Health Benefits, In terms of Life Years 0.720 
(0.533 -  0.897) 
0.358 
(0.004 – 0.631) 
Incremental NHB LY -0.36 (-0.735 – -0.06)* 
Third Party Payer Perspective 
Net Heath Benefits, In terms of QALY 0.257 
(0.159 – 0.349) 
0.247 
(0.133 – 0.352) 
Incremental NHB QALY -0.01 (-0.16 -0.141) 
Net Health Benefits, In terms of Life Years 0.449 
(0.346 - 0.546) 
0.347 
(0.246 – 0.542) 
Incremental NHB LY -0.05 (-0.23 – 0.135) 
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Table 6-6: Bootstrap Mean and Percentile Intervals of Costs and Effectiveness for Patients 





Total Hospital Perspective Costs (US $) 47150 
(40208 – 54593) 
53632 
(42176 – 65505) 
Incremental Hospital Perspective Costs (US $) 6482 (-7111 – 21159) 
Total Third Party Payers Perspective Costs 
(US $) 
73802 
(68483 – 80015) 
86518 
(75033 – 100319) 
Incremental Third Party Payers Costs (US $) 12717 (-40 – 26702) 
QALY, mean, SD 1.678 
(1.641 – 1.710) 
1.674 
(1.622 – 1.719) 
Incremental QALY -0.004 (-0.06 – 0.5110) 
LIFE_YRS, mean, SD 1.969 
(1.932 – 2) 
2 
(2 – 2) 
Incremental LY 0.031 (0 – 0.0683) 
Cost-effectiveness Estimates 
Hospital Perspective 
Net Heath Benefits, In terms of QALY 0.735  
(0.5867 – 0.8839) 
0.602  
(0.3551 – 0.8634) 
Incremental NHB QALY -0.1338 (-0.4237- 0.1502) 
Net Health Benefits, In terms of Life Years 1.969 
(1.932 – 2) 
2 
(2 – 2) 
Incremental NHB LY -0.0990 (-0.5643 – 0.1826) 
Third Party Payer Perspective 
Net Heath Benefits, In terms of QALY 0.202  
(0.071 – 0.3212) 
-0.056  
(-0.335 – 0.1950) 
Incremental NHB QALY -0.2585 (-0.5643 – 0.0225) 
Net Health Benefits, In terms of Life Years 0.493  
(0.364 – 0.6010) 
0.269  
(-0.006 – 0.4993) 
Incremental NHB LY -0.2237 (-0.5070 - 0.0276) 
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Figure 6-1: Survival for Patients Undergoing Off-pump and  On-pump CABG 
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Figure 6-2: Distribution of Propensity Scores by Type of Procedure (Propensity Score 
Model 1: With Region in the Model) 
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Figure 6-3: Distribution of Propensity Scores by Type of Procedure (Propensity Score 
Model 2: Without Region in the Model) 
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Figure 6-4: Survival for Matched Patients 
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A: CE Plane when Effectiveness in terms of QALY 
B: CE Plane when Effectiveness in terms of Life Years 






A: CE Plane when Effectiveness is in terms of QALY 
B: CE Plane when Effectiveness is in terms of Life Years 






A: Cost-Effectiveness Acceptability Curve from the Hospital Perspective 
B: Cost-Effectiveness Acceptability Curve from the Third Party Payers Perspective 
Figure 6-7: Cost-effectiveness Acceptability Curve for Off-pump 
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7.1 ABSTRACT 
Background: Majority of patients fail to respond to the initial treatment for major 
depressive disorder. There are multiple treatment options available after initial treatment failure. 
However, there are no specific guidelines for choosing one second-line therapy over another. 
Previous results from Sequenced Treatment Alternatives to Relieve Depression (STAR*D) 
project show that bupropion, sertraline and venlafaxine are comparable in terms of therapeutic 
effectiveness when used as a second-line after initial treatment failure with citalopram. In this 
study, we extend these STAR*D results to incorporate costs and determine if one option is cost-
effective relative to other.  
Methods: The total costs pertaining to bupropion, sertraline and venlafaxine included the 
costs of the second-line antidepressant (study medication), other concomitant medication and 
anti-depressants that patient might have used to manage side-effects and symptoms, and 
healthcare utilization. The missing healthcare facility utilization costs were imputed using 
propensity score multiple imputation method. Effectiveness was in terms of remission and 
response. Cost-effectiveness was assessed as net health benefits. Stochastic analysis was 
performed using the bootstrapping method. 
Results: Over the duration of Level 2 of the trial, venlafaxine medication cost was 
significantly higher than bupropion and sertraline medication costs (Bupropion : $608 (sd = 
464), Sertraline: $698 (sd =$ 689), Venlafaxine: $959 (sd = $915). There were no significant 
differences in other medications and healthcare facility utilization costs. Total costs were 
significantly different between the three study medications, however none of the pair-wise 
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differences were significant. The net health benefits were also not significantly different between 
the three drugs. 
Conclusion: The switch options of bupropion, sertraline and venlafaxine, after initial 
treatment failure with citalopram, are comparable to each other in terms of cost-effectiveness. 
There is thus no rationale to change the clinical conclusion that states that any of the medications 
will provide a reasonable second-step choice for patients with depression.   
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7.2 INTRODUCTION 
Major depressive disorder (MDD) is a common and debilitating condition, associated 
with poor quality of life, increased utilization of healthcare resources and high personal and 
societal costs212, 213. MDD is the most prevalent life time disorder amongst the World Mental 
Health Survey Initiative Version of the World Health Organization Composite International 
Diagnostic Interview (WMH-CIDI)/ Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) diagnoses214. In 2004, depressive disorders resulted in 65.5 million 
disability adjusted life years (DALYs) and were responsible for about 4.3% of total DALYs151.  
A recent review estimated that 2.5% (1.9% - 3.2%) global DALYs were due to major depressive 
disorders. Depression can cost $44 billion – 53 billion (US 1990 dollars) in a year, including 
direct and indirect costs215. Depression treatment has only been partially effective. Typically, in 
clinical trials (of 6 – 8 weeks duration) less than fifty percent of patients respond to initial 
treatment for depression, and only 30-45% patients achieve symptomatic remission. Patients who 
are do not tolerate treatment or do not show sufficient response to the initial treatment often 
require secondary treatment for depression.  Moreover, patients who fail to respond after one or 
more adequate treatment trials add substantially to the depression costs216. 
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project was 
designed to evaluate the relative efficacy and tolerability of various antidepressant treatment for 
outpatients with nonpsychotic major depressive disorder and who failed the initial selective 
serotonin –reuptake inhibitor (SSRI) or subsequent treatments. In this trial, 47% responded and 
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33% remitted after a maximum of 14 weeks of treatment with Citalopram (SSRI), and 35% of 
the patients moved to the next level for a secondary treatment (Level 2)217.  In the trial, patients 
could recieve Bupropion (Wellbutrin SR, GlaxoSmithKline), Sertraline (Zoloft, Pfizer) or 
Venlafaxine (Effexor XR, Wyeth-Ayerst Laboratories) at Level 2. Previously published results 
show that the response and remission rates are comparable between the three drug switch options 
218.  However, the cost-effectiveness of treatment among these switch options has not been 
evaluated. Though there have been studies evaluating efficacy and tolerability of antidepressant 
medications, data on cost-effectiveness comparing the treatments remain limited.  Most of the 
existing economic evaluations for depression treatment focus on the first-line treatment options, 
though some do consider switch, titration and augmentation in their calculations160.  Thus 
decision guidelines on which second line treatment to choose remain sparse. 
This study aims to estimate the costs incurred during the Level 2 of STAR*D clinical 
trial and then determine if any of the switch option is more cost-effective than other.  
7.3 METHODS 
The STAR*D trial design and protocol have been previously described in detail156, 218.  
STAR*D was a multi-level trial and the patients were moved to the next level or a 12-month 
naturalistic follow-up phase (wherein they continue the indicated treatment) depending on their 
therapeutic response assessed by Quick Inventory of Depressive Symptomatology – Clinician 
Rating (QIDS-C16) and side-effects. Those without response at completion of a treatment level 
could move to the next treatment level, while those with remission entered the follow-up phase. 
Those with response but without remission could enter follow-up, but were encouraged to 
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proceed to the next treatment level after an adequate dose and duration had been achieved. 
Participants with intolerance or minimal reduction in baseline symptom severity (e.g., <15% by 
week 6 or <25% by week 9) were encouraged to move to the next treatment level. There were 
1,439 patients who moved to Level 2 of the trial after initial failure with Citalopram, of which 
727 (50.5%) were randomly assigned to one of the drug switch options (Bupropion, Sertraline or 
Venlafaxine) for depression treatment.  
We evaluated the costs of medication (depression drugs and other concomitant 
medications that were used to manage the known side-effects of depression) and healthcare 
utilizations during Level 2 for each of the three treatment options. Calculated costs were based 
on 3 components: 1) antidepressant medications, 2) other medications including any other 
antidepressant use and concomitant medications that could be used to manage treatment side-
effects and 3) all healthcare utilization. The antidepressant medications included the study 
medications to which the patient was randomly assigned. Other medications included the 
antidepressants other than the assigned treatment (like citalopram or any other prescribed 
antidepressants) that the patient might have used while at Level 2 and concomitant medications 
required to manage side-effects of the antidepressants. The concomitant medications included 
trazodone, anxiolytics, sedatives, treatment for constipation and antiemetics, and sexual 
dysfunction medications. Utilization of all medication types was based on total dose intake, 
which depended on specific doses taken for the respective time durations.   For antidepressant 
medications, doses were obtained from the trial data. For concomitant medications, doses were 
determined using the mid value of the ranges recommended in the UptoDate database219. The 
duration of use was determined using the recorded start and end dates. To accurately reflect the 
study medication use at level 2 of the trial, the start date was either the date of beginning of level 
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2 or the recorded medication start date, whichever was later. In case of missing end dates at any 
assessment, the medication was assumed to be continued until the start date of the subsequent 
record of the same medication (or same medication type in case of concomitant medications). If 
the end date was missing at the last observed for a patient then the study medication was 
assumed to be continued up until level the end of the level.  
Healthcare facility utilization included the outpatient visits, emergency room visits and 
hospitalizations that occurred during level 2. Healthcare facility utilization data for the course of 
level 2 were collected using an interactive voice response (IVR) system. The IVR system was 
implemented using telephone and involved a script of recorded instructions followed by a set of 
questions. The patients responded to the questions by pressing the appropriate number on their 
phone keypad. The protocoled outpatient visits (post-baseline of level 2) were also considered 
while assessing outpatient utilization. During the course of the trial, protocol clinic visits were 
scheduled at weeks 0, 2, 4, 6, 9, and 12 at all treatment levels. The visit schedule was flexible 
and could be held within +/-6 days of the assigned week. Extra visits could be held if clinically 
needed. If a participant started exhibiting a response or remission at week 12, two additional 
visits could be used to determine if that status is sustained. The product of net utilization and unit 
costs estimated the associated costs.  
The total costs for each of the three treatment switch arms were calculated as sum of 
costs of study medication, other antidepressant medications, concomitant medications and the 
healthcare facility utilization during the course of level 2. All medication unit costs were 
obtained from the Red Book, Pharmacy’s Fundamental Reference167.   The costs associated with 
a single outpatient and emergency room visit were obtained from the Physician Fee Schedule220. 
Hospitalization costs per day were obtained from the Healthcare Cost and Utilization Project 
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(HCUP)221 database.  Costs can be highly variable and typically a few patients are likely to incur 
high costs which commonly leads to cost data being highly skewed to the right222. To reflect the 
skewed nature, costs were modelled as gamma distribution223.  The mean and standard deviation 
of costs along with source are listed in Table 7-1. 
All missing cost information for healthcare facility utilization was handled using multiple 
imputation methods. The Markov Chain Monte Carlo Method (MCMC) method224 was used to 
impute missing patient baseline scores or information. Non parametric propensity score multiple 
imputation method was used to impute missing cost information225. We used existing IVR cost 
information and patient characteristics of those with and without IVR data to impute missing 
IVR cost data. Costs were compared between the three groups using Kruskal Wallis test. As a 
sensitivity analysis, we also compared costs among the completers only.   
Effectiveness has been previously assessed in terms of remission and response based on 
the Quick Inventory of Depressive Symptomatology – Self-Report Scores (QIDS-SR-16). QIDS-
SR-16 remission was defined as a total score at study exit of 5 or less.  QIDS-SR-16 response 
was defined as a reduction of 50 percent or more at level 2 exit (as compared to level 2 baseline). 
Both response and remission were used as effectiveness measures in this paper. 
The cost-effectiveness analyses were carried out using the net health benefits (NHB) 
framework. The net health benefits was calculated using the following formula: 
In this formula, µE and µC are the average effectiveness and costs, respectively, for 
treatment i. λ is the willingness to pay per unit effectiveness. The treatment option with the 
134 
highest NHB is considered to be the cost-effective option. Most of the cost-effectiveness studies 
use willingness-to-pay per quality adjusted life years (QALY). The standard willingness-to-pay 
thresholds of $50,000 per QALY have been used over many years but remain controversial43. 
There are no recommendations on thresholds of willingness-to-pay based on remission from 
depression or response to depression treatment. For our analyses, we assume the willingness-to-
pay to be $30,000 over the duration of Level 2  for remission or response achieved. Further, a 
sensitivity analysis varied the willingness-to-pay from $10,000 - $50,000 per effectiveness 
outcome (remission or response). Stochastic analysis was performed using the bootstrapping 
method, which involved resampling costs and effects randomly with replacement (in a joint 
manner) 1000 times to obtain estimates of the variability of  NHB estimates for each treatment 
option.  Using the bootstrapped sample, the average and percentile intervals (2.5%, 97.5%) for 
NHB were determined.  
7.4 RESULTS 
In STAR*D Level 2, 727 patients were randomly assigned to a switch drug treatment 
after initial failure with citalopram; 239 (32.9%) were randomized to bupropion,  238 (32.7%) to 
sertraline and 250 (34.4%) to venlafaxine. The duration of time spent in Level 2, and subsequent 
actions at end of Level 2 were comparable between the three groups (Table 7-2).  Overall, the 
average time in Level 2 was 8.9 ± 5.03 weeks. At the end of level 2, 227 (31.2%) moved to level 
3, 257 (35.4%) entered the follow-up phase and 243 (33.4%) terminated from the study. 
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Cost of Study Medications 
The average dose prescribed for bupropion, sertraline, venlafaxine was 223 (sd = 61) 
mg/day, 94 (sd = 34) mg/day and 122 (sd = 53) mg/day within the respective assigned treatment 
arms. Over the duration of level 2, on an average patients in the specific treatment arms used 
total 16,339 (sd = 11,675) mg bupropion, 7,557 (sd = 5,193) mg sertraline and 10,730 (sd = 
8,089) mg venlafaxine. Accounting for utilization and unit costs, the translated study medication 
costs were significantly different among the three treatment groups (Table 7-3). The bupropion 
and sertraline costs over the duration of level 2 were comparable (bonferroni adjusted p-value = 
0.5016), however venlafaxine costs were significantly higher than each of the other two 
medications (p ≤ 0.0001). 
Cost of Other Medications 
Besides the assigned study medication, 694 (95.4%) patients used other antidepressants 
to manage the disorder. All of these patients had records of citalopram use (Level 1 medication) 
in Level 2. These patients used citalopram for an average of 9 days and the average prescribed 
dose was 38mg/ day. Over the entire duration, patients used approximately 278 mg of 
citalopram(Patients assigned to bupropion, sertraline, venlafaxine used  184 (sd = 227) mg , 341 
(sd = 484) mg, 310 (sd = 464) mg of citalopram respectively). In addition to citalopram, in the 
sertraline group, 2 patients used venlafaxine, 1 used bupropion and 1 patient used nortriptyline. 
Table 7-3 shows that patients in sertraline group had significantly higher costs, due to other 
antidepressants use, as compared to bupropion and sertraline. 
Three hundred seventeen (43.6%) patients required at least one concomitant medication 
to manage the side effects of antidepressant medications. Amongst the patients requiring 
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concomitant medication, 124 (39.1%) used trazodone, 120 (37.8%) used sedatives, 86 (27.1%) 
needed anxiolytics, 35 (11.0%) needed GI medications and 47 (14.8%) used medications for 
erectile dysfunction.  Overall, patients required a median of 2 (range: 1 – 6) concomitant 
medications. The proportion of patients requiring concomitant medications was not significantly 
different between the three treatment options. The costs incurred due to concomitant medications 
were similar between the three groups (Table 7-3).  
Overall, the total costs related to other medications (other antidepressant and concomitant 
medication costs) were not significantly different between the three groups. 
Cost of Healthcare Facility Utilization 
Only 229 (31.5%) had complete information on healthcare facility utilization as collected 
by the IVR system at exit of Level 2.  In this system, patients reported healthcare utilization for 
depression (140 of 229), mental health condition (29 of 229), and general medical conditions (90 
of 229).  Table 7-4 compares the characteristics between patients who completed the IVR 
questionnaire versus those who did not. The patients who had missing IVR data were more likely 
to be those who terminated from the trial, had shorter duration of time in level 2, had greater 
severity of depression symptoms at Level 2 baseline or had exited level 1 due to intolerance. For 
IVR cost imputation, the propensity score model was based on the assigned treatment, 
achievement of the remission and response outcome (as assessed by the QIDS at end of level 2), 
and characteristics that were significantly different between patients having IVR data and 
patients missing IVR data at alpha = 0.20 (Table 7-5).  
After imputation of missing costs, the healthcare facility utilization costs were 
comparable among the three groups (average $1116, $1280 and $1076 for patients in the 
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bupropion, sertraline and venlafaxine group respectively). The costs related to healthcare facility 
utilization recorded by the IVR system and protocoled outpatient visits were not significantly 
different between the groups (Table 7-3). When considering only the IVR completers, healthcare 
facility utilization costs were marginally different among the bupropion, sertraline and 
venlafaxine (average healthcare facility utilization costs for bupropion, sertraline and venlafaxine 
were $910 (95% CI: $541 – $1,279), $1542 (95% CI: $439 – $2,644), and $782 (95% CI: $439 – 
$1,125) respectively, p-value = 0.0497). 
Total Costs and Effectiveness 
Figure 7-1 shows the total costs (mean, confidence interval) for each of the treatment 
arms. The total costs, including study medications, other medications and healthcare facility 
utilization, were significantly different among the three groups, with venlafaxine tending to have 
higher costs (Table 7-3). There however were no significant differences for any of the pairwise 
comparisons when adjusting for multiplicity using Bonferonni correction.   Among the IVR 
questionnaire completers, there were no significant differences in total costs among the three 
groups (average $1824, $2749, $2354, p-value = 0.1131).  The proportion of patients achieving 
remission and response were comparable among the three groups.  
Cost-Effectiveness 
Table 7-6 shows the net health benefits obtained if patients used the specified drug as 
opposed to spending the money in a marginally cost-effective treatment for a given willingness 
to pay. The average NHB represents the net benefit (in terms of health) that is achieved by 
investing resources in a given treatment as compared to the standard marginally cost-effective 
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program (which has a fixed willingness-to-pay). Here, the willingness-to-pay to achieve response 
or remission is assumed to be $30,000. The higher the NHB indicates the better the treatment 
option. The point estimates show that when effectiveness is expressed in terms of response, 
venlafaxine has a numerically higher NHB as compared to other drugs (an incremental 20% of 
patients would respond, if the costs associated with venlafaxine were spent instead on a 
marginally effective treatment that costs $30,000 to achieve response). When effectiveness is 
assessed in terms of remission, venlafaxine had the lowest net health benefit as compared to 
bupropion and sertraline. The bootstrap percentile intervals indicate however that none of these 
differences are statistically significant. The cost-effectiveness acceptability curves varying the 
willingness to pay (Figure 7-2) show that when effectiveness is expressed in terms of response, 
the curves are very overlapping (Figure 7-2A). When effectiveness is assessed in terms of 
remission, venlafaxine appears to be the dominated strategy (Figure 7-2B) due to its slightly 
higher costs and slightly lower proportion of patients achieving remission, but the confidence 
intervals for the net health benefits are overlapping.  
7.5 DISCUSSION 
This study shows that the three drug switch options of bupropion, sertraline and 
venlafaxine in Level 2 of STAR*D project are comparable in terms of cost-effectiveness, 
assessed using the net health benefits framework. This study extends the previously published 
study which showed that the effectiveness was similar between the three drug switch options. 
Bupropion-SR is a non-SSRI agent which does not inhibit serotonin reuptake, sertraline is 
within-class switch, and venlafaxine is a dual action agent that inhibits reuptake of both 
139 
serotonin and norepinephrine. Venlafaxine study medication costs are significantly higher than 
bupropion and sertraline. The overall costs were significantly different among the three groups. 
However, there were no pairwise differences in overall costs among the three drugs. This can be 
because of large standard deviations in costs and greater degree of freedom for the comparison of 
three groups. Thus overall treatment costs need to be considered rather than drug costs alone in 
order to make unbiased decisions.  
We used the net health benefits framework proposed by Stinett et al,42 as opposed to the 
incremental cost-effectiveness ratios (ICERs). Interpretation of ICERs can be ambiguous 
because of the nature of the ratios. A positive ICER can result from a combination of positive 
incremental costs and positive incremental effects or negative incremental costs and negative 
incremental effects when comparing interventions. Likewise, a negative ICER can result from a 
combination of negative incremental costs and positive incremental effects or positive 
incremental costs and negative incremental effects. Thus, interpretation gets complicated when 
considering uncertainty in cost-effectiveness results extending across different quadrants. 
However the NHB is a linear expression of effects and costs and has a straightforward 
interpretation.  
Also, calculating ICERs for multiple comparators involves ranking options in an 
increasing order of cost after removing the dominated options from consideration. When 
performing a stochastic analysis (like bootstrapping method) for multiple comparators, a single 
intervention might have non zero probabilities of being dominated and of being ranked 
differently between possible comparators. This methodology can have uncertainties in the 
ranking of the treatments that can lead to a more complicated interpretation of stochastic 
analyses results.  
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The literature on economic analyses of second-line treatment options for depression is 
sparse. There are two cost analysis studies which used an administrative database to compare 
second-line therapies for MDD.  Both studies showed that the costs associated with various 
second-line therapies were not significantly different.161, 162, although one of them revealed 
differences in depression-coded expenditures between SSRI and tricyclic antidepressant therapy 
even after adjusting for baseline characteristics162. However, these were observational studies 
and medication prescribing patterns have been questioned. In contrast, STAR*D is a clinical trial 
in which the patients are randomized to one of the investigated medication. 
Also, two recently published studies used computational models to evaluate second-line 
MDD treatment options. One of the studies developed a decision analysis model to compare 
generic SSRIs consisting of citalopram, fluoxetine, and paroxetine; escitalopram (Lexapro); 
paroxetine CR (Paxil CR); sertraline (Zoloft); and venlafaxine XR (Effexor XR) 163. The study 
reported generic SSRI to have the lowest cost per patient while venlafaxine was the most 
favorable option in terms of costs per patient achieving remission. However, this study obtained 
costs data from an observational study which included patients from a single prepaid health plan 
and also did not consider differences in side effect profiles between various agents. Another 
modeling study used STAR*D clinical data to compare the cost-effects of sertraline and 
venlafaxine after initial failure with SSRI in Thailand settings164. The generalizability of both the 
studies is questionable. In our cost analyses, we use cost estimates from United States national 
databases like HCUP and Physician Fee Schedule. Also we included costs of concomitant 
medications that a patient might have used to manage the side-effects of anti-depressants. None 
of the studies have appropriately represented the uncertainty of the cost-effective analyses. We 
capture the uncertainties in analyses by incorporating the variances in costs using gamma 
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distributions. Also stochasticity is captured using the bootstrapping methodology.  To the best of 
our knowledge no previous study has simultaneously compared the cost-effectiveness of the 
three switch options (Bupripion-SR, Sertraline or Venlafaxine-XR) after initial SSRI treatment 
failure. 
Our study has some limitations. The information collected by the IVR system resulted in 
68.5% having missing data. We however employed appropriate statistical imputations to 
minimize bias due to missingness.    Also, our analyses focused on cost-effectiveness from a 
clinical trials perspective and only during the level 2 of the STAR*D study.  A different 
perspective such as patients’ or society’s for the long-term effect may yield different 
conclusions. Willingness to pay is another factor of uncertainty in our analyses. There are no 
fixed standards for willingness to pay and moreover there are no recommendations for this 
measure when effectiveness is assessed in terms of response and remission. To overcome this 
limitation, we systematically varied the willingness to pay over a wide range of values. Also the 
dosing of the antidepressants that patients used were well characterized in the STAR*D project 
and were directly translated into costs. Since STAR*D included a broad population and was 
designed to closely reflect real practice, the cost-effectiveness results are highly generalizable. 
7.6 CONCLUSION 
Our results show that costs of the study medication costs differ significantly between 
bupropion, sertraline and venlafaxine. However, there are no significant differences in the cost-
effectiveness of the three medications. Thus, we conclude that after considering costs and cost-
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effectiveness there is no rationale to change the conclusions based on therapeutic effectiveness. 
Any of the three options is reasonable relative to one another. There might be other factors like 
clinician’s preference, family history, or treatment of most evident cardinal symptoms that might 
lead to choice of one antidepressant over another. 
7.7 TABLES AND FIGURES 
Table 7-1: Unit Costs for Healthcare Utilization 
Costs/unit Mean (SD) Reference 
Depression Medications ($/ gm) 
Bupropion 0.03 (0.006) Red Book, Fundamental Reference 
Sertraline 0.08 (0.05) Red Book, Fundamental Reference 
Venlafaxine 0.08 (0.04) Red Book, Fundamental Reference 
Citalopram 0.21 (0.13) Red Book, Fundamental Reference 
Nortryptline 1.04 (0.95) Red Book, Fundamental Reference 
Concomitant Medications ($/day) 
Trazodone 1.9 (1.6) Red Book, Fundamental Reference 
Sedatives 5.3 (5.7) Red Book, Fundamental Reference 
Anxiolytics 8.9 (7.3) Red Book, Fundamental Reference 
GI Medications 1.7 (2.9) Red Book, Fundamental Reference 
Erectile Dysfunction Medications 19.1 (11.7) Red Book, Fundamental Reference 
Healthcare Facility 
Outpatient Visit ($/visit) 66.7 (44.5) Physician Fee Schedule 
Emergency Room ($/visit) 83.3 (62.2) Physician Fee Schedule 
Hospitalization ($/day) 1001.3 (77.0) HCUP 
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Table 7-2: Treatment Characteristics at Level 2 
BUP 






Time in Level 2 (weeks), 
Mean (SD) 
8.3 (5.01) 9.1 (5.0) 9.3 (5.1) 0.0584 
Action at Level 2 End 0.0921 
Follow-up (n = 257) 69 (28.9%) 87 (36.6%) 101 (40.4%) 
Terminate (n = 243) 87 (36.4%) 75 (31.5%) 81 (32.4%) 
Enrolled in L3 (n =227) 83 (34.7%) 76 (31.9%) 68 (27.2%) 
*Kruskal-wallis for continuous variable and chi-square for categorical variable
Table 7-3: Costs and Effectiveness for Patients who Switched to Pharmacotherapy after 







Costs ($), mean, SD 
Study Medications 607.5, 464.6 698.3, 688.9 958.9, 915.0 0.0022 
Other Medications 249.7, 522.7 286.6, 526.2 372.5, 805.4 0.1019 
     Depression Drugs 43.5, 70.3 95.6, 359.8 76.0, 186.8 0.0028 
     Concomitant Medications 206.2, 507.6 191.1, 388.2 296.5, 780.8 0.8813 
Healthcare Facilities 1115.9, 1470.9 1279.6, 3079.7 1076.0, 1591.7 0.7293 
     IVR Recorded Utilization 903.6, 1476.3 1056.4, 3063.2 846.4, 1599.5 0.3461 
     Protocoled Outpatient 
Visit 
212.3, 200.6 223.2, 202.5 229.6, 211.9 0.6035 
Total Costs 1973.1, 1628.0 2264.5, 3254.6 2407.4, 2133.9 0.0214 
Effectiveness, N (%) 
Response based on QIDS-
SR 
62 (25.9%) 63 (26.6%) 70 (28.0%) >0.05 
Remission based on QIDS-
SR 
61 (25.5%) 63 (26.6%) 62 (24.8%) >0.05 
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Table 7-4: Characteristics of Patients having IVR  Response at Exit as compared  to those 
not having IVR Response at Exit not Present 







Treatment (L2), % 
BUP 33.9 30.6 0.6385 
SER 32.5 33.2 
VEN 33.5 36.2 
ACTION, % 
Follow-up 26.7 54.1 <.0001* 
Randomize to L3 30.1 33.6 
Terminate 43.2 12.2 
Duration of level 2 (weeks), mean, SD 7.7, 5.1 11.6, 3.7 <.0001* 
Age, mean, SD 41.4, 12.8 42.8, 12.7 0.1861 
Race, % 
White 76.5 74.2 0.7594 
Black 17.3 18.3 
Other 6.2 7.4 
Hispanic, % 
Yes 10.2 12.7 0.3322 
No 89.8 87.3 
Female sex, % 
Yes 58.6 59.0 0.9356 
No 41.4 41.0 
Education (yr), mean, SD 13.3, 2.9 13.4, 3.1 0.4871 
Employment, % 
Employed 53.5 53.3 0.6221 
Unemployed 41.6 40.2 
Retired 4.8 6.6 
Highest degree received, % 
None 12.2 11.4 0.2100 
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HS Diploma 43.0 37.6 
GED 9.8 9.6 
Assoc degree 11.8 18.3 
College diploma 15.5 14.4 
Masters degree 6.2 5.7 
Doc/professional degree 1.4 3.1 
Monthly household income, mean, SD 2141.6, 2808.2 1808.9, 1905.3 0.4477 
Medical insurance, % 
Any private 45.7 42.2 0.6687 
Public only 14.5 14.7 
None 39.9 43.1 
Marital status, % 
Never married 27.9 26.2 0.7367 
Married/cohabiting 38.8 41.5 
Divorced/separated 28.9 26.6 
Widowed 4.4 5.7 
Age at first episode, mean, SD 24.9, 14.0 25.1, 13.9 0.6881 
Number of MDEs, mean, SD 6.9, 12.7 7.4, 13.2 0.2973 
Duration of index episode (mo), mean, SD 31.6, 73.0 25.1, 47.0 0.5705 
Recurrent depression, % 
Yes 74.4 78.8 0.2288 
No 25.6 21.2 
Duration of index episode 2+ years, % 
Yes 27.1 26.9 0.9555 
No 72.9 73.1 
Family history of depression, % 
Yes 54.4 52.9 0.7049 
No 45.6 47.1 
Prior suicide attempt, % 
Yes 17.3 17.1 0.9476 
No 82.7 82.9 
CIRS Total score, mean, SD 4.8, 4.0 4.7, 3.7 0.9790 
Psychiatric Care, % 
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Table 7-4 Continued
Yes 61.4 57.2 0.2781 
No 38.6 42.8 
Heart problems, % 
Yes 17.7 15.3 0.4252 
No 82.3 84.7 
Vascular problems, % 
Yes 27.1 28.4 0.7205 
No 72.9 71.6 
SF-12 Mental, mean, SD 29.2, 9.6 29.9, 10.0 0.5170 
SF-12 Physical, mean, SD 45.2, 12.7 45.5, 12.5 0.7973 
QLESQ, mean, SD 39.7, 16.2 42.2, 17.4 0.1415 
WSAS, mean, SD 24.7, 9.4 22.9, 10.0 0.0507 
HRSD-17, mean, SD 19.3, 7.2 18.0, 7.5 0.0295* 
IDS-C30, mean, SD 34.8, 12.6 32.6, 13.8 0.0608 
QIDS-C16, mean, SD 14.2, 4.4 13.5, 4.8 0.0640 
QIDS-SR16, mean, SD 13.5, 4.9 12.7, 4.9 0.0174* 
Anxious features, % 
Yes 44.2 44.9 0.8795 
No 55.8 55.1 
Atypical features, % 
Yes 19.4 22.3 0.3821 
No 80.6 77.7 
Duration of Level 1 (weeks), mean, SD 8.2, 4.0 7.7, 4.5 0.1827 
CITLAST1, mean, SD 42.1, 17.3 40.6, 18.5 0.3153 
Exited prior level due to intolerance, % 
Yes 28.7 10.9 <.0001 
No 71.3 89.1 
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Table 7-4 Continued
Table 7-5: Logistic Regression Model for Calculating the Propensity of Missingness 





Intercept 1.0158 0.0996 104.0142 <.0001 
Assigned to Bupripion 0.0285 0.1030 0.0768 0.7817 
Assigned to Sertraline 0.0298 0.1006 0.0877 0.7671 
Moved to Follow-up -0.3881 0.1509 6.6115 0.0101 
Moved to Level 2 -0.3920 0.1281 9.3642 0.0022 
Age -0.0777 0.0899 0.7464 0.3876 
Weeks in Level 2 -0.7430 0.1367 29.5467 <.0001 
Qlesq score at  Level 2 baseline -0.0631 0.1442 0.1916 0.6616 
wsas score at  Level 2 baseline 0.0664 0.1419 0.2188 0.6400 
Hrsd score at  Level 2 baseline 0.1283 0.2328 0.3038 0.5815 
ids score at  Level 2 baseline -0.0550 0.2534 0.0472 0.8281 
Qids-sr score at  Level 2 baseline 0.0951 0.1673 0.3232 0.5697 
QIDSC score at  Level 2 baseline -0.0474 0.1517 0.0976 0.7548 
Weeks in Level 1 0.2424 0.0920 6.9376 0.0084 
Moved to Level 2 due to Intolerance at Level 1 -0.1088 0.1230 0.7829 0.3762 
QIDSS_remission at 2 0.0603 0.1395 0.1872 0.6653 
QIDSS_response at 2 -0.00589 0.1387 0.0018 0.9661 
Table 7-6: Net Health Benefits for Patients who switched to Pharmacotherapy after Initial 
Failure with Citalopram (lambda = 30,000) 
BUP (N = 239) SER (N = 238) VEN (N = 250) 
Point Estimates 
Effectiveness: 
Response 0.1940 0.1884 0.2000 
Effectiveness: 
Remission 0.1900 0.1894 0.1680 




(0.1400 – 0.2498) 
0.1898  
(0.1309 – 0.2491) 
0.1994  
(0.1444 – 0.2550) 
Effectiveness: 
Remission 
0.1896   
(0.1324 – 0.2522) 
0.1907  
(0.1314 – 0.2509) 
0.1675  
(0.1167 – 0.2203) 
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Figure 7-1: Total Costs (US Dollars) for the Treatment Arms 
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A: Effectiveness in terms of Response 
B: Effectiveness in terms of Remission 
Figure 7-2: Cost-effectiveness Acceptability Curve 
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8.0  PUBLIC HEALTH SIGNIFICANCE 
The advancement of medical research and technologies has made a multitude of options 
available to consumers for almost any particular medical issue. Decisions about which option to 
use are of high value to the health-care systems226.  Moreover, in an environment of limited 
resources available for healthcare, identifying the cost-effective strategy becomes indispensable. 
This not only holds true for resource-constrained countries but also for the wealthier nations 
which have many competing priorities. It is pertinent that the society gets the greatest value per 
dollar thus gaining maximum health benefits for the amount of money spent.  Identification and 
adoption of cost-effective options translates to considerable costs saved per effectiveness unit, 
given the willingness to pay. 
8.1 PUBLIC HEALTH SIGNIFICANCE OF USING COST-EFFECTIVE SUTURE 
(COATED SUTURES VERSUS UNCOATED SUTURES)        
Operating room procedures account for nearly one-third of all hospitalization stays. 
According to the data published by the Agency for Healthcare Research and Quality (AHRQ), 
Center for Delivery, Organization, and Markets, Healthcare Cost and Utilization Project 
(HCUP), National Inpatient Sample (NIS), there were more than 28 million non-maternal and 
non-neonatal hospital stays in US in the year 2012, with operating room procedures performed 
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during 28.0 percent of these stays227. The data show that procedures involving the digestive 
system were among the most common procedures in the operating room. These surgeries 
included cholecystectomy (removal of the gall bladder, 406,300 stays; 129.4 stays per 100,000 
population ); colorectal resection (305,900 stays, 97.4 stays per 100,000 population); excision, 
lysis peritoneal adhesions (305,800 stays, 97.4 stays per 100,000 population); and appendectomy 
(removal of the appendix, 293,000 stays, 93.3 stays per 100,000 population)227. Overall, 
approximately 4 million surgeries in United States are open abdominal surgeries174. Moreover 
the abdominal incisions have a high surgical infection rate. SSI rates for abdominal surgeries 
vary from study to study   depending on the population, facility and procedure type ranging <5% 
- 25%170-173, 228.  Assuming that digestive system surgeries have a 15% SSI rate for all 
procedures, there will be 196,650 infections nationwide. Using a coated suture which has a 10% 
efficacy (that saves $9,497 per SSI prevented) can potentially save gastrointestinal departments 
$1.8 billion (US dollars) nationwide.  Third party payers reimbursing gastrointestinal surgeries 
will also save similar amounts of money. From a societal perspective (that saves 50,187 per SSI 
prevented), almost $9.8 billion can be saved nationwide based on the point estimates of costs 
saved per infection prevented. The extrapolated costs were three times the above extrapolations 
when considering all abdominal open procedures. With greater awareness and adoption of 
prevention measures, certain procedures and facility types have substantially lower SSI rates. 
Surgeons and physicians should be cognizant to not use coated sutures for surgical procedures 
which have <5% SSI rate in order to avoid extra costs.   
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8.2 PUBLIC HEALTH SIGNIFICANCE OF USING ON-PUMP VERSUS OFF-PUMP 
CABG 
According to the most recent data available from National Hospital Discharge Survey, 
there were 395,000 CABG procedures performed in the United States in 2010229. Off-pump 
CABG was introduced in the early 1990s and gained popularity over the next decade as a 
potential means of avoiding several of the complications and adverse effects of cardiopulmonary 
bypass (CPB). The data from Society of Thoracic Surgeons Adult Cardiac Surgery Database 
(STS ACSD) show that the relative use of off-pump CABG peaked at 23% in 2002. The rate of 
off-pump use has been steadily decreasing over time. In 2008, 21% of CABGs were performed 
as off-pump and in 2012, 17% of CABG procedures were off-pump. Over the period of 2002 – 
2012, there have been 1,458,732 isolated CABG procedures. Of these, ~40% (N = 574,367) were 
performed on patients with diabetes mellitus. Among diabetic patients, 20% of procedures were 
performed off-pump and the rest were performed on-pump. Our results support the use of on-
pump procedures as opposed to off-pump CABG for diabetic patients230. Diabetic patients 
undergoing off-pump procedures in the long term were almost twice as likely to experience 
adverse events of death/MI/stroke as compared to those undergoing on-pump. In the BARI 2D 
trial, 16.7% of the patients undergoing CABG suffered from major cardiovascular events 
(death/MI/stroke). The unadjusted rate of major cardiovascular events among off-pump and on-
pump patients was 20% and 15% respectively. Extrapolating these point estimates of event rates 
to the STS data, we estimate that 23,723 patients may have experienced death/MI/stroke that 
could have been avoided. Also, from the hospital’s perspective, off-pump procedure results in 
lower net health benefits, indicating that off-pump is not the cost-effective strategy compared to 
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on-pump strategy. Thus these results confirm the current trend that the on-pump procedure 
should continue to be used as the standard surgical treatment for diabetic patients.    
8.3 PUBLIC HEALTH SIGNIFICANCE OF USING SECOND LINE SWITCH 
OPTIONS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER  
Previous STAR*D results have shown that bupropion, sertraline and venlafaxine switch 
options after initial failure with citalopram for treatment of depression exhibit similar therapeutic 
response and remissions. The third project in this dissertation extends this comparison to 
incorporate cost and determine if one switch option is more cost-effective than another. The 
results show that even though the study medication costs are significantly different among the 
three groups, the net health benefits (which incorporate costs and effectiveness) are similar 
among the three groups. Thus, in terms of cost-effectiveness, any of these is a viable option. A 
survey in the past reflects that more than 50% of the professionals base their choice of 
antidepressants on their personal experiences with the drug and observing trends in psychiatric 
practices231. In addition, some drugs may be cheaper or more expensive for different health 
plans. There are no fixed guidelines for prescribing the second-line antidepressants based on 
either clinical effect or overall cost-effectiveness. Cardinal symptoms of depression including 
behavioral changes, psychosis, cognition, and mood disorder can help guide treatment selection. 
Other factors like family history of response and drug interactions should also be considered 
while administrating antidepressant options232. Further research is warranted to identify a well-
defined prescription algorithm of second-line depressants after initial treatment failure with 
citalopram. 
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9.0  DISCUSSION 
The three projects in this dissertation evaluate the economic value of a specified 
intervention, procedure or treatment in three different clinical areas. This dissertation document 
illustrates a range of methods that can be employed to estimate the cost-effectiveness of the 
option. Each of the three projects uses a different approach to estimate the respective costs and 
effectiveness measures. The first project compares antimicrobial coated sutures to regular sutures 
using a decision tree model; the second project compares two non-randomized CABG procedure 
options within BARI 2D clinical trial; and the third project compares three randomized drug 
switch options using data from the STAR*D trial. The methods employed have distinct 
advantages and disadvantages. 
9.1 SIMULATION STUDY FOR COST-EFFECTIVENESS ANALYSES 
Decision trees are simulation models that use mathematical relationships to define a 
series of possible consequences following each of the options being evaluated233. Simulation 
models are a way of representing the complexity of the real world in a simple and 
comprehensible form. Many studies have used simulated decision trees to compare multiple 
alternatives and adjudicate the decision making process.  Clinical trials, although the gold 
standards for comparing alternatives, are limited in number of comparisons and are often 
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constrained in terms of range of outcome (including cost and utility information) collected234, 235. 
In contrast, the decision trees can include multiple comparators in the model and depending on 
the research question being analyzed can include a range of outcomes, with no or minimal 
impacts on to the project budget. Clinical trials have short-follow-up time and often assess 
effectiveness in terms of intermediate endpoints, while the final consequences of disease may 
take many years to manifest themselves. Economic evaluations restricted to immediate end 
points do not give a complete picture. Computational models with assigned probabilities can 
extrapolate the events into long term outcomes. Models can also be used to explore alternative 
scenarios which have not been studied in the key clinical trials. Moreover, models can be used to 
simulate experiments when true experiments are infeasible or impractical due to ethical 
constraints, time pressures, and political considerations. Overall, models with explicit structure 
and working can help gain insight into many complex questions. 
9.2 CLINICAL TRIALS FOR COST-EFFECTIVENESS ANALYSES 
The above listed advantages of models over clinical trials do not imply that the gold 
standard trials and other epidemiological studies are not needed. Since models are simplified 
representation of real life scenarios, the heterogeneity among patients observed in real world may 
or may not be accurately captured depending on the details. Certain simplifying assumptions of 
simulation models can result in a homogenous population that impact the economic outcome and 
lead to incorrect conclusions236. For example, a treated group in a randomized study could 
experience fewer as well as less severe complications manifesting in shorter lengths of stay for 
the same cause of admission. This, in a classic model based approach, might be ignored as a 
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result of assuming the same costs per complication. The variability of parameters and pay-offs 
should be incorporated in the model. One of the major concerns for simulation models is that the 
variables and their ranges included are at the discretion of analyst and have the potential to be 
biased. The uncertainty of parameters is commonly handled by varying the parameters 
individualistically as sensitivity analyses. However such analyses ignore interactions with other 
parameters and might yield incorrect estimates. Thus, validating a model and exploring beyond 
internal consistency is of prime importance. Also, a model is only as good as the data it utilizes; 
the source of data obtained is the existing published literature or an on-going clinical study. This 
further emphasizes the need of unbiased and detailed data from other observational and/or 
prospective studies. An estimate from a biased study will lead to an incorrectly calibrated model. 
For example, if in a study, the adverse events are obtained from a patient population within 
which there might be differences resulting in sub-populations; certain differences might remain 
unmeasured. Such estimates if incorporated in the model can result in misleading conclusions as 
it will not appropriately account for differences in characteristics that can affect the event rates. 
Cost-effectiveness analyses alongside clinical trials also fill in many of the limitations of 
computational simulation models and are increasingly being implemented. Economic evaluation 
alongside clinical trials can be used to estimate the covariance between costs and outcomes and 
can help construction and validation of models. Clinical trials are also free of structural 
assumptions that are present within a model which might be spurious. Clinical trials and other 
prospective and observational studies are required to generate reliable estimates to feed the 
simulation models, and in-fact provide patient-level data for reliably dealing with the 
heterogeneity present in real life. 
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9.3 OBSERVATIONAL STUDY DESIGN FOR COST-EFFECTIVENESS ANALYSES 
Clinical trials primarily designed to evaluate differences between randomized branches, 
can also be used to compare non-randomized options. Comparing non-randomized options using 
clinical trials data is similar to comparing options in an observational study. Highly structured 
protocol from a trial though may have advantages over most observational studies regarding 
uniformity of care but on the flip side the trials have the disadvantage of not being reflective of 
the real world. However, both observational studies and comparing non-randomized options 
within a trial are subjected to treatment-selection bias. The treatment choice might be based on 
patient/disease characteristics, physician’s personal preferences or site/regional practices. 
Treatment-selection bias should be handled using appropriate statistical methods such as 
propensity score methods. One should be cognizant that propensity score methods do not account 
for unmeasured confounders. 
One issue, however, for conducting economic evaluations alongside clinical trials is the 
lack of agreement on study design issues like methods of efficient data collection, reliable 
measurement of patient outcomes and methods of extrapolation. Further research on 
standardization of these methods can help minimize bias and lead to more acceptable cost-
effectiveness estimates. Other concerns regarding the prospective collection of cost and resource 
utilization data are the limited by the budget available for such studies. Also, most clinical trials 
have a sample size too small to be able to generalize their findings to a broader population.  
Electronic medical records (EMRs), which virtually have no costs after the installation and 
implementation, can serve as a rich alternate source to provide valuable information. The EMRs 
contain granular measurements of a patient’s hospitalization, including detailed records of 
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symptoms, test measurements, data from monitoring devices, clinicians’ observations and billing 
data. The increasing adoption of EMR system by hospitals will increase the availability of the 
EMR system data. However the researchers should be aware of the limitations of EMR data237. 
The set of recorded patients having EMR data is not a random sample from the population. 
Instead, it varies depending on the nature of particular practice, the care unit, and the 
geographical location of the medical institution. All analysis using EMR data should deal with 
the censored data if present. EMR data can be left or right censored in case the patient gets 
transferred too late or discharged too early resulting in a skewed distribution. Also, there can be 
interventions performed by the caregivers that affect the outcome and hence the associated costs. 
These confounding medical interventions should be incorporated and accounted for while 
assessing the economic value of a treatment option.  
9.4 SUMMARY 
Irrespective of the methodology and the data source used, the cost-effectiveness analyses 
need to include comprehensive information about numerous factors related to treatment effects, 
health-related preferences, resource use, and costs. However, most epidemiological studies focus 
only on establishing a product’s efficacy and safety as it is the primary information required to 
obtain a pharmaceutical product license. This results in evidence gaps and highly imprecise 
estimates of resource use, costs and health utilities226.  The uncertainties associated with 
parameters need to be handled appropriately. One method of handling the uncertainty is stating 
the data collection and study methods explicitly at the outset. However, researchers and decision 
makers may not share the exact same views on certain methodologies. Thus, it is preferred that 
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the uncertainty is internalized in the study itself. In case of decision trees, conditional 
probabilities, resource use consequences and utilities can be modeled as distributions. While in 
clinical trials these uncertainties are accounted for by heterogeneity and randomized nature of the 
study.  The clinical trials are increasingly being used to collect economic data prospectively that 
help describe distributions of data and to represent uncertainty as a point estimate accompanied 
by a confidence interval through the use of standard statistical techniques46. 
The method of cost estimation leads to additional uncertainty. The different methods used 
for cost estimation vary in precision and detail. The costs can vary depending on the method of 
identification of cost components (gross costing versus micro-costing) and the method of 
validation of the components (top-down versus bottom-up)238. In gross-costing method, 
resources are defined at an aggregated level and a unit cost is attached. In micro-costing method, 
all relevant costs are defined at the most detailed level239.  For example, in a gross-costing 
approach the number of hospital days could be measured and valued by the unit cost of a hospital 
day. In micro-costing, the costs like staff time spent administering a drug could be measured and 
valued by staff cost per hour would also be detailed out. Costs information for micro-costing 
methodology can be collected using either the top-down or the bottom-up approach240. The top-
down approach separates out the relevant costs for an intervention from comprehensive sources 
(for example hospital or center annual budgets). The use of such readily available data from 
routine accounts is a low cost approach but could limit transparency and consistency. In contrast, 
the bottoms-up approach identifies all the resources directly employed for a patient or 
intervention, resulting in detailed costs. Though the bottoms-up micro-costing approach is very 
time consuming it provides most accurate information. Many economic evaluations combine the 
approaches for assessing total costs.  
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Thus to conclude, cost-effectiveness analyses alongside clinical trials and decision 
models are important and complementary components of cost-effectiveness research. These 
methods in isolation from each other may lead to biased decisions with high degree of errors. 
Both the research methods are highly influenced by uncertainties of costs and effectiveness 
measures. These uncertainties might defer investments in order to wait for new information. 
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